YEDİTEPE UNIVERSITY

FACULTY OF MEDICINE

PHASE III

ACADEMIC PROGRAM BOOK

2015 - 2016

Student's
Name : .....
Number : .....

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE
PHASE III

Contents

YEDİTEPE UNIVERSITY FACULTY OF MEDICINE
AIM and OUTCOMES OF MEDICAL EDUCATION PROGRAM*,**

*"Consensus Commission Report" based on draft compiled at "*Workshop for Revision of Aim and Outcomes of Medical Education Program at Yeditepe University Faculty of Medicine*"

AIM

The aim of medical education program ***is to graduate physicians*** who

- **are aware of** the local and global health issues
- **have acquired competence** in knowledge, skills and attitudes to manage and provide primary health care service
- **know**, **apply** and **care** for ethical principles of the medical profession
- **keep up with** current knowledge at national and international level
- **are capable of** systematical thinking
- **are** investigative and questioning
- continually **renovate** and **improve** themselves
- **are capable of** teamwork
- **use** technology competently in medicine and related areas
- **have** effective communication skills
- **have** community leadership qualifications
-

OUTCOMES

Graduate should be able to:

1) *practice* as a physician,

- **oriented towards**
  - **individual and non-individual factors affecting health**
  - **sustainment and improvement of healthy condition**
  - **clinical conditions which**
    - **are frequent in community**

    and/or
    - **pose high risk for individual or community health**

    and/or
    - **life-threatening or constitute an emergency**
- **at a competency level appropriate to deliver primary health care services compatible with surrounding context of health determinants.**

1.1 ***explain*** normal structural components of human body, their functions and operational mechanisms at organismal, multisystem, system, organ, tissue, cellular and molecular levels.
1.2 ***explain*** healthy condition and factors affecting health.
1.3 ***explain*** and ***relates*** causes of clinical conditions, courses of effect and outcomes.
1.4 ***explain*** changes (*i.e. physiological and pathological*) in structural components of body, their functions and operational mechanisms under healthy and clinical conditions.
1.5 ***explain*** most frequently occurring or most important clinical complaints (*i.e. chief complaint*), symptoms, signs, laboratory and imaging findings and their emergence mechanisms in clinical conditions.
1.6 ***explain*** current medical and surgical methods used in interventions directed towards health conditions.
1.7 ***use*** contextually appropriate medical history taking method, out of different types (*e.g. comprehensive, focused or hypothetico-deductive*) and systematically, to gather medical information from healthy individual, patient or patient's companions (*i.e. heteroanamnesis*), in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.
1.8 ***employ*** physical examination methods for systems in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.
1.9 accurately ***interpret*** findings in medical history and physical examination, in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.

1.10 ***implement*** diagnostic procedures (*e.g. point of care testing, physician office testing*) required for primary health care, in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.

1.11 ***select*** (***utilize***) tests shown to be highly effective in clinical decision making by evidence-based medicine from the aspects of reliability, practicality and outcome measures, in case of an encounter with a healthy person or a patient who seeks health care service for a health condition, and ***interpret*** results.

1.12 ***make*** clinical decisions (*e.g. benefit estimation, risk estimation, prevention, screening, test requisition, diagnosis, triage, staging, consultation, prognosis, watchful-waiting, intervention, monitoring, end of intervention, discharge, control, end of follow-up*) shown to be highly effective from the aspects of outcome measures by evidence-based medicine, in case of an encounter with a healthy person or a patient who seeks health care service for a health condition.

1.13 accurately ***perform*** interventional procedures (*i.e. interventional clinical skills, competencies and proficiencies*) required for primary health care, in case of an encounter with a healthy person or a patient who seeks health care service for a clinical condition.

1.14 ***coordinate*** referral or transport of patient, when necessary and with patient-centered approach, to secondary health care institution, without posing any risk to patient's health, security and confidentiality, in case of an encounter with a patient who seeks health care service for a clinical condition.

1.15 ***manage*** request or symptom, healthy or clinical condition, and healthy individual or patient, with beneficiary-centered approach, and with clinical decisions made by analytical and critical thinking, clinical reasoning and problem solving methods, in case of an encounter with a patient who seeks health care service for a health condition.

1.16 ***execute*** protective and therapeutic medical practices that are individual, family and community-oriented, easily accessible, integrated and coordinated, continuous, comprehensive, and based on the principles of confidentiality, in primary health care services.

1.17 ***identify*** factors that pose a high risk to individual and community health, and ***determine*** individuals or populations at risk in advance or at an early stage and implement the necessary measures.

1.18 ***value*** preventive health services, ***offer*** primary prevention (*i.e. prevention of diseases for the protection of health*), secondary prevention (*i.e. early diagnosis and treatment*) and tertiary prevention (*i.e. rehabilitation*) services, and ***provide*** consultancy on these issues.

1.19 ***provide*** life-style consultancy and design services to sustain and improve individual and community health.

2) *manage* primary health care services.

2.1 ***manage*** health care team in primary health care organization.

2.2. ***lead*** community with sense of responsibility, good behavior and manners in consideration of individual behaviors and social dynamics of community, and if there is a necessity, ***develop*** projects directed towards health care services.

2.3 ***define*** health management and economics principles, models for organization and finance of health care services.

2.4 ***use*** health care resources with cost-effective manners.

3) *advocate* individual and community health under all circumstances.

3.1. ***provide*** consultancy services to sustain and promote the health of individual and community.

3.2. ***explain*** epidemiology of clinical conditions, and ***define*** measures to reduce frequencies.

3.3. ***describe*** completely all high risk factors for the community health (*e.g. natural disasters, nuclear accidents, fire, war, bio-terrorism, etc.*), and ***implement*** necessary measures in order to prevent effects on health.

3.4. ***explain*** health determinants completely (*e.g. physical environment, social environment, genetic background, individual response -behavior, biology-, health care services, welfare, etc.*), including conditions that prevent access to health care.

4) *perform* medical practices according to regulatory and ethical principles and in consideration of behavioral sciences, social sciences, and humanities.

4.1 ***recognize*** determinants affecting individual behaviors and attitudes, and social dynamics.

4.2 ***recognize*** basic ethical principles completely, and ***distinguish*** ethical and legal problems.
4.3 ***recognize*** regulations concerning national and international health systems.
4.4 ***employ*** safety, security and confidentiality principles completely for beneficiaries of health care services, companions and visitors, and health care workers.
4.5 ***use*** medical record and information systems according to regulations and ethical principles.
4.6 ***value*** informed consent taking in the framework of patients' rights, and ***employ*** fully.
4.7 ***interpret*** historical, anthropological and philosophical evolution of medicine, health and disease concepts, and ***relate*** to current medical practice

5) *establish* correct and effective communication with all stakeholders of health care services and collaborate.

5.1. ***communicate*** by using problem solving abilities during all of professional life with health care beneficiaries, co-workers, accompanying persons, visitors, patient's relatives, care givers, colleagues, other individuals and organizations.
5.2. ***collaborate*** with related organizations and institutions, with other professionals and health care workers as a team member through using problem solving abilities.
5.3. ***communicate*** with all stakeholders with consideration of socio-cultural differences.

6) *promote* self medical knowledge and skills in view of the current scientific developments throughout own career.

6.1. ***adopt*** and ***implement*** the importance of lifelong self-learning.
6.2. ***recognize*** importance of updating knowledge and skills; ***search*** current advancements and improve own knowledge and skills.
6.3. ***speak*** at least one foreign language at advanced level to follow the international literature and communicate with colleagues.
6.4. ***recognize*** methods to reach current scientific knowledge, and ***use*** available technology.
6.5. ***recognize*** principles of evidence-based medicine, and ***implement*** in health care services.
6.6. ***develop*** and ***present*** research projects.

7) *manage* own postgraduate career.

7.1. ***recognize*** and ***investigate*** postgraduate work domains and job opportunities.
7.2. ***determine*** postgraduate work domains, job opportunities and requirements for application, ***distinguish*** and ***plan*** requirements for further training and work experience.
7.3. ***prepare*** a resume, and **recognize** job interview methods.
7.4***. recognize*** health technologies expected to be implemented in near future and emerging work areas.

COORDINATION COMMITTEE
(TEACHING YEAR 2015–2016)

Ferda KALEAĞASIOĞLU, MD, Assoc. Prof. (Coordinator)
Işın Doğan Ekici, MD, Prof. (Co-coordinator)
Yeşim GÜROL, MD, Assoc. Prof. (Co-coordinator)
Ayşegül Ç. KUŞKUCU, MD, PhD, Assist. Prof. (Co-coordinator)
Hale ARIK TAŞYIKAN, MD, MPH, Assist. Prof. (Co-coordinator)

ICP-III COORDINATION COMMITTEE

Özlem TANRIÖVER MD, Assoc. Prof. (Coordinator)
Ayşe Arzu AKALIN MD, Assist. Prof. (Co-coordinator)

DESCRIPTION and CONTENT

Physiopathological process and pathological process.

Infectious Diseases, Cardiovascular System, Respiratory System, Hematopoietic System, Gastrointestinal System, Endocrine System, Urogenital System, Nervous System, Psychiatry, Musculoskeletal System, Basic Clinical Skills, Biomedical Ethics and Deontology, Biostatistics.

Emergency Medicine, Family Medicine, Anesthesiology and Reanimation, Neurosurgery, Biostatistics, Biomedical Ethics and Deontology, Pediatrics, Pediatric Surgery, Pediatric Psychiatry, Endocrinology, Infectious Diseases, Immunology, Phytotherapy, Physical Therapy and Rehabilitation, Physiopathology, Gastroenterohepathology, General Surgery, Pulmonary Diseases, Thoracic Surgery, Ophtalmology, Public Health, Hematology/Oncology, Obstetrics and Gynecology, Cardiology, Otorhinolaryngology, Nephrology, Neurology, Orthopedics and Traumatology, Pathology, Psychiatry, Radiology, Rheumatology, Medical Pharmacology, Medical Genetics, Medical Microbiology, Urology, Medical Education.

AIMS and LEARNING OBJECTIVES of PHASE III

AIMS

In evidence based manner:

1. ***to remind*** anatomy, histology and physiology of body systems,
2. ***to convey*** necessary knowledge, related to body systems, on prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions.
3. at multi-system level or related to a body system, for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
   3.1. ***to convey*** necessary knowledge on risk factors, etiopathogenesis, physiopathology, and pathology,
   3.2. ***to convey*** knowledge on epidemiology,
   3.3. ***to convey*** knowledge on frequently encountered clinical complaints, symptoms, signs and findings,
   3.4. ***to convey*** necessary knowledge on health care processes, clinical decision making process, clinical decisions and clinical practices, with performance measures, for managing at the level of primary health care service,
4. ***to convey*** knowledge on pharmacology of drugs that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
5. ***to convey*** knowledge on phytotherapeutic agents that are effective at multi-system level, specifically on a body system or on clinical conditions involving a specific body system,
6. ***to convey*** knowledge on biostatistical analysis,
7. ***to convey*** basic legal and ethical principles that should be followed in practice of medical profession,
8. ***to equip with*** basic and advanced professional and clinical (interventional or non-interventional) skills necessary for practice of medical profession.

LEARNING OBJECTIVES

At the end of this phase, student should be able to:

1.0. ***recall*** anatomy, histology and physiology of body systems.
2.0. ***list*** necessities for prevention of clinical conditions' emergence, protection and improvement of health in healthy conditions in relation to body systems.
3.0. ***explain*** risk factors and etiopathogenesis, at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.
4.0. at cellular or tissue level,
4.1. ***recognize*** morphological characteristics,
4.2. ***show*** basic pathological changes that occur in clinical conditions.
5.0. at multi-system level or related to a body system, of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency;
5.1. ***explain*** mechanisms of destruction at molecule, cell, tisssue, organ, system, multi-system and organismal level,
5.2. ***describe*** structural and functional changes caused,
5.3. ***list*** clinical courses in time.
6.0. ***explain*** mechanisms of emergence for frequently encountered;

6.1. clinical complaints,
6.2. symptoms,
6.3. signs,
6.4. laboratory and imaging findings

of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency.

7.0. at multi-system level or related to a body system,

- for healthy conditions in an individual or community with a request, or
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes,
- acquisition of subjective or objective data, information and knowledge required for clinical decision making,
- clinical decision making process,
- clinical decisions and
- clinical practices

which are required for management at primary health care service level.

7.1. practice of history taking and physical examination (*cardiovascular-C2, pulmonary-C2, gastrointestinal-C4, gynecological-C5, breast-C5, neonatal, prepubertal/pubertal-C6, neurological/neuropsychiatric-C7, musculoskeletal-C8*)

7.2. evaluation of emergency case (*sepsis and septic shock-C1, dyspnea-C2, acute abdominal pain-C4, urological emergencies-C6, neurological emergencies-C7, trauma-C8*)

7.3. approach to healthy individual or patient (*fever-C1, cardiovascular disease-C2, chest pain-C2, cough and hemoptysis-C2, dyspnea-C2, anemia-C3, lymphadenopathy-C3, diarrhea-C4, pregnancy-C5, urinary tract infection-C6, neurological symptoms-C7, headache-C7, depression-C7, dementia-C7, musculoskeletal dysfunction-C8*)

7.4. laboratory and imaging tests/examinations

7.4.1. based on laboratory disciplines/subdisciplines;

1. medical biochemistry tests:
   i. *(venous blood collection-C5*)
   ii. *(thyroid function tests-C5, diabetes tests-C5)*
2. medical microbiology tests:
   i. *(urine sample collection-C1, throat swab specimen-C5, sputum sample collection-C5, urethral-vaginal-cervical discharge/swab specimen-C6, fecal specimen collection-C6, wound sample collection-,blood collection for culture-*)
   ii. *(urine strip/dipstick test-C1, urine culture-C1, rapid screening (antigen/antibody) tests-C5, throat culture-C5, sputum culture-C5, urethral-vaginal-cervical discharge culture-C6, fecal culture-C6, wound culture-, blood culture-)*
3. medical pathology tests:
   i. *(C2, C4, C6, C7, C8, Pap smear collection)*
   ii. *(C2, C4, C6, C7, C8, Pap smear)*
4. other laboratory tests:
   i. *(peripheral/venous blood collection for hematology tests-C3, blood sample collection for therapeutic drug monitoring-C8)*
   ii. *(pulmonary function tests-C2, hematology tests for anemia-C3, monitarization of drug therapy-C8)*

7.4.2. imaging tests/examinations based on disciplines/subdisciplines:

5. radiological examinations: *(radiological examinations in gynecology-C5, breast imaging-C5, uroradiology-C6, conventional neuroradiological examinations-C7, spinal neuroradiology-C7, cranial CT-C7, cranial MRI-C7, radiological imaging of musculoskeletal system-C8, radiological examinations in benign ve malign tumors of bones-C8)*
6. nuclear medicine examinations: *(nuclear medicine tests in infectious diseases-C1, radionuclide ventriculography-C2, myocardial scintigraphy-C2, cardiac PET-C2, ventilation/perfusion scintigraphyi-C2, PET in lung cancer-C2, nuclear medicine tests in hematology-C3, scintigraphy of liver/spleen-C4, PET in gastrointestinal system tumors-C4, radioisotope imaging of thyroid and parathyroid-C5, renal scintigrahy (GFR, ERPF, Renogram)-C6, brain perfusion scintigraphy-C7, brain PET-C7, bone scintigraphy-C8)*

7.4.3. point of care testing

a. based on laboratory disciplines/subdisciplines;

1. medical biochemistry tests: *(diabetes tests-C5, cardiac markers-, coagulation tests-, blood gases-).*
2. medical microbiology tests: *(urine strip/dipstick test-C1, rapid screening (antigen/antibody tests-C5)*
3. other laboratory tests: *(hematology-peripheral blood smear examination-C3, hematology-complete blood count-)*

7.5. making preliminary diagnosis or definitive diagnosis decision

7.6. making non-intervention or intervention decision

7.7. practicing non-intervention or intervention

7.8. referral/transport of healthy individual or patient

INTRODUCTION to CLINICAL PRACTICE I (ICP-III)
(MED 303)

Objectives
This course aims to equip the students with basic medical skills such as history taking regarding to systems and in general, physical and mental examination in simulated environments in pre-clinical period and to give the students opportunity to develop skills by applying invasive procedures on the manniquins before encountering with real patients.

Description
ICP is a three year longitudinal course that aims to introduce students to the concepts and main elements of medical practice. It will also be an introduction to the medical profession as a whole and will provide a foundation for clinical practice. The course provides knowledge, cognitive and motor skills and experience in fundamental processes and aspects of medical practice. It involves the application of scientific theory, quality assurance and evidence-based best practice protocols. ICP 1 has two components; in the Fall semester it starts with “First Aid” and in the Spring semester it continues with “Communication Skills in Medicine”.

Credit facility:
This course has 5 ECTS credits for the first and third year students while it is 4 ECTS for the second year students and all of the students are required to pass this course in order to pass the year.

Content of the ICP I-II-III
First year medical students learn how to take medical histories from simulated patients (SP’s) as well as basic life support and transportation and bandaging tecniques regarding to first aid. Second year students add procedural skills such as insertion of nasogastric tube, bladder catheterization, and intramuscular, subcutanous, intradermal injections, while the third year medical students use SP’s to learn their clinical skills like the physical and mental examination and add some procedural skills such as suturing techniques.
Clinical cases are created through research and extensive training of the patients portraying these roles. Each exam room is equipped with video cameras and microphones to record the encounter. An observation area at the center of the lab allows faculty and students to observe the encounters live or view digital recordings for subsequent analysis.

Clinical Skills Laboratory
The lab provides learners with the ideal setting to practice the clinical skills of history taking, physical examination, communication, and gives opportunities to practice invasive and non invasive procedural skills on manniquins.

Simulated Patients (SPs)
The simulated patient encounters provide transition of students from the classroom to standardized patient contact in safe environments. Encounters with specially trained individuals, known as simulated patients (SPs), simulate specific cases in outpatient and emergency settings. The pool of SPs consist of adults, from various backgrounds.

Assessment: The Assessment procedure of ICP, which is performed by the Objective Structured Clinical Examination (OSCE) shown under the heading “Assessment Procedure” in this Academic Program Book.

Rules for attendance of the students: Students are grouped into 4 and group lists are announced in the announcement board at the beginning of the year. Any changes to practical groups on a week by week basis, will only be considered in exceptional situations such as a medical one. Any changes must be requested by a petition along with relevant documentation to the course coordinator. Any change in sessions will only be accepted interchangibly with another student in an another group based on availability of work spaces and course coordinator's discretion (based on evidence provided).
Students are required to follow the rules of professional ethics in the lab at any time.

When an OSCE is completed both students and faculty members complete an evaluation of the event for the improvement of the course.

SPECIFIC SESSIONS/PANELS

Introductory Session

Aim of the session:
The session provides basic information about Yeditepe Medical Faculty Undergraduate Program in Medicine (YMF-GPM) and the educational phase relevant to the students. This session orients the students to the program and the phase.

Objectives of the Session:
1. To provide basic information about the YMF-GPM.
2. To provide basic information about the phase.
3. To provide essential information on social programs and facilities.

Rules of the Session:
1. The session will be held in two types, conducted by Phase Coordinator and Committee/Clerkship Coordinator, respectively.
2. The first type will be held once in the first week of the educational phase. The second type will be held at the beginning of each committee/clerkship.
3. Students should attend the session.

Implementation of the Session:
In the first type, Phase Coordinator will present brief information on the following topics:
- Organizational Chart of Yeditepe Medical Faculty Graduate Program in Medicine (YMF-GPM), Work Descriptions and Introduction of Committees/Clerkships/Members,
- Directives on YMF-GPM,
- YMF-GPM Program Outcomes
- Learning Objectives of the Phase
- Academic Program of the Phase
- Teaching and Learning Methods
- Learning Environments and Sources/Resources
- Attendance
- Elective Courses (only in Phase I)
- Assessment Procedure
- Grade Point Average (GPA, cGPA) Calculation
- Pass/Fail Conditions
- Feedback of the Previous Years and Program Improvements
- Social Programs and Facilities

In the second type, Committee/Clerkship Coordinator will present brief information on the following topics:
- Learning Objectives of the Committee/Clerkship
- Academic Program of the Committee/Clerkship
- Teaching and Learning Methods
- Learning Environments and Sources/Resources, References
- Attendance
- Assessment Methods and Question Distribution Table
- Committee/Clerkship Score Calculation Method
- Pass/Fail Conditions
- Feedback of the Previous Years and Program Improvements
- Social Programs and Facilities

Program Evaluation Session

Aim of the Session:

The aim of the session is to evaluate the committee educational program, with all its components, by the students and the committee coordinators. This session will contribute to the improvement of the curriculum in general by giving the opportunity to identify the strengths of the committee educational program and revealing the areas which need improvement.

Objectives of the Program Evaluation Session are to;

- establish a platform for oral feedbacks in addition to the systematically written feedback forms
- give the opportunity to the students and the coordinators to discuss the committee period face to face
- allow the students to review the committee exam questions together with faculty members.

Process:

The total duration of the session is 90 minutes and the session consists of three parts. In the first part (15 minutes) the students will complete the End of Committee Feedback Forms. Twice in a year also End of Midterm Questionnaires will be subjected to the same procedure. This forms have to be filled in with pencils and should be thrown in locked Feedback boxes, which will be provided by the committee coordinators. This forms should not be folded as this might cause difficulty during evaluation process. The second part (35 minutes) is dedicated to oral feedback by the students. All of the oral feedback will be recorded and reported by the committee coordination team. In the third part (40 minutes) committee exam questions will be reviewed and discussed by students and faculty.

Rules of the Program Evaluation Session:

1. The program evaluation session will be held on the last day of each committee after the assessment session.
2. Students are required to attend the session.
3. The Committee coordinator will lead the session.
4. In the third part of the session the faculty members who had questions in the committee exam should attend the session.
5. Students must comply with the feedback rules when they are giving verbal feedback and all participants shall abide by rules of professional ethics.

Program Improvement Session

Aim:

The aim of this session is sharing the program improvements based on the evaluation of the educational program data, with the students and the faculty members.

Objectives:

1. To share the improvements within educational program with the students and the faculty members.
2. To inform the students and the faculty members about the processes of the program improvement
3. To encourage student participation in the program improvement processes.

Rules:

1. Program improvements session will be implemented once a year. The implementation will be performed at the begining of the spring semester.
2. Students are required to attend the session.
3. The phase coordinator will monitor the session. If necessary the dean, vice deans and heads of the educational boards will attend to the session.
4. All faculty members will be invited to the session.

Implementation:

Before the Session

1. Phase coordinator will report the results of the improvements of the educational program.
2. The program improvements report has three parts. The first part of the report includes improvements that have been completed, and those that are currently in progress. The second part of the report includes, improvements that are planned in medium term, and the third part of the report includes, improvements that are planned in the long term.
3. The program improvements report also includes the program evaluation data (student feedbacks, faculty feedbacks, results of the educational boards meetings etc.) in use of improvements.

During the Session

4. The phase coordinator will present the program improvements report to the students and the faculty members.
5. Students can ask questions about, and discuss, the results of the program improvement.

Process: The total period of session is 30 minutes and has two parts. The first part (15 minutes) covers, presenting of the program improvement report. The second part (15 minutes) covers, students' questions and discussion.

After the Session

6. The program improvement brief will be published on the website of Yeditepe University Faculty of Medicine (http://med.yeditepe.edu.tr).

Multidisciplinary Case Discussion Panel

Aim:

The aim of this instructional method is, to integrate what students learnt during committee, to fit in the clinical context and to promote deep learning.

Objectives:

1. To relate learning objectives of the committee,
2. To relate clinical cases and learning subjects,
3. To explain learning objectives in the resolution of clinical cases,
4. To value the importantance of multidisiplinary study in the resolution of clinical cases.

Implementation:

Before the Panel

1. Case/cases that will be discussed in the panel will be chosen by a multidisiplinary team, in compliance with committee learning objectives.
2. The resources to analyse the cases will be specified by multidisiplinary team.
3. Students can get hard copies of the cases and the list of sources from student affairs at the beginning of the committee.
4. Students shall study cases in the context of learning objectives before the panel.
5. Before the panel, students may consult the faculty members for information about cases.

During the Panel

6. Cases will be shared visually with students by the multidisiplinary team.
7. Possible resolution of cases will be shared and discussed with students by the multidisiplinary team.
8. After the resolution of cases, students can ask questions to faculty members about the commitee learning obcetives in the context of cases.
   Process: The total duration of the Panel is 60 minutes and has 2 parts. The first part (40 minutes), covers the presentation of cases, resolution of cases, asking questions to students and discussion as suitable to learning objectives during the resolution by multidisiplinary team. The second part (20 minutes), covers students' questions and discussion.

After the Panel

9. Students may continue reviewing the cases in the context of committee learning objectives.
10. The multidisiplinary team will review the usefulness of cases as a learning tool in the context of committee learning objectives. "The Panel Report" will be written by the multidisiplinary team.

INDEPENDENT LEARNING

Description:

"Independent learning" is a process, a method and a philosophy of education in which a student acquires knowledge by his or her own efforts and develops the ability for inquiry and critical evaluation. It includes freedom of choice in determining one's learning objectives, within the limits of a given project or program and with the aid of a faculty adviser. It requires freedom of process to carry out the objectives, and it places increased educational responsibility on the student for the achieving of objectives and for the value of the goals (1).

Aim:

The aim of this instructional strategy is to develop the students' ability, to learn individually, so they are prepared for the classroom lessons, lectures, laboratory experiences and clinical practices, exams, professional life and have the abilities needed for lifelong learning.

Objectives:

With this instructional strategy, students will develop;

- the skills that will help them to learn independently.
- self-discipline in their work habits.
- their evidence based research skills by using reliable resources.
- their teamwork skills by studying together.
- their clinical skills as self-directed working in the clinical skills laboratory.

Rules:

1. All of the students will define independent learning process according to below algorithm.
2. All of the students will be required to fill out a form, which is a self-assessment form for the independent learning (methodology: timing, sources, strategy, etc.).
3. The students' academic performance and independent learning methodology will be analyzed comparatively, and feed-back on further improvements will be provided.

What a student should do for learning independently?

1. **Analyzing:** First you will need to analyze carefully, what your problems and weaknesses are. For example, if you are studying anatomy, is your weak area broadly upper limb, lower limb, or what?
2. **Addressing:** Once you've decided your specific problems, you can list them. Which one needs to be addressed urgently? Work out your priorities. Whatever your subject area is, don't be afraid to return to the basics if necessary. It may give you more confidence in the long run to ensure you have a proper understanding of basic concepts and techniques.
3. **Accessing:** If you need reliable information, or if you need to read about a subject and put it into context, a textbook may be the best place to start. However, the Internet may be helpful if you need very up-to-date information, specific facts, or an image or video etc. If you need an academic research article, reports or case studies for your topic, then a database (Pubmed etc.) would be the best option.
4. **Timing:** In the weekly syllabus you will see, a specific time called "independent learning hour" for your independent work. In addition to these hours, the students should also have their own time schedule for their study time at home.
5. **Planning:** Your next step will be to work out a realistic study-plan for your work. What goals could you literally set for yourself? Don't make them too ambitious but set minor goals or targets that you know you will be able to achieve without having to spend a very long time working on them. How many hours will you need to achieve them? How will you know when you've achieved them?
6. **Recording:** When you work independently, it's a good idea to keep a written record of the work you've done. This can help with further planning and also give a sense of achievement as well as provide something to include in a progress file. As time goes by you may surprise yourself with what you've been able to achieve. This could motivate you to keep going, as could increase your confidence, and even improve your results
7. **Reflecting:** Reflecting on what you've done can help you decide whether the activity was really effective, whether an alternative approach might be better on another occasion, whether you spent the right amount of time and whether you have achieved the target you'd set yourself.

8. **Improving:** Once you've achieved the target, the process of planning can start again. Your needs and priorities may have changed, so think about them and then set yourself to another target.

Reminder: For further information about the independent learning, please contact the Department of Medical Education.

Reference:

1. Candy, P. (1991) Self-direction for lifelong learning: a comprehensive guide to theory and practice. San Francisco: Jossey Bass.

For further reading useful resources to recommend to students:

- Burnapp, D. (2009). Getting Ahead as an International Student. London: Open University Press.
- Marshall, L. & Rowland, F. (1998) A Guide to learning independently. London: Open University Press.
- University of Southampton / UKCISA online resource 'Prepare for Success'

ASSESSMENT PROCEDURE

The Assessment Procedure of the Phase III covers exams and scores and their abbrevations that shown below.

- Exams:
  - Committee Exam (CE)
  - Mid-term Exam (MTE)
  - Final Exam (FE)
  - Incomplete Exam (ICE)
  - Make-up Exams (MUE)
- Scores:
  - Committee Score (CS)
  - Committees Mean Score (CMS)
  - Introduction to Clinical Practice Score (ICPS)
  - Scientific Project Score (SPS)
  - Interm Score (ITS)
  - Final Exam Score (FES)
  - Incomplete Exam Score (ICES)
  - Term Score (TS)

* All scores have a range of 0-100 points.

Assessment approaches, assessment methods and assessment tools, that related with the exam and score types, are shown in below table.

Assessment Approaches	Assessment Methods	Question Types / Assessment Tools	Exams	Derived Scores
Knowledge-based Assessment	WE: Written Examination	MCQ: Multiple Choice Questions	CE, MTE, FE, ICE	CS, ICPS, FES, ICES
		EMQ: Extended Matching Questions	CE	CS
		MEQ: Modified Essay Questions	MUE	CS
Competency–based Assessment	OSCE: Objective Structured Clinical Examination	OSCE Checklist		ICPS
Performance–based Assessment	PWPE: Project Writing and Presenting Evaluation	PWPE Checklist		SPS

Exams Information	
CE	CE consists of 90% MCQs and 10% EMQs. For the proportional correspondence of individual learning objectives, please see the committee's assessment matrix table/page.
FE	FE consists of 200 MCQs. For the proportional contribution of each committee, please see the committee's assessment matrix table/page.
ICE	ICE consists of 200 MCQs. For the proportional contribution of each committee, please see the committee's assessment matrix table/page.
MUE	MUE will be held only twice in a term. MUE content will be developed by the coordination committees.

Scores Information	
CS	The committee score is based on various question types/numbers and/or assessment tools (MCQ, EMQ, MEQ or Checklists). Please see the committee's assessment matrix table/page for the specifications.
CMS	= Average of CSs
ICPS	= (50% OSCE1) + (50% OSCE2)
SPS	= Score information is shown in below Scientific Projects Assessment Table.
ITS	= (96 % of CMS) + (4 % of SPS)
FES	= Final Exam Score
ICES	= Incomplete Exam Score
TS	= (60% of ITS) + (40% of FES or ICES)

Pass or Fail Calculations of the Courses
Introduction to Clinical Sciences (MED 302)
Pass; *TS* **≥ *50***
Fail; *FES* **< *50*** *(barrier point), ICES* **< *50*** *(barrier point), or/and TS* **< *50***
The student is exempted from FE, if the ITS is **≥ *75*** *and all CSs are* **≥ *50***
The FE and ICE barrier point is not applied to the students whose all CSs are **≥ *50***
The TS for students, who are exempted from FE, is ITS.
Introduction to Clinical Practice III (MED 303)
Pass; *ICPS* **≥ *50***
Fail; *ICPS* **< *50***

The Assessment Procedure of the Phase III will be announced and explained in the introductory session at the beginning of the academic year.

Definitions of the Assessment Methods and Question Types

MCQ consist of a question, followed by five plausible alternative responses from which the student has to select the correct one.

EMQ are similar to multiple choice questions but with one key difference, that they test knowledge in a far more applied, in depth, sense. EMQ is based on a single theme, two or more questions and has a long option list.

MEQ is made up of one or more short answer questions. The student is provided with basic science or clinical information and then asked to write brief responses to one or more questions. When a series of questions is presented, additional information about the original problem can be provided at each subsequent step, guiding the students through an analytical process.

OSCE describes a form of competency-based testing used to measure a student's clinical competence. During an OSCE, students are observed and evaluated as they go through a series of stations in which they interview, examine and treat simulated patients who present with some type of medical problem.

SCIENTIFIC PROJECTS – III

The aim of Scientific Projects program is to develop awareness in medical students for the importance of scientific projects in profession and provide them opportunity to gain knowledge, skills and attitudes in writing and conducting a scientific project. Throughout the year, each Phase Three student is expected to prepare a scientific project proposal. Students are free to choose their research area and advisor for their prospective research project. Students who wish to apply for a "TUBITAK 2209-A National Grant Program for University Students" has to send in their proposals before February 2016, the rest should hand in their proposals before the end of March. Scientific Projects course has 4% contribution to In-term Score (ITS).

SCIENTIFIC PROJECTS ASSESSMENT TABLE

CRITERIA	Unsatisfactory	Below Expectations	Meets Expectations	Above Expectations	Clearly Outstanding	Not Addressed / Observed
Is the question/ problem presented clearly?	1	2	3	4	5	0
Creativity/originality of the Project	1	2	3	4	5	0
Is set up of the Project suitable to obtain aims?	1	2	3	4	5	0
Presentation of aims in an easy to understand format	1	2	3	4	5	0
Review of project proposal in light of literature	1	2	3	4	5	0
Proposal presentation in correct format	1	2	3	4	5	0
Does proposal explain the project's significance and contributions well?	1	2	3	4	5	0
Project calendar presentation	1	2	3	4	5	0
TOTAL POINTS	**40 x 2.5=100 pts (if all criteria has 5 points)**					

Exam Rules

- **Seating-** Students will be seated by the exam observers or proctors. Students are not allowed to change their seats without permission.
- **Electronics** – During examinations or tests, students are prohibited from using electronic devices or any other means of communication and recording that have not been approved beforehand. All electronic devices are prohibited. Anyone who fails to comply with these regulations may be charged with academic fraud.
- **Absence** – No additional time will be given to students who are absent for part of the exam, regardless of the reason for their absence.
- **Scratch Paper** – Students are not allowed to bring scratch paper into the exam room.
- **Meaning of Questions** – Students may not consult the supervisor as to the meaning of any question.
- **Signature** – Students must sign their multiple-choice answer sheets and/or written-answer sheets.

- **Other activities requiring disciplinary action**-
    - Students must not give or receive assistance of any kind during the exam.
    - Gaining access to exam questions before the exam.
    - Using an unauthorized calculator or other mechanical aid that is not permitted.
    - Looking in the exam book before the signal to begin is given.
    - Marking or otherwise writing on the exam book or answer sheet before the signal to begin is given.
    - Making any changes, additions, deletions or other marking, erasing or writing on the exam book or answer sheet after the time for the exam has expired.
    - Having access to or consulting notes or books during the exam.
    - Looking at or copying from another student's paper.
    - Enabling another student to copy from one's paper.
    - Talking or otherwise communicating with another student during the exam or during the read through period.
    - Disturbing other students during the exam.
    - Consulting other persons or resources outside the exam room during the exam.
    - Copying questions or answers either on paper or with an electronic device to take from the exam room.
    - Taking an exam book or other exam materials from the exam room.
    - Taking an exam in place of another student.
    - Arranging to have another person take an exam for the student.
    - Disobeying to the conduct of supervisor during the exam.
    - Disclosing the contents of an exam to any other person.
    - Failing to remain in the exam room for a given period of time by the supervisors.
    - Failing to follow other exam instructions.

Those students found to have committed academic misconduct will face administrative sanctions imposed by the administration of Yeditepe University Faculty of Medicine according to the disciplinary rules and regulations of the Turkish Higher Education Council (YÖK) for students (published in the Official Journal on August 18th, 2012). The standard administrative sanctions include, the creation of a disciplinary record which will be checked by graduate and professional life, result in grade "F" on the assignment, exams or tests or in the class. Students may face suspension and dismissal from the Yeditepe University **for up to one school year**. In addition, student may loose any academic and non academic scholarships given by the Yeditepe University **for up to four years**. The appropriate sanctions are determined by the Yeditepe University administration according to egregiousness of the Policy violation.

COURSE LOCATIONS

COURSE CODES	COURSE NAMES	LOCATIONS
MED 302	Introduction to Clinical Sciences	**Lectures/Sessions/Panels:** Room Number: B309, Base Floor, Medical Faculty Block, Yeditepe University Campus. **Microbiology Laboratory:** Room Number: 934, 5th Floor, Medical Faculty Block, Yeditepe University Campus. **Pathology Laboratory:** Room Number: 929-930, 5th Floor, Medical Faculty Block, Yeditepe University Campus.
MED 303	Introduction to Clinical Practice	**ICP-CSL:** Room Number: 442, Base Floor, Medical Faculty Block, Yeditepe University Campus. **YH:** Yeditepe University Hospital.

Yeditepe University Campus Address: İnönü Mah. Kayışdağı Cad. 26 Ağustos Yerleşimi, 34755, Ataşehir, İstanbul.

Yeditepe University Hospital Address: İçerenköy Mah. Hastane Yolu Sok. No:102-104. Ataşehir, İstanbul.

ACADEMIC CALENDAR (2015 – 2016)

COMMITTEE I		
INFECTIOUS DISEASES (4 Weeks)		
Beginning of Committee	September 7, 2015	Monday
End of Committee	October 01, 2015	Thursday
Committee Exam	**October 02, 2015**	**Friday**
Religious Holiday	**September 23$^{1/2}$-27 2015**	**Wednesday**
COMMITTEE II		
CARDIOLOGY AND RESPIRATORY SYSTEM (7 Weeks)		
Beginning of Committee	October 05, 2015	Monday
End of Committee	November 19, 2015	Thursday
Committee Exam	**November 20, 2015**	**Friday**
National Holiday	**October 28$^{1/2}$-29, 2015**	**Wednesday -Thursday**
Commemoration of Atatürk	**November 10, 2015**	**Tuesday**
COMMITTEE III		
HEMATOPOIETIC SYSTEM (3 Weeks)		
Beginning of Committee	November 23, 2015	Monday
End of Committee	December 10, 2015	Thursday
Committee Exam	**December 11, 2015**	**Friday**
COMMITTEE IV		
GASTROINTESTINAL SYSTEM (4 Weeks)		
Beginning of Committee	December 14, 2015	Monday
End of Committee	January 06, 2016	Wednesday
Committee Exam	**January 08, 2016**	**Thursday**
OSCE I (Exam)	**February 18, 2016**	**Friday**
New Year	**January 01, 2016**	**Friday**
MIDTERM BREAK	**January 11, 2016**	**January 25, 2016**

COMMITTEE V		
ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEMS (5 Weeks)		
Beginning of Committee	January 25, 2016	Monday
End of Committee	February 25, 2016	Thursday
Committee Exam	**February 26, 2016**	**Friday**
Make-up Exam I	**February 1, 2016**	**Monday**
COMMITTEE VI		
URINARY SYSTEM (4 Weeks)		
Beginning of Committee	February 29, 2016	Monday
End of Committee	March 24, 2016	Thursday
Committee Exam	**March 25, 2016**	**Friday**
Physicians' Day	**March 14, 2016**	**Monday**
COMMITTEE VII		
NERVOUS SYSTEM and PSYCHIATRY (6 Weeks)		
Beginning of Committee	March 28, 2016	Monday
End of Committee	May 05, 2016	Thursday
Committee Exam	**May 06, 2016**	**Friday**
COMMITTEE VIII		
MUSCULOSKELETAL SYSTEM (4 Weeks)		
Beginning of Committee	May 09, 2016	Monday
End of Committee	June 02, 2016	Thursday
Committee Exam	**June 03, 2016**	**Friday**
OSCE II (Exam)	**June 06, 2016**	**Monday**
Make-up Exam II	**June 13, 2016**	**Monday**
National Holiday	**May 19, 2016**	**Thursday**
Final Exam	June 24, 2016	Friday
Incomplete Exam	July 20, 2016	Wednesday
1. Coordination Committee Meeting	October 22, 2015	Thursday
2. Coordination Committee Meeting	January 07, 2016	Thursday
3. Coordination Committee Meeting	May 12, 2016	Thursday
4. Coordination Committee Meeting	July 14, 2016	Thursday

RECOMMENDED TEXTBOOKS

Biomedical Ethics & Deontology

1. Marcia Lewis , Carol D. Tamparo. Medical Law, Ethics, & Bioethics for the Health Professions, F.A. Davis Publishing House, 2012, ISBN: 0803627068
2. Michael Boylan. Medical Ethics, Wiley-Blackwell Publishing House, 2013, ISBN: 978-1118494752

Bioistatistics

1. Pagano, Marcello, Gauvreau, Kimberlee. Principles of Biostatistics. Duxbury Press, 2000 ISBN 0534229026, 9780534229023.

2. Glantz, Stanton A. Primer of Biostatistics. 7th Edition. McGraw Hill Professional, 2011. ISBN 0071447814, 9780071447812.

Infectious Diseases and Clinical Microbiology

1. Murray, Patrick R, Rosenthal, Ken S, Pfaller, Michael A.. Medical Microbiology with STUDENT CONSULT Online Access. 7th Edition, 2012, ISBN-10: 0323086926, ISBN-13: 978-0323086929.

Medical Genetics

1. Turnpenny, Peter D, Ellard, Sian. Emery's Elements of Medical Genetics. 14th Edition. Churchill Livingstone, 2012, ISBN: 9780702040436

Neurosurgery

1. Microneurosurgery, Volume I to VolumeV, Thieme Kindle Edition by Mahmut Gazi Yasargil (Author)
2. Neurology and Neurosurgery Illustrated,5th Edition by Kenneth W. Lindsay PhD FRCS (Author), Ian Bone FRCP FACP (Author), Geraint Fuller MD FRCP (Author)
3. Handbook of NeurosurgeryFeb 22, 2010 by Mark S. Greenberg

Pharmacology

1. Harvey, Richard A. Lippincott's Illustrated Review of Pharmacology. , Wolters Kluwer Health, 2012. ISBN-13: 978-1451113143; ISBN-10: 1451113145
2. Katzung, Bertram G., Masters, Susan B., Trevor Anthony J. Katzung's Basic & Clinical Pharmacology. 12th Edition. McGraw Hill Companies, 2012. ISBN-13: 978-0071825054; ISBN-10: 0071825053.
3. Brunton, Laurence, Chabner, Bruce, Knollman, Bjorn. Goodman&Gilman's The Pharmacological Basis of Therapeutics. Editors: 12th Edition. McGraw Hill Companies, 2011. ISBN-13: 978-0071624428

Orthopedic Surgery

1. Ortopedik Fizik Muayane, çeviri ed. Uğur Şaylı, Güneş Tıp Kitapevi
2. Review of Orthopaedics, 6th edition (ed. Mark D. Miller)
3. AAOS Comprehensive Orthopaedic Review, 2nd edition (ed. Martin I. Boyer)

Pathology

1. Abbas Aster, Kumar. Robbıns Basıc Pathology. 9th edition, Saunders, Elsevıer Inc. 2013. ISBN:978-0-8089-2432-6

Psychiatry

1. Öztürk O. Ruh Sağlığı ve Bozuklukları. 2. Baskı, Ankara 2011. ISBN: 9786058617292
2. Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 9. Ed. 2009, Lippincott Williams & Wilkins, PA, USA. ISBN: 9780781768993
3. Purves D, Augustine GJ. Fitzpatrick D. et al. Neuroscience. 5. Ed. 2012, Sinauer Assoc, Mass, USA. ISBN: 9780878936953

Surgery

1. Brunicardi, F. Schwartz's Principles of Surgery, 10th edition, July 16, 2014, ISBN: 0071796754 / 9780071796750

Urology

1. Campbell-Walsh Urology, 11th Edition 4-Volume Set. By Alan J. Wein, MD, FACS, PhD (hon), Louis R. Kavoussi, MD, Alan W. Partin, MD, PhD and Craig A. Peters, MD, FACS, FAAP. Imprint: Elsevier. ISBN: 978-1-4557-7567-5. Copyright: 2016

COMMITTEES

In phase I, II and III, the formation of committees is based on a thematic structure. This structure corresponds to organizational levels of human body such that macromolecule, organelle, cell, tissue, organ systems and finally introduction to pathogenesis.

- Phase I: Normal structure and function of human body at molecular, cellular, tissue and organ level.
- Phase II: Normal structure and function of human body at system and multi-system level, and introduction to pathogenesis.
- Phase III: Physiopathological and pathological processes in human body.

Besides this thematic structure, there is a continuous clinical skills education in Phase I, II and III, as “Introduction to Clinical Practice -I, -II and -III” courses.

Therefore, the core medical courses are;

- Phase I: MED 104 Basic Medical Sciences I, MED 102 Introduction to Clinical Practice I, MED 103 Anatomical Drawing,
- Phase II: MED 201 Basic Medical Sciences II, MED 202 Introduction to Clinical Practice II,
- Phase III: MED 302 Introduction to Clinical Sciences, MED 303 Introduction to Clinical Practice III.

The learning objectives of the phase include learning objectives of core courses. The learning objectives of committees include learning objectives of core courses’ components for the committee.

COMMITTEE I - INFECTIOUS DISEASES

DISTRIBUTION of LECTURE HOURS

September 07, 2015 - October 02, 2015

COMMITTEE DURATION: 4 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY	IDCM	16		2 (4 Groups)		**18**
	PHARMACOLOGY	PC	15				**15**
	PATHOLOGY	PT	8				**8**
	PUBLIC HEALTH	PH	8				**8**
	BIOMEDICAL ETHICS & DEONTOLOGY	BED	8				**8**
	BIOSTATISTICS	BS	2			2	**4**
	INTERNAL MEDICINE	IM	2				**2**
	PATHOPHYSIOLOGY	PP	2				**2**
	FAMILY MEDICINE	FM	3				**3**
	MEDICAL GENETICS	MG	2				**2**
	EMERGENCY MEDICINE	EM	1				**1**
	PEDIATRICS	PED	1				**1**
	SCIENTIFIC PROJECTS-III	SP	1				**1**
	INTERDISCIPLINARY	MCDP				2	**2**
MED 303	**INTRODUCTION TO CLINICAL PRACTICE III**	ICP III			3 (4 Groups)		**3**
TOTAL			**69**		**5**	**2**	**76**

Coordination Committee

HEAD	Gülden Çelik, MD, Prof.
SECRETARY	Yeşim Gürol, MD, Assoc. Prof.
MEMBER	Meral Sönmezoğlu, MD, Prof.
MEMBER	Işın D. Ekici, MD, Prof.

COMMITTEE I - INFECTIOUS DISEASES
LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY	Gülden Çelik, MD, Prof. Meral Sönmezoğlu, MD, Prof. Yeşim Gürol, MD, Assoc. Prof. İ. Çağatay Acuner, MD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Ferda Kaleağasıoğlu, MD, Assoc.Prof.
INTERNAL MEDICINE	Yaşar Küçükardalı, MD. Prof.
PATHOLOGY	Ferda Özkan, MD, Prof. Işın Doğan Ekici, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, PhD, Assoc. Prof.
PEDIATRICS	Defne Çöl, MD, Assist. Prof.
PUBLIC HEALTH	Erol Sezer, MD, Prof Hale Arık Taşyıkan, MD, Assist. Prof
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc.Prof. Özlem Tanrıöver, MD, Assoc.Prof.
CLINICAL SKILLS LAB	Sezgin Sarıkaya, MD, Assoc. Prof. Mustafa Ferudun Çelikmen, MD, Assist Prof.
EMERGENCY MEDICINE	Mustafa Ferudun Çelikmen, MD, Assist Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu, MD Assist. Prof.
BIOISTATISTICS	Çiğdem Kaspar, PhD, Assist. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, PhD, Assist. Prof.
SCIENTIFIC PROJECTS-III	Gülderen Yanıkkaya Demirel, MD, PhD, Assoc. Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Sezgin Sarıkaya, MD, Assoc. Prof. Mustafa Ferudun Çelikmen, MD, Assist Prof.

COMMITTEE I - INFECTIOUS DISEASES
AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on structures of agents that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
2. ***to convey*** knowledge on epidemiology of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
3. ***to convey*** knowledge on pathogenesis mechanisms of agents that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
4. ***to convey*** necessary knowledge on prevention of infectious clinical conditions, and protection or improvement of health against these conditions,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing infectious clinical conditions, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** necessary knowledge on pharmacology of drugs used in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
8. ***to convey*** necessary knowledge on ethical problems encountered in health care service and utilization, and on principles of solutions,
9. ***to convey*** biostatistical knowledge required in design of medical research,
10. ***to convey*** necessary knowledge on genetical basis of clinical conditions,
11. ***to equip with*** basic clinical skills, (intravenous injection on phantom model), required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0. ***explain*** basic characteristics of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
2.1. ***recall*** structures, and
2.2. ***explain*** mechanisms of pathogenesis of agents (bacteria, viruses, fungi, parasites, prions) that cause infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,
3.0. ***classify*** infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, based on causative agents and systems,
4.0. ***explain*** mechanisms of change in structure and function at molecular, cellular, tissue, system, multi-system and organismal levels in infectious clinical conditions which are frequent in community

and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

5.0. ***explain*** mechanisms of host immune response to and consequences in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

6.0. ***explain*** epidemiology of infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

7.0. ***explain*** requirements for prevention of infectious clinical conditions, and protection or improvement of health against these conditions, in healthy or susceptible individual or community,

8.0. ***explain*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

9.0. at multi-system level or related to a body system,

- for healthy conditions in an individual or community with a request against infectious clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices which are required for management at primary health care service level:

9.1. practice of history taking and physical examination

9.2. evaluation of emergency case (sepsis and septic shock-C1)

9.3. approach to healthy individual or patient (fever-C1)

9.4. laboratory tests/examinations (urine sample collection-C1, urine strip/dipstick test-C1, urine culture-C1)

9.5. imaging tests/examinations (nuclear medicine tests in infectious diseases-C1)

9.6. point of care testing (urine strip/dipstick test-C1)

9.7. making preliminary diagnosis or definitive diagnosis decision

9.8. making non-intervention or intervention decision

9.9. practicing non-intervention or intervention

9.10. referral/transport of healthy individual or patient

10.1.***list*** goals and principles of drug use,

10.2.***describe*** effects,

10.3.***explain*** mechanism of action (pharmacodynamics),

10.4.***list*** indications, contraindications, pharmacological features, pharmacokinetic characteristics, drug-drug inreactions and side effects,

10.5.***explain*** resistance mechanisms of drugs (principles of antimicrobial chemotherapy, antibacterial, antifungal, antiviral, antiprotozoal, antihelmintic drugs, antiseptics and disinfectants) used in infectious clinical conditions,

11.0. ***explain*** interactions of health conditions (healthy and clinical conditions) at individual, family and community levels in relation to infectious agents, and importance of infectious agents and infectious clinical conditions from the aspect of public health,

12.0.***define*** approaches (education, santitation, hygiene, disinfection/antisepsis/sterilization, screening, surveillance, vaccination, prophylaxis, isolation, design/renovation) to control risks in infectious clinical conditions which are frequent in community and/or pose high risk for individual or community health,

14.0. ***explain*** hereditary immune system disorders,

15.0.***explain*** ethical problems (violation of truthfulness, responsibilities of physician and patient, allocation of scarce resources) encountered in health care service and utilization, and principles of solutions,

16.0. ***define*** biostatistical knowledge required in design of medical research (research design, planning medical research,

17.0. ***perform*** basic clinical skills, practiced on phantom models (intravenous injection-C1), required at primary health care service level.

18.0.***explain*** ethical problems (violation of truthfulness, responsibilities of physician and patient, allocation of scarce resources) encountered in health care service and utilization, and principles of solutions,

19.0. ***define*** biostatistical knowledge required in design of medical research (research design, planning medical research,

20.0. ***perform*** basic clinical skills, practiced on phantom models (intravenous injection-C1), required at primary health care service level.

COMMITTEE I - INFECTIOUS DISEASES
COMMITTEE ASSESSMENT MATRIX

LEARNING OBJECTIVES	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of MCQs			
			CE	FE	IE	TOTAL
1.0, 2.0.,3.0. (4.0.-12.0.)	IDCM	G. Çelik	24	6	6	**36**
1.0.,3.0. (4.0.-12.0.)		M. Sönmezoglu				
9.4.		Y. Gürol				
4.0.,5.0.	PT	F. Özkan	10	2	2	**14**
4.0.,5.0.		I. D. Ekici				
4.0.,5.0.,8.0.	PP	M. Kaçar	3	1	1	**5**
6.0.,7.0.,11.0.,12.0.	PH	R.E. Sezer	10	2	2	**14**
6.0.,7.0.,11.0.,12.0.		H.A.Taşyıkan				
8.0.,9.0., 9.1.	IM	Y. Küçükardalı	3	1	1	**5**
8.0.,9.0., 9.1.	PED	D. Çöl	1	0	0	**1**
9.2.	EM	F. Çelikmen	1	0	0	**1**
9.3. (6.0.-9.0.,11.0.,12.0.)	FM	Ö. Tanrıöver	2	2	2	**6**
9.3. (6.0.-9.0.,11.0.,12.0.)		G. Izbırak				
10.0.	PC	E.Genç	20	5	5	**30**
10.0.		F.Kaleağasıoğlu				
14.0.	MG	A. Ç. Kuskucu	3	2	2	**7**
15.0.	BED	E. Vatanoglu	8	3	3	**14**
16.0.	BS	Ç. Kaspar	5	1	1	**7**
		TOTAL	**90**	**25/200****	**25/200****	**140**

LEARNING OBJECTIVES	DISCIPLINE	LECTURER/INSTRUCTOR	NUMBER of EMQs			TOTAL
1.0, 2.0.,3.0. (4.0.-12.0.)	IDCM	G. Çelik / M. Sönmezoglu	2	-	-	**2**
10.0.	PC	E. Genç / F. Kaleağasıoğlu	2	-	-	**2**
4.0.,5.0.	PT	F. Özkan / I. D. Ekici	1	-	-	**1**
		TOTAL	**5**	-	-	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 points**
*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.
MCQ: Multiple Choice Question
EMQ: Extending Matching Question
CE: Committee Exam
CS: Committee Score
FE: Final Exam
ICE: Incomplete Exam
pts: Points
****25** out of 200 FE and ICE MCQs will be from Committee I (Each question is of worth **0.5** pts).

COMMITTEE I - INFECTIOUS DISEASES
WEEK I / 7-11 Sep 2015

	Monday 7-Sep-2015	Tuesday 8-Sep-2015	Wednesday 9-Sep-2015	Thursday 10-Sep-2015	Friday 11-Sep-2015
09.00- 09.50	**Introductory Session** Introduction to Phase III Phase III Coordination Committee Introduction to Committee I Head of Committee	**Lecture** Public Health and Communicable Diseases-I R.E.Sezer	**Lecture** Prevention and Control of Communicable Diseases I R.E. Sezer	**Independent Learning**	**Lecture** Introduction to Clinical Genetics A. Ç. Kuşkucu
10.00- 10.50	**Lecture** Diagnosis of Infectious Diseases I G. Çelik	**Lecture** Public Health and Communicable Diseases-II R.E.Sezer	**Lecture** Prevention and Control of Communicable Diseases II R.E. Sezer		**Lecture** Inherited Immune System Disorders A. Ç. Kuşkucu
11.00- 11.50	**Lecture** Diagnosis of Infectious Diseases II G. Çelik	**Lecture** Introduction to the Course I E.Vatanoğlu	**Lecture** Epidemiology of Communicable Diseases I H.A.Taşyıkan		**Lecture** Pathology of Bacterial Infections F. Özkan
12.00- 12.50	**Lecture** Pathophysiology of Infectious Diseases I M. Kaçar	**Lecture** Introduction to the Course II E.Vatanoğlu	**Lecture** Epidemiology of Communicable Diseases II H.A.Taşyıkan		**Lecture** Pathology of Mycobacterial Infections I F. Özkan
12.50 - 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Pathophysiology of Infectious Diseases II M. Kaçar	**Lecture** Planning Medical Studies I Ç. Kaspar	**Lecture** Confidentiality and Truthfulness I E. Vatanoğlu	**Lecture** Physician-Patient Relationship I E.Vatanoğlu	**Lecture** Introduction to Antimicrobial Chemotherapy F. Kaleağasıoğlu
15.00- 15.50	**Lecture** Semiology-I Y. Küçükardalı	**Lecture** Planning Medical Studies II Ç. Kaspar	**Lecture** Confidentiality and Truthfulness II E. Vatanoğlu	**Lecture** Physician-Patient Relationship II E.Vatanoğlu	**Lecture** ß Lactam Antibiotics I F. Kaleağasıoğlu
16.00- 16.50	**Lecture** Semiology-II Y. Küçükardalı	**Lecture** Scientific Projects - III: Project Writing G. Yanıkkaya Demirel	**Lecture** Research Design I Ç. Kaspar	**Lecture** Investigation of a Disease Outbreak or Epidemic I H.A.Taşyıkan	**Lecture** ß Lactam Antibiotics II F. Kaleağasıoğlu
17.00-17.50	**Independent Learning**	**Independent Learning**	**Lecture** Research Design II Ç. Kaspar	**Lecture** Investigation of a Disease Outbreak or Epidemic I H.A.Taşyıkan	**Independent Learning**

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE I - INFECTIOUS DISEASES
WEEK II / 14-18 Sep 2015

	Monday 14-Sep-2015	Tuesday 15-Sep-2015	Wednesday 16-Sep-2015	Thursday 17-Sep-2015	Friday 18-Sep-2015
09.00- 09.50	**Lecture** Tissue Response to Infections I. D. Ekici	**Lecture** Tuberculosis & Other Mycobacterial Infections I İ.Ç. Acuner	**Lecture** Pathology of the Parasitic Infections F. Özkan	**Independent Learning**	**Lecture** Bacterial and Viral Skin & Soft Tissue Infections M. Sönmezoğlu
10.00- 10.50	**Lecture** Pathology of Mycobacterial Infections II I. D. Ekici	**Lecture** Tuberculosis & Other Mycobacterial Infections II M. Sönmezoğlu	**Lecture** Pathology of Fungal Infections F. Özkan		**Lecture** Parasitic Infections II M. Sönmezoğlu
11.00- 11.50	**Lecture** Other Cell Wall Inhibitors F. Kaleağasıoğlu	**Lecture** Antimycobacterial Drugs E.Genç	**Lecture** Fungal and Parasitic Skin and Soft Tissue Infections Y. Gürol		**Lecture** Hospital Infection M. Sönmezoğlu
12.00- 12.50	**Lecture** Macrolides F. Kaleağasıoğlu	**Lecture** Pathology of Viral Infections I I. D. Ekici	**Lecture** Parasitic Infections I Y. Gürol		**Lecture** Febril Neutropenia M. Sönmezoğlu
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Aminoglycosides E.Genç	**Lecture** Pathology of Viral Infections II I. D. Ekici	**ICP-CSL** (Intravenous Injection & iv Cannulation) S.Sarıkaya/P. Tura/M.F. Çelikmen	**Lecture** Zoonotic Diseases I M. Sönmezoğlu	**Lecture** Antiprotozoal Drugs F. Kaleağasıoğlu
15.00- 15.50	**Lecture** Sulfonamides, Chloramphenicol & Tetracyclines E.Genç	**Lecture** Principles of Autonomy and Informed Consent I E. Vatanoğlu	**Group A IL** / **Group B** / **Group C IL** / **Group D IL**	**Lecture** Zoonotic Diseases II M. Sönmezoğlu	**Lecture** Antimalarial Drugs F. Kaleağasıoğlu
16.00- 16.50	**Lecture** Quinolones F. Kaleağasıoğlu	**Lecture** Principles of Autonomy and Informed Consent II E. Vatanoğlu		**Lecture** Anthelminthic Drugs F. Kaleağasıoğlu	**Independent Learning**
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**

COMMITTEE I - INFECTIOUS DISEASES
WEEK III / 21-25 Sep 2015

	Monday 21-Sep-2015	Tuesday 22-Sep-2015	Wednesday 23-Sep-2015	Thursday 24-Sep-2015	Friday 25-Sep-2015
09.00- 09.50	**Lecture** Antiviral Drugs F. Kaleağasıoğlu	**Lecture** Infections in Immuncompromised Host G. Çelik	**Independent Learning**	**Religious Holiday**	**Religious Holiday**
10.00- 10.50	**Lecture** Antifungal Drugs F. Kaleağasıoğlu	**Lecture** Vaccines G. Çelik			
11.00- 11.50	**Lecture** Occupational Health Hazards I G. Çelik	**Lecture** Antiseptics and Disinfectants F. Kaleağasıoğlu			
12.00- 12.50	**Lecture** Occupational Health Hazards II G. Çelik	**Lecture** Approach to the Pediatric Patient with Fever D. Çöl			
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**ICP-CSL** (Intravenous Injection & iv Cannulation) S.Sarıkaya/P. Tura/M.F. Çelikmen	**Lecture** Approach to the Patient with Fever in Primary Care Ö. Tanrıöver	**Religious Holiday**	**Religious Holiday**	**Religious Holiday**
15.00- 15.50	**Group A** / **Group B IL** / **Group C IL** / **Group D IL**	**Lecture** Emergency Evaluation of Sepsis and Septic Shock M. F. Çelikmen			
16.00- 16.50		**Multidisciplinary Case Discussion Panel**			
17.00-17.50	**Independent Learning**	**Multidisciplinary Case Discussion Panel**			

COMMITTEE I - INFECTIOUS DISEASES

WEEK IV / 28 Sep-2 Oct 2015

	Monday 28-Sep-2015	Tuesday 29-Sep-2015	Wednesday 30-Sep-2015	Thursday 1-Oct-2015	Friday 2-Oct-2015
09.00- 09.50	**ICP-CSL** (Intravenous Injection& iv Cannulation) S.Sarıkaya/P. Tura/ M.F.Çelikmen	**ICP-CSL** (Intravenous Injection& iv Cannulation) S.Sarıkaya/P. Tura/M.F. Çelikmen	**Independent Learning**	**Independent Learning**	**Independent Learning**
10.00- 10.50	**Group A IL** / **Group B IL** / **Group C** / **Group D IL**	**Group A IL** / **Group B IL** / **Group C IL** / **Group D**			**COMMITTEE EXAM**
11.00- 11.50					
12.00- 12.50	**Lecture** Introduction to the Program of Family Medicine G. İzbırak	**Independent Learning**			
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Group A** **Microbiology Laboratory** (Techniques and Diagnostic Tests) İ.Ç.Acuner/ Y.Gurol/G.Çelik	**Microbiology Laboratory** (Techniques and Diagnostic Tests) İ.Ç.Acuner/ Y.Gurol/G.Çelik	**Independent Learning**	**Independent Learning**	**Program Evaluation Session** Committee I Coordination Committee Members
15.00- 15.50	**Group B IL** / **Group A IL** / **Group C IL** / **Group D IL**	**Group C** / **Group D IL** / **Group A IL** / **Group B IL** / **Group C IL**			**Independent Learning**
16.00- 16.50	**Group B** / **Group D**	**Group D**			
17.00-17.50	**Independent Learning**	**Independent Learning**			

COMMITTEE II - CARDIOVASCULAR & RESPIRATORY SYSTEMS

DISTRIBUTION of LECTURE HOURS
October 5, 2015 – November 20, 2015
COMMITTEE DURATION: 7 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	PHARMACOLOGY	PC	25				**25**
	PATHOLOGY	PT	24	1x3=3 (2 Groups)			**27**
	CHEST MEDICINE	CHM	17			1x1=1	**18**
	CARDIOLOGY	CRD	14				**14**
	PUBLIC HEALTH	PH	9				**9**
	BIOMEDICAL ETHICS & DEONTOLOGY	BED	9				**9**
	PATHOPHYSIOLOGY	PP	6				**6**
	INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	5				**5**
	ENT DISEASES	ENT	4				**4**
	THORACIC SURGERY	TS	3				**3**
	FAMILY MEDICINE	FM	3				**3**
	MEDICAL GENETICS	MG	2				**2**
	BIOISTATISTICS	BS	2			1x2=2	**4**
	PEDIATRICS	PED	2				**2**
	RADIOLOGY	RAD	1				**1**
	EMERGENCY MEDICINE	EM	1				**1**
	SCIENTIFIC PROJECTS-III	SP	1				**1**
	INTERDISCIPLINARY	MCDP				2	**2**
MED 303	**INTRODUCTION TO CLINICAL PRACTICE III**	ICP III			2x3=6 (4 Groups)		**6**
TOTAL			**128**	**3**	**6**	**5**	**142**

Coordination Committee

HEAD	Sevda Özdoğan, MD, Prof.
SECRETARY	Zekeriya Küçükdurmaz, MD, Assoc. Prof
MEMBER	Ferda Kaleağasıoğlu, MD, Assoc. Prof. Dr
MEMBER	Işın D. Ekici, MD, Prof

COMMITTEE II - CARDIOVASCULAR & RESPIRATORY SYSTEMS LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
CARDIOLOGY	Muzaffer Değertekin, MD, Prof. Zekeriya Küçükdurmaz, MD, Assoc. Prof. Olcay Özveren, MD, Assist. Prof.
CHEST MEDICINE	Emine Sevda Özdoğan, MD, Prof.
THORACIC SURGERY	Sina Ercan, MD, Prof.
PATHOLOGY	Ferda Özkan, MD Prof. Işın Doğan Ekici, MD Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, PhD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Ferda Kaleağasıoğlu MD, Assoc. Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof. Hale Arık Taşyıkan, MD, Assist. Prof.
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc.Prof. Özlem Tanrıöver, MD, Assoc.Prof.
PEDIATRICS	Hülya Sarıçoban, MD, Assoc. Prof. Defne Çöl, MD Assist. Prof.
RADIOLOGY	Ali Özgen, MD Assist.Prof.
EAR- NOSE -THROAT (ENT)	Yavuz Selim Pata, MD Prof. Müzeyyen Doğan, MD Assoc. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Gülden Çelik, MD Prof. Meral Sönmezoğlu, MD Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu, MD, Assoc. Prof
EMERGENCY MEDICINE	Mustafa Ferudun Çelikmen, MD, Assist.Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD, Assist. Prof
SCIENTIFIC PROJECTS- III	Gülderen Yanıkkaya Demirel, MD, PhD, Assoc. Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Zekeriya Küçükdurmaz, MD, Assoc. Prof Olcay Özveren, MD, Assist. Prof. Serdar Özdemir, MD, Assist. Prof. Ferdi Menda MD, Assoc.Prof. Sevgi Bilgen, MD, Assist. Prof

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of cardiovascular and respiratory systems,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to cardiovascular and respiratory systems,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
6. ***to convey*** necessary knowledge together **with performance measures** on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to cardiovascular and respiratory systems, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, **at the level of primary health care service,**
7. ***to convey*** knowledge on principles of prescription,
8. ***to convey*** necessary knowledge on pharmacology of drugs effective on cardiovascular system,
9. ***to convey*** necessary knowledge on radiation physics and biology and its use in oncology,
10. ***to convey*** necessary knowledge on ethical problems encountered in health care service and utilization, and on principles of solutions,
11. ***to convey*** knowledge on principles of biostatistical analysis,
12. **to equip with basic and advanced clinical skills** (advanced cardiac life support-C2, approach to patient with cardiovascular clinical condition-C2) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.***recall*** anatomy, histology and physiology of cardiovascular and respiratory systems,

2.***explain*** etiopathogenesis of clinical conditions (*upper respiratory tract problems -nasal obstruction, etc.-, infectious clinical conditions with upper and lower respiratory tract and lung involvement -pneumonia, tuberculosis, etc.-, circulatory lung disorders -pulmonary embolism, etc.-, obstructive/restrictive lung diseases, respiratory insuffiency, tobacco use, lung tumors,other lung diseases; diseases of coronary circulation and coronary arteries, diseases of cardiac valves, myocardial and pericardial diseases, blood stream infections and sepsis, cardiac problems in adults and children, mediastinal diseases, nasopharyngeal and oropharyngeal diseases, nasal and paranasal sinus diseases, diseases of middle ear and eustachian tube, laryngeal diseases, voice disorders*) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,

3.***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,

4.***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to cardiovascular and respiratory systems,

5.***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,

6.at multi-system level and/or related to cardiovascular and respiratory systems,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes, health care processes, clinical decision making process, clinical decisions and clinical practices

- which are required for management at primary health care service level:

6.1. practice of history taking and physical examination (cardiovascular-C2, pulmonary-C2)

6.2. evaluation of emergency case (dyspnea-C2)

6.3. approach to healthy individual or patient (cardiovascular disease-C2, chest pain-C2, cough and hemoptysis-C2, dyspnea-C2)

6.4. laboratory tests/examinations (cardiac markers-, coagulation tests-, blood gases-, pulmonary function tests-C2)

6.5. imaging tests/examinations (radionuclide ventriculography-C2, myocardial scintigraphy-C2, cardiac PET-C2, ventilation/perfusion scintigraphyi-C2, PET in lung cancer-C2)

6.6. point of care testing (urine strip/dipstick test-C1)

6.7. making preliminary diagnosis or definitive diagnosis decision

6.8. making non-intervention or intervention decision

6.9. practicing non-intervention or intervention

6.10. referral/transport of healthy individual or patient

7.***define*** radiation physics, biology and its use in oncology,

8.***explain*** implementation of hypertension treatment guidelines,

9.***explain*** pharmacology of drugs effective on cardiovascular system (autonomic system pharmacology, renin-angiotensin system pharmacology, calcium channel blockers, pharmacological approach to ischemic and congestive cardiovascular conditions, drugs effecting body fluids and volume, anti-hypertension drugs, hypolipidemic drugs, antiarrhythmic drugs, antiplatelet, antithrombotic and thrombolytic drugs, drugs used in the treatment of asthma and chronic obstructive pulmonary disease, antitussive, expectorant and surfactant drugs),

10.***explain*** ethical problems (rejection of treatment, organ transplantation, paternalism, reproductive and negative rights),

11.***explain*** principles of biostatistical analysis,

12.***perform*** basic clinical skills, practiced on phantom models (advanced cardiac life support-C2), and advanced clinical skills, practiced on simulated/standardized patients (approach to patient with cardiovascular clinical condition-C2), required at primary health care service.96

COMMITTEE II - CARDIOVASCULAR and RESPIRATORY SYSTEMS
COMMITTEE ASSESSMENT MATRIX

LEARNING OBJECTIVES	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of MCQs			
			CE	FE	IE	Total
1.0.,2.0.	PT	F. Özkan	18	5	5	**28**
1.0.,2.0.		I D. Ekici				
1.0.,2.0.,5.0.,6.0.	ENT	M. Dogan	2	0	0	**2**
1.0.,2.0.,5.0.,6.0.		Y. S. Pata				
1.0.,2.0.,5.0.,6.0.	PED	H. Sarıçoban	3	0	0	**3**
1.0.,2.0.,5.0.,6.0.		D. Çöl				
1.0.,2.0.,5.0.,6.0.	TS	S. Ercan	2	0	0	**2**
1.0.,2.0.,5.0.,6.0.6.4.	CRD	M.Degertekin	12	4	4	**20**
1.0.,2.0., 5.0., 6.0.6.1.,6.3.		Z.Küçükdurmaz				
1.0.,2.0.,5.0.,6.0.6.4.		O. Özveren				
1.0.,2.0.,5.0.,6.0.,6.1.,6.4.,6.5.,6.6.	CHM	S. Özdogan	10	3	3	**16**
2.0.,5.0.	MG	A.Ç. Kuskucu	2	0	0	**2**
2.0.,5.0.	PP	M. Kaçar	3	1	1	**5**
2.0.,5.0.,6.0.	IDCM	M. Sönmezoğlu	3	1	1	**5**
2.0.,5.0.,6.4.		G Çelik				
3.0.,4.0.	PH	R.E. Sezer	5	2	2	**9**
3.0.,4.0.		H.A.Taşyıkan				
6.2.	EM	F. Çelikmen	1	0	0	**1**
6.3.	FM	G.Izbırak	2	0	0	**2**
6.3.		Ö. Tanrıöver				
6.5.	RAD	A.Özgen	1	0	0	**1**
8.0.,9.0.	PC	F.Kaleağasıoğlu	18	7	7	**33**
9.0.		E. Genç				
10.0.	BED	E. Vatanoglu	5	2	2	**9**
11.0.	BS	Ç. Kaspar	3	1	1	**5**
		TOTAL	**90**	**26/200****	**26/200****	**142**

LEARNING OBJECTIVES	DISCIPLINE	LECTURER/INSTRUCTOR	NUMBER of EMQs			TOTAL
1.0.,2.0.,5.0.,6.0.,6.1.,6.4.,6.5.,6.6.	CHM	S. Özdogan	2	-	-	2
1.0.,2.0.,5.0.,6.0.,6.3.,6.4.	CRD	Z. Küçükdurmaz	2	-	-	2
8.0.,9.0.	PC	F. Kaleağasıoğlu	1	-	-	1
		TOTAL	**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 points**

*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

MCQ: Multiple Choice Question

EMQ: Extending Matching Question

CE: Committee Exam

CS: Committee Score

FE: Final Exam

ICE: Incomplete Exam

pts: Points

****26** out of 200 FE and ICE MCQs will be from Committee II (Each question is of worth **0.5** pts).

COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS
WEEK I / 5-9 Oct 2015

	Monday 5-Oct-2015	Tuesday 6-Oct-2015	Wednesday 7-Oct-2015	Thursday 8-Oct-2015	Friday 9-Oct-2015
09.00- 09.50	**Introductory Session** Introduction to Commitee II Head of Commitee	**Lecture** Examination of the Heart M. Değertekin	**Lecture** Electrocardiography I Z. Küçükdurmaz	**Independent Learning**	**Lecture** General Signs and Principal Symptoms in Cardiovascular System Diseases O.Özveren
10.00- 10.50	**Lecture** Pathophysiology of Cardiovascular System Disorders I M. Kaçar	**Lecture** Coronary Artery Disease I M. Değertekin	**Lecture** Electrocardiography II Z. Küçükdurmaz		**Lecture** Congestive Heart Failure I O.Özveren
11.00- 11.50	**Lecture** Pathophysiology of Cardiovascular System Disorders II M. Kaçar	**Lecture** Coronary Artery Disease II M. Değertekin	**Lecture** Acetylcholine and Directly Acting Parasympathomimetic Drugs E. Genç		**Lecture** Congestive Heart Failure II O.Özveren
12.00- 12.50	**Lecture** Pathophysiology of Cardiovascular System Disorders III M. Kaçar	**Lecture** Introduction to Autonomic System Pharmacology E. Genç	**Lecture** Acetylcholinesterase Inhibitors E. Genç		**Independent Learning**
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Epidemiology and Prevention of Cardiovascular Diseases I H.A.Taşyıkan	**Lecture** Principles of Beneficence and Nonmaleficence I E.Vatanoğlu	**Lecture** Preparing to Analyse Data I Ç.Kaspar	**Lecture** Approach to the Patient with Cardiovascular System Diseases Z. Küçükdurmaz	**Lecture** Congestive Heart Failure F. Özkan
15.00- 15.50	**Lecture** Epidemiology and Prevention of Cardiovascular Diseases II H.A.Taşyıkan	**Lecture** Principles of Beneficence and Nonmaleficence II E.Vatanoğlu	**Lecture** Preparing to Analyse Data II Ç.Kaspar	**Lecture** Cardiac Arrhythmias I Z. Küçükdurmaz	**Lecture** Congestive Heart Failure & Pericardium F. Özkan
16.00- 16.50	**Lecture** Epidemiology and Prevention of Cardiovascular Diseases III H.A.Taşyıkan	**Lecture** End of Life Decisions I E. Vatanoğlu	**Lecture** Pharmacology of ReninAngiotensin System F. Kaleağasıoğlu	**Lecture** Cardiac Arrhythmias II Z. Küçükdurmaz	**Lecture** Myocardium F. Özkan
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS
WEEK II / 12-16 Oct 2015

	Monday 12-Oct-2015	Tuesday 13-Oct-2015	Wednesday 14-Oct-2015	Thursday 15-Oct-2015	Friday 16-Oct-2015
09.00- 09.50	**Lecture** Parasympatholitic Drugs E. Genç	**Lecture** Adrenergic Receptor Blockers E. Genç	**Lecture** Pathology of Endocardium & Heart Valves I I. D. Ekici	**Independent Learning**	**Lecture** Infective Endocarditis and Acute Rheumatic Fever O. Özveren
10.00- 10.50	**Lecture** Sympathomimetic Drugs: Catecholamines & Noncatecholamines E. Genç	**Lecture** Adrenergic Neuron Blockers E. Genç	**Lecture** Pathology of Endocardium & Heart Valves II I. D. Ekici		**Lecture** Rheumatic Heart Disease I. D. Ekici
11.00- 11.50	**Lecture** End of Life Decisions II E.Vatanoğlu	**Lecture** Diuretic Agents I F. Kaleağasıoğlu	**Lecture** Aortic Valvular Heart Diseases O. Özveren		**Lecture** CVS Tumors I .D. Ekici
12.00- 12.50	**Lecture** End of Life Decisions III E.Vatanoğlu	**Lecture** Diuretic Agents II F. Kaleağasıoğlu	**Lecture** Mitral Valvular Heart Diseases O. Özveren		**Independent Learning**
12.50 - 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Ischemic Heart Disease I F. Özkan	**Lecture** Bloodstream Invasion & Sepsis I G. Çelik	**ICP-CSL** (Advanced Cardiac Life Support) F.Menda/S.Bilgen	**Lecture** Bloodstream Invasion & Sepsis II M. Sönmezoğlu	**Lecture** Ethics of Distribution I E.Vatanoğlu
15.00- 15.50	**Lecture** Ischemic Heart Disease II F. Özkan	**Lecture** Respiratory Muscles and Surgical Anatomy of Thorax S. Ercan	**Group A IL** / **Group B IL** / **Group C** / **Group D IL**	**Lecture** Cardiac Infections M. Sönmezoğlu	**Lecture** Ethics of Distribution II E.Vatanoğlu
16.00- 16.50	**Lecture** Approach to Patient with Chest Pain in Primary Care G. İzbırak	**Lecture** Surgical Disorders of Mediastinum and the Diaphragm S. Ercan		**Lecture** Atherosclerosis & Hypertension I I.D. Ekici	**Independent Learning**
17.00-17.50	**Independent Learning**	**Lecture** Surgical Treatment of Pulmonary Diseases S. Ercan	**Independent Learning**	**Lecture** Atherosclerosis & Hypertension II I.D. Ekici	

COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS
WEEK III / 19-23 Oct 2015

	Monday 19-Oct-2015	Tuesday 20-Oct-2015	Wednesday 21-Oct-2015	Thursday 22-Oct-2015	Friday 23-Oct-2015
09.00- 09.50	**Lecture** Anti-hypertensive Drugs I F. Kaleağasıoğlu	**Lecture** Drugs Used in Congestive Heart Disease I F. Kaleağasıoğlu	**Lecture** Drugs Used in Cardiac Arrythmias I F. Kaleağasıoğlu	**Independent Learning**	**Independent Learning**
10.00- 10.50	**Lecture** Anti-hypertensive Drugs II F. Kaleağasıoğlu	**Lecture** Drugs Used in Congestive Heart Disease II F. Kaleağasıoğlu	**Lecture** Drugs Used in Cardiac Arrythmias II F. Kaleağasıoğlu		**Lecture** Pathology of Upper Respiratory Tract F. Özkan
11.00- 11.50	**Lecture** Congenital Heart Disease I I.D. Ekici	**Lecture** Congenital Heart Disease in Pediatrics D. Çöl	**Lecture** Anticoagulant, Antiplatelet & Thrombolytic drugs F. Kaleağasıoğlu		**Lecture** History and Symptoms in Pulmonary Diseases S. Özdoğan
12.00- 12.50	**Lecture** Congenital Heart Disease II I.D. Ekici	**Independent Learning**	**Lecture** Inherited Cardiovascular Disorders A.Ç. Kuşkucu		**Lecture** Physical Examination and Signs in Pulmonary Diseases S. Özdoğan
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Hypertension Treatment Guidelines F. Kaleağasıoğlu	**Lecture** Drugs Used in the Treatment of Dyslipidemias I F. Kaleağasıoğlu	**ICP-CSL** (Advanced Cardiac Life Support) F.Menda/S.Bilgen	**Lecture** Pathophysiology of Respiratory System Disorders I M. Kaçar	**ICP-CSL** (Advanced Cardiac Life Support) F.Menda/S.Bilgen
15.00- 15.50	**Lecture** Pharmacology Case Studies F. Kaleağasıoğlu	**Lecture** Drugs Used in the Treatment of Dyslipidemias II F. Kaleağasıoğlu	**Group A** **Group B IL** **Group C IL** **Group D IL**	**Lecture** Pathophysiology of Respiratory System Disorders II M. Kaçar	**Group A IL** **Group B IL** **Group C IL** **Group D**
16.00- 16.50	**Lecture** Drugs Used in the Treatment of Angina Pectoris F. Kaleağasıoğlu	**Independent Learning**		**Lecture** Pathophysiology of Respiratory System Disorders III M. Kaçar	
17.00-17.50	**Independent Learning**		**Independent Learning**	**Independent Learning**	**Independent Learning**

COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS
WEEK IV/ 26-30 Oct 2015

	Monday 26-Oct-2015	Tuesday 27-Oct-2015	Wednesday 28-Oct-2015	Thursday 29-Oct-2015	Friday 30-Oct-2015
09.00- 09.50	**Lecture** Diagnostic Methods in Pulmonary Medicine S. Özdoğan	**Lecture** Lung Diseases and Tobacco S. Özdoğan	**Independent Learning**	**REPUBLIC DAY**	**Independent Learning**
10.00- 10.50	**Lecture** Clinical Application of Pulmonary Function Tests S. Özdoğan	**Lecture** Interstitial Lung Diseases S. Özdoğan			
11.00- 11.50	**Lecture** Pulmonary Tuberculosis S. Özdoğan	**Lecture** Pleural Diseases S. Özdoğan			
12.00- 12.50	**Lecture** Pulmonary Infections I F. Özkan	**Lecture** X-Ray Examination of the Lungs A. Özgen			
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Pulmonary Infections II F. Özkan	**ICP-CSL** (Advanced Cardiac Life Support) F.Menda/S.Bilgen	**REPUBLIC DAY**	**REPUBLIC DAY**	**Independent Learning**
15.00- 15.50	**Lecture** Inherited Respiratory System Disorders A.Ç.Kuşkucu	**Group A IL** / **Group B** / **Group C IL** / **Group D IL**			
16.00- 16.50	**Lecture** Scientific Projects- III: Project Writing G. Yanıkkaya Demirel				
17.00-17.50	**Independent Learning**	**Independent Learning**			

COMMITTEE II - CARDIOVASCULAR AND RESPIRATORY SYSTEMS
WEEK V / 2-6 Nov 2015

	Monday 2-Nov-2015	Tuesday 3-Nov-2015	Wednesday 4-Nov-2015	Thursday 5-Nov-2015	Friday 6-Nov-2015
09.00-09.50	**Lecture** Sleep Apnea Syndrome S. Özdoğan	**Lecture** Pneumonia S. Özdoğan	**Lecture** Chronic Obstructive Pulmonary Diseases F. Özkan	**Independent Learning**	**Lecture** Pulmonary Hypertension S. Özdoğan
10.00-10.50	**Lecture** Lung Cancer S. Özdoğan	**Lecture** Respiratory Failure S. Özdoğan	**Lecture** Asthma Bronchiale F. Özkan		**Lecture** Special Pulmonary Problems S. Özdoğan
11.00-11.50	**Lecture** Tracheobronchitis S. Özdoğan	**Lecture** Principals of Statistical Analysis Ç. Kaspar	**Lecture** Congenital Lung Anomalies & Atalectasis F. Özkan		**Lecture** Palliative Care Ethics I E. Vatanoğlu
12.00-12.50	**Lecture** Treatment of Cough & Drugs Used in the Treatment of Common Cold F. Kaleağasıoğlu	**Lecture** Principals of Statistical Analysis Ç. Kaspar	**Lecture** Emergency Evaluation of Dyspnea M.F. Çelikmen		**Lecture** Palliative Care Ethics II E. Vatanoğlu
12.50 – 14.00	**LUNCH BREAK**				
14.00-14.50	**ICP-CSL** (History taking & examination of cardiovascular system) Z.Küçükdurmaz / O.Özveren/S. Özdemir/G. İzbırak	**ICP-CSL** (History taking & examination of cardiovascular system) Z.Küçükdurmaz / O.Özveren/ S. Özdemir/G. İzbırak	**Lecture** Laryngeal and Voice Diseases M. Doğan	**Lecture** Tumors of the Respiratory System I I.D. Ekici	**Pathology Laboratory** (Cardiovascular and Respiratory Systems) F. Özkan/ I.D. Ekici **Group A** / **Group B IL**
15.00-15.50	**Group A IL** / **Group B IL** / **Group C IL** / **Group D**	**Group A** / **Group B IL** / **Group C IL** / **Group D**	**Lecture** Diseases of the Middle Ear and Eustachian Tube M. Doğan	**Lecture** Tumors of the Respiratory System II I.D. Ekici	**Group A IL** / **Group B**
16.00-16.50			**Lecture** Approach to the Pediatric Patient with Pneumonia H. Sarıçoban	**Lecture** Pathology of Pleural and Mediastinal Diseases I.D. Ekici	
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**

COMMITTEE II – CARDIOVASCULAR AND RESPIRATORY SYSTEMS
WEEK VI / 9-13 Nov 2015

	Monday 9-Nov-2015	Tuesday 10-Nov-2015	Wednesday 11-Nov-2015	Thursday 12-Nov-2015	Friday 13-Nov-2015
09.00- 09.50	**Lecture** Epidemiology, Prevention and Control of Chronic Non-Communicable Respiratory Diseases R.E. Sezer	**Commomeration of Ataturk (Rectorate Building, Inan Kıraç Conference Hall)**	**Lecture** Upper and Lower Respiratory System Infections I G. Çelik	**Independent Learning**	**Lecture** Tobacco Control and Chronic Non-Communicable Diseases I R.E. Sezer
10.00- 10.50	**Lecture** Public Health and Chronic Non-Communicable Diseases H.A. Taşyıkan		**Lecture** Upper and Lower Respiratory System Infections II M. Sönmezoğlu		**Lecture** Tobacco Control and Chronic Non-Communicable Diseases II R.E. Sezer
11.00- 11.50	**Lecture** Approach to the Patient with Cough and Heameoptysis in Primary Care Ö. Tanrıöver		**Lecture** Chronic Restrictive Pulmonary Diseases I I D. Ekici		**Lecture** Pharmacology and Toxicology of Tobacco F. Kaleağasıoğlu
12.00- 12.50	**Independent Learning**	**Independent Learning**	Chronic Restrictive Pulmonary Diseases II I D. Ekici		**Lecture** Drugs Used in the Treatment of Asthma & Chronic Obstructive Lung Disease F. Kaleağasıoğlu
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**ICP-CSL** (History taking & examination of cardiovascular system) Z.Küçükdurmaz/O.Özveren/ S. Özdemir/G. İzbırak	**Lecture** Diseases of the Nose and Paranasal Sinuses Y. S. Pata	**ICP-CSL** (History taking & examination of cardiovascular system) Z.Küçükdurmaz / O.Özveren/ S. Özdemir/G. İzbırak	**Lecture** Pulmonary Embolism S. Ozdoğan	**Lecture** Tobacco Control and Chronic Non-Communicable Diseases III R.E. Sezer
15.00- 15.50	**Group A IL** / **Group B IL** / **Group C** / **Group D IL**	**Lecture** Nasopharyngeal and Oropharyngeal Diseases Y. S. Pata	**Group A IL** / **Group B** / **Group C IL** / **Group D IL**	**Lecture** Bronchial Hyperreactivity and Asthma S. Özdoğan	**Lecture** Tobacco Control and Chronic Non-Communicable Diseases IV R.E. Sezer
16.00- 16.50		**Lecture** Chest Medicine Case Reports H. Sarıçoban		**Lecture** Chronic Obstructive Pulmonary Disease S. Özdoğan	**Multidisciplinary Case Discussion Panel** (Respiratory Diseases)
17.00-17.50	**Independent Learning**	**Lecture** General Physical Exam G.İzbırak	**Independent Learning**	**Lecture** Approach to the Patient with Dyspnea in Primary Care Ö. Tanrıöver	**Multidisciplinary Case Discussion Panel** (Respiratory Diseases)

COMMITTEE II – CARDIOVASCULAR AND RESPIRATORY SYSTEMS
WEEK VII / 16-20 Nov 2015

	Monday 16-Nov-2015	Tuesday 17-Nov-2015	Wednesday 18-Nov-2015	Thursday 19-Nov-2015	Friday 20-Nov-2015
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					COMMITTEE EXAM
11.00- 11.50					
12.00- 12.50					
14.00- 14.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Program Evaluation Session Committee II Coordination Committee Members
15.00- 15.50					Independent Learning
16.00- 16.50					
17.00-17.50					

COMMITTEE III – HEMATOPOIETIC SYSTEM

DISTRIBUTION of LECTURE HOURS

November 23, 2015 – December 11, 2015

COMMITTEE DURATION: 3 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	HEMATOLOGY	HEM	17				**17**
	PATHOLOGY	PT	10				**10**
	PHARMACOLOGY	PC	9				**9**
	PEDIATRICS	PED	7				**7**
	INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	4				**4**
	MEDICAL GENETICS	MG	3				**3**
	PHYTOTHERAPY	PHY	3				**3**
	ONCOLOGY	ONC	3				**3**
	RADIATION ONCOLOGY	RONC	2				**2**
	PATHOPHYSIOLOGY	PP	2				**2**
	BIOISTATISTICS	BS	2			1X2=2	**4**
	BIOMEDICAL ETHICS&DEONTOLOGY	BED	2				**2**
	FAMILY MEDICINE	FM	1				**1**
	SCIENTIFIC PROJECTS- III	SP	1				**1**
	INTERDISCIPLINARY	MCDP				2	**2**
MED 303	**INTRODUCTION TO CLINICAL PRACTICE III**	ICP III			1X3=3 (4 Groups)		**3**
TOTAL			**66**		**3**	**4**	**73**

Coordination Committee

HEAD	Işın D. Ekici , MD, Prof
SECRETARY	Atilla Özkan , MD Assist. Prof
MEMBER	Sema Yılmaz, MD Assoc. Prof
MEMBER	Orhan Önder Eren, MD, Assist. Prof

COMMITTEE III – HEMATOPOIETIC SYSTEM

LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
HEMATOLOGY	Atilla Özkan, MD, Assist.Prof.
ONCOLOGY	Orhan Önder Eren, MD, Assist. Prof.
PATHOLOGY	Ferda Özkan, MD, Prof. A.Işın Doğan Ekici, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, PhD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Ferda Kaleağasıoğlu, MD, Assoc. Prof.
PHYTOTHERAPY	Erdem Yeşilada, PhD, Prof.
PEDIATRICS	Sabri Kemahlı, MD, Prof Hülya Sarıçoban, MD, Assoc. Prof. Sema Yılmaz, MD, Assoc. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, PhD, Assist. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Gülden Çelik, MD, Prof. Meral Sönmezoğlu, MD, Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD, Assist. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu, MD, PhD, Assoc. Prof.
FAMILY MEDICINE	Hülya Akan, MD, Assoc. Prof.
SCIENTIFIC PROJECTS – III	Gülderen Yanıkkaya Demirel, MD., PhD., Assoc. Prof.
RADIATION ONCOLOGY	Halim Aydın, MD Assoc. Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Güldal İzbırak, MD Assoc. Prof. Serdar Özdemir, MD Assist Prof.

COMMITTEE III – HEMATOPOIETIC SYSTEM
AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of hematopoietic system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to hematopoietic system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** knowledge on pharmacology of drugs that are effective on hematopoietic system or on clinical conditions involving hematopoietic system,
8. ***to convey*** knowledge on phytotherapeutic agents that have immune-modulatory effects,
9. ***to convey*** basic knowledge on phytotherapy
10. ***to convey*** knowledge on comparative biostatistical analysis of study groups,
11. ***to equip with*** basic and advanced clinical skills (arterial blood sample collection-C3) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1. ***recall*** anatomy, histology and physiology of hematopoietic system,
2. ***explain*** etiopathogenesis of clinical conditions (hematological syndromes, disorders and diseases, lenforeticular infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
3. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
4. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to hematopoietic system,
5. ***describe*** mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to hematopoietic system,
6. at multi-system level and/or related to hematopoietic system,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

6.1. practice of history taking and physical examination
6.2. evaluation of emergency case
6.3. approach to healthy individual or patient (anemia-C3, lymphadenopathy-C3)
6.4. laboratory tests/examinations (peripheral/venous blood collection for hematology tests-C3, hematology tests for anemia-C3)
6.5. imaging tests/examinations (nuclear medicine tests in hematology-C3)
6.6. point of care testing (hematology-peripheral blood smear examination-C3, hematology-complete blood count-)
6.7. making preliminary diagnosis or definitive diagnosis decision
6.8. making non-intervention or intervention decision
6.9. practicing non-intervention or intervention
6.10. referral/transport of healthy individual or patient

7. ***classify*** blood products and blood groups,
8. ***define*** principles of transfusion,
9. ***explain*** pharmacology of drugs (antianemic drugs, antineoplastic drugs, hematostatic drugs and blood products, immunomodulators) that are effective on hematopoietic system or on clinical conditions involving hematopoietic system,
10. ***explain*** mechanisms of bone marrow toxicity of drugs and other chemicals,
11. ***list*** principles of cancer chemotherapy,
12. ***explain*** chemotherapy in leukemia and lymphoma,
13. ***list*** phytotherapeutic agents with immunomodulatory effects,
14. ***list*** principles of comparative biostatistical analysis of study groups,
15. **perform** basic clinical skills, practiced on phantom models (arterial blood sample collection-C3), required at primary health care service.
16. ***explain*** basic knowledge on phytotherapy (basic concepts and terms, uses in modern medicine, regulations, standardization and quality control),

COMMITTEE III – HEMATOPOIETIC SYSTEM
COMMITTEE ASSESSMENT MATRIX

LEARNING OBJECTIVES	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of MCQs			
			CE	FE	IE	Total
1.0.-6.0.	HEM	A.Özkan	15	6	6	**27**
1.0.-6.0.	IM-ONC	O. Ö.Eren	4	1	1	**6**
1.0.-6.0.	PED	S. Kemahlı	12	3	3	**18**
1.0.-6.0.		H. Sarıçoban				
1.0.-6.0.		S. Yılmaz				
2.0.	MG	A. Ç. Kuskucu	6	1	1	**8**
2.0.,5.0.	PP	M. Kaçar	4	1	1	**6**
2.0.,5.0.,6.4.	PT	I D. Ekici	14	4	4	**22**
2.0.-6.0.	IDCM	M. Sönmezoglu	7	2	2	**11**
2.0.-6.4.		G. Çelik				
6.3.	FM	H. Akan	1	1	1	**3**
9.0.-12.0.	PC	E. Genç	14	4	4	**22**
9.0.-12.0.		F. Kaleağasıoğlu				
14.0.	BS	Ç. Kaspar	6	1	1	**8**
10.0	BED	E. Vatanoglu	4	1	1	**6**
	PHR	E. Yesilada	3	0	0	**3**
		TOTAL	**90**	**25/200****	**25/200****	**140**

LEARNING OBJECTIVES	DISCIPLINE	LECTURER/INSTRUCTOR	NUMBER of EMQs			TOTAL
1.0.-6.0.	HEM	A.Özkan	2	-	-	**2**
1.0.-6.0.	PED	S. Kemahlı	2	-	-	2
2.0.,5.0.,6.4.	PT	I.D. Ekici	1	-	-	1
		TOTAL	**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 points**
*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.
MCQ: Multiple Choice Question
EMQ: Extending Matching Question
CE: Committee Exam
CS: Committee Score
FE: Final Exam
ICE: Incomplete Exam
pts: Points
****25** out of 200 FE and ICE MCQs will be from Committee III (Each question is of worth **0.5** pts).

COMMITTEE III – HEMATOPOIETIC SYSTEM
WEEK I / 23-27 Nov 2015

	Monday 23-Nov-2015	Tuesday 24-Nov-2015	Wednesday 25-Nov-2015	Thursday 26-Nov-2015	Friday 27-Nov-2015
09.00- 09.50	**Introductory Session** Introduction to Committee III Head of Committee	**Lecture** Immune Acquired Hemolytic Anemias / Non Immune Acquired Hemolytic Anemias A . Özkan	**Lecture** Iron Metabolism and Iron Deficiency Anemia A. Özkan	**Independent Learning**	**Lecture** Chronic Leukemia A. Özkan
10.00- 10.50	**Lecture** Introduction to Hematology, Signs and Symptoms in Hematological Diseases A. Özkan	**Lecture** Thalassemias and Hemoglobinopathies (Sickle Cell Anemia and Others) A. Özkan	**Lecture** Vitamin B_{12} and Folic acid Metabolism and Megaloblastic Anemias A. Özkan	**ICP-CSL** (General Physical Examination) G. İzbırak/S.Özdemir	**Lecture** Lymphoma A. Özkan
11.00- 11.50	**Lecture** Classification of Anemias A. Özkan	**Lecture** Introduction to Anemias in Childhood S. Kemahlı	**Lecture** Antianemic Drugs E. Genç	**Group A IL** / **Group B** / **Group C IL** / **Group D IL**	**Lecture** Disorders of White Blood Cells& Leukemia I I D. Ekici
12.00- 12.50	**Lecture** Pathophysiology of Hematopoietic System Disorders I M. Kaçar	**Lecture** Introduction to Hemolytic Anemias S. Kemahlı	**Lecture** Molecular Basis of Hemoglobinopathies A. Ç. Kuşkucu		**Lecture** Disorders of White Blood Cells& Leukemia II I D. Ekici
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Pathophysiology of Hematopoietic System Disorders II M. Kaçar	**Independent Learning**	**ICP-CSL** (General Physical Examination) G. İzbırak/ S.Özdemir	**Lecture** Approach to the Patient with Anemia and Laboratory Tests in Diagnosis with Anemia A. Özkan	**Lecture** Introduction to Clinical Oncology I O .Ö.Eren
15.00- 15.50	**Lecture** Pathology of Bone Marrow-1 I D. Ekici		**Group A** / **Group B IL** / **Group C IL** / **Group D IL**	**Lecture** Hematopoiesis: Stem Cell and Bone Marrow A. Özkan	**Lecture** Introduction to Clinical Oncology II O .Ö.Eren
16.00- 16.50	**Lecture** Pathology of Bone Marrow-2 I D. Ekici			**Lecture** Aplastic and Hypoplastic Anemias A. Özkan	**Lecture** Treatment Approaches of Cancer O .Ö.Eren
17.00-17.50	**Lecture** Scientific Projects- III: Project Writing G. Yanıkkaya Demirel		**Independent Learning**	**Lecture** Hodgkin's Lymphoma I D. Ekici	**Independent Learning**

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE III - HEMATOPOIETIC SYSTEM
WEEK II / 30 Nov-4 Dec 2015

	Monday 30-Nov-2015	Tuesday 1-Dec-2015	Wednesday 2-Dec-2015	Thursday 3-Dec-2015	Friday 4-Dec-2015
09.00- 09.50	**Lecture** Acute Leukemias A.Özkan	**Lecture** Non/Hodgkin's Lymphoma I I D. Ekici	**Lecture** Antineoplastic Drugs II F. Kaleağasıoğlu	**Independent Learning**	**Lecture** Hemophilia and other Coagulopathies in Childhood I S. Yılmaz
10.00- 10.50	**Lecture** Myeloproliferative Diseases A.Özkan	**Lecture** Non/Hodgkin's Lymphoma II I D. Ekici	**Lecture** Antineoplastic Drugs III F. Kaleağasıoğlu		**Lecture** Hemophilia and other Coagulopathies in Childhood II S. Yılmaz
11.00- 11.50	**Lecture** Pharmacological Basis of Cancer Therapy I F. Kaleağasıoğlu	**Lecture** Non/Hodgkin's Lymphoma III I D. Ekici	**Lecture** Comparing Groups-categorical Data Ç. Kaspar		**Lecture** Coagulation Defects A.Özkan
12.00- 12.50	**Lecture** Pharmacological Basis of Cancer Therapy II F. Kaleağasıoğlu	**Lecture** Antineoplastic Drugs I F. Kaleağasıoğlu	**Lecture** Comparing Groups-categorical Data Ç. Kaspar		**Lecture** Quantitative and Qualitative Platelet Disorders A.Özkan
12.50-14.00	**LUNCH BREAK**				
14.00- 14.50	**ICP-CSL** (General Physical Examination) G. İzbırak/ S.Özdemir	**Lecture** Genetics of Oncology I A.Ç. Kuşkucu	**ICP-CSL** (General Physical Examination) G. İzbırak/ S.Özdemir	**Lecture** Lenforeticular Infections I G. Çelik	**Lecture** Comparing Groups-Continous Data Ç. Kaspar
15.00- 15.50		**Lecture** Genetics of Oncology II A.Ç. Kuşkucu		**Lecture** Lenforeticular Infections II M. Sönmezoğlu	**Lecture** Comparing Groups-Continous Data Ç. Kaspar
16.00- 16.50	**Group A IL** **Group B IL** **Group C** **Group D IL**	**Lecture** Introduction to Radiation Oncology H. Aydın	**Group A IL** **Group B IL** **Group C IL** **Group D**	**Lecture** Lymphoreactive Disease I D. Ekici	**Lecture** Congenital Hemolytic Anemias I S. Yılmaz
17.00-17.50	**Independent Learning**	**Lecture** Basics of Radiation Biology and Radiation Physics H. Aydın	**Independent Learning**	**Lecture** Pathology of Spleen I D. Ekici	**Lecture** Congenital Hemolytic Anemias II S. Yılmaz

COMMITTEE III - HEMATOPOIETIC SYSTEM
WEEK III / 7-11 Dec 2015

	Monday 7-Dec-2015	Tuesday 8-Dec-2015	Wednesday 9-Dec-2015	Thursday 10-Dec-2015	Friday 11-Dec-2015
09.00-09.50	**Lecture** Blood Components and Transfusion Indications M. Sönmezoğlu	**Lecture** Responsible Biomedical Research I E. Vatanoğlu	**Independent Learning**	**Independent Learning**	**Independent Learning**
10.00-10.50	**Lecture** Blood Groups M. Sönmezoğlu	**Lecture** Responsible Biomedical Research II E. Vatanoğlu			**COMMITTEE EXAM**
11.00-11.50	**Lecture** Hypercoagulability A.Özkan	**Lecture** Immunomodulators F. Kaleağasıoğlu			
12.00-12.50	**Lecture** Multiple Myelom A.Özkan	**Lecture** Phytotherapy I E. Yeşilada			
12.50-14.00	**LUNCH BREAK**				
14.00-14.50	**Lecture** Hematostatic Drugs and Hematostatic Blood Products I E. Genç	**Lecture** Phytotherapy II E. Yeşilada	**Independent Learning**	**Independent Learning**	**Program Evaluation Session** Committee III Coordination Committee Members
15.00-15.50	**Lecture** Hematostatic Drugs and Hematostatic Blood Products II E. Genç	**Lecture** Phytotherapy III E. Yeşilada			**Independent Learning**
16.00-16.50	**Lecture** Congenital Immunodeficiency Disease H. Sarıçoban	**Multidisciplinary Case Discussion Panel** (Hematology / Oncology)			
17.00-17.50	**Lecture** Approach to the Patient with LAP H. Akan	**Multidisciplinary Case Discussion Panel** (Hematology / Oncology)			

COMMITTEE IV - GASTROINTESTINAL SYSTEM

DISTRIBUTION of LECTURE HOURS

December 14, 2015 - January 8, 2016

COMMITTEE DURATION: 4 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	PATHOLOGY	PT	14		1x3=3 (2 Groups)		**17**
	GASTROENTEROHEPATOLOGY	GE	20				**20**
	INTERNAL MEDICINE	IM	3				**3**
	BIOMEDICAL ETHICS&DEONTOLOGY	BED	4				**4**
	PHARMACOLOGY	PC	4				**4**
	PUBLIC HEALTH	PH	4				**4**
	INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	4				**4**
	BIOSTATISTICS	BS	2			1X2=2	**4**
	PHYTOTHERAPY	PHY	3				**3**
	PATHOPHYSIOLOGY	PP	2				**2**
	FAMILY MEDICINE	FM	2				**2**
	PEDIATRICS	PED	1				**1**
	PEDIATRIC SURGERY	PEDS	1				**1**
	RADIOLOGY	RAD	1				**1**
	MEDICAL GENETICS	MG	1				**1**
	SURGERY	GS	1				**1**
	EMERGENCY MEDICINE	EM	1				**1**
	INTERDISCIPLINARY	MCDP				2	2
MED 303	**INTRODUCTION TO CLINICAL PRACTICE III**	ICP III			1X3=3 (4 Groups)		**3**
TOTAL			**68**		**6**	**4**	**78**

Coordination Committee

HEAD	Orhan Tarçın, MD Prof
SECRETARY	Atakan Yeşil , MD Assoc. Prof
MEMBER	Işın D. Ekici, MD, Prof.
MEMBER	Ece Genç , PhD, Prof

COMMITTEE IV - GASTROINTESTINAL SYSTEM
LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
INFECTIOUS DISEASES AND CLINICAL MICROBIOLOGY	Gülden Çelik, MD, Prof. Meral Sönmezoğlu, MD, Prof. Yeşim Gürol, MD, Assoc. Prof. İ. Çağatay Acuner, MD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Ferda Kaleağasıoğlu, MD, Assoc.Prof.
INTERNAL MEDICINE	Yaşar Küçükardalı, MD. Prof.
PATHOLOGY	Ferda Özkan, MD, Prof. Işın Doğan Ekici, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, PhD, Assoc. Prof.
PEDIATRICS	Defne Çöl, MD, Assist. Prof.
PUBLIC HEALTH	Erol Sezer, MD, Prof Hale Arık Taşyıkan, MD, Assist. Prof
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc.Prof. Özlem Tanrıöver, MD, Assoc.Prof.
EMERGENCY MEDICINE	Mustafa Ferudun Çelikmen, MD, Assist Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu, MD Assist. Prof.
BIOISTATISTICS	Çiğdem Kaspar, PhD, Assist. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, PhD, Assist. Prof.
SCIENTIFIC PROJECTS-III	Gülderen Yanıkkaya Demirel, MD, PhD, Assoc. Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Sezgin Sarıkaya, MD, Assoc. Prof. Mustafa Ferudun Çelikmen, MD, Assist Prof.

COMMITTEE IV - GASTROINTESTINAL SYSTEM

AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of gastrointestinal system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to gastrointestinal system,
5. ***to convey*** knowledge on mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to gastrointestinal system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** knowledge on pharmacology of drugs that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
8. ***to convey*** knowledge on phytotherapeutic agents that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
9. ***to convey*** knowledge on biostatistical analysis of association between variables,
10. ***to convey*** necessary knowledge on legal regulations and ethical principles for end-of-life decisions,
11. ***to equip with*** basic and advanced clinical skills (approach to patient with gastrointestinal clinical condition-C4) required at primary health care service level.
12. ***to convey*** knowledge on use of phytotherapy in an evidence based manner and drug interactions in phytotherapy,

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0. ***recall*** anatomy, histology and physiology of gastrointestinal system,

2.0. ***explain*** etiopathogenesis of clinical conditions (infections, nutritional disorders, bleedings, clinical conditions related to gastrointestinal organs) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,

3.0. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,

4.0. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to gastrointestinal system,
5.0. ***explain*** importance of healthy nutrition, principles of balanced diet, and measurement of nutritional status,
6.0. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to gastrointestinal system,
7.0. at multi-system level and/or related to gastrointestinal system,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

7.1. practice of history taking and physical examination (gastrointestinal-C4)
7.2. evaluation of emergency case (acute abdominal pain-C4)
7.3. approach to healthy individual or patient (diarrhea-C4)
7.4. laboratory tests/examinations
7.5. imaging tests/examinations (scintigraphy of liver/spleen-C4, PET in gastrointestinal system tumors-C4)
7.6. point of care testing
7.7. making preliminary diagnosis or definitive diagnosis decision
7.8. making non-intervention or intervention decision
7.9. practicing non-intervention or intervention
7.10. referral/transport of healthy individual or patient

8. ***list*** differences of gastrointestinal clinical conditions that may occur in children,
9. ***explain*** liver transplantation (indications, contraindications, conditions, risks, methods, patient care, results and monitorization),
10. ***explain*** pharmacology of drugs (agents used in the treatment of peptic ulcer, emetic and antiemetic agents, laxatives) that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
11. ***explain*** genetics of gastrointestinal system,
12. ***explain*** phytotherapeutic agents that are effective on gastrointestinal system or on clinical conditions involving gastrointestinal system,
13. ***define*** biostatistical analysis of association between variables,
14. ***tell*** legal regulations and ethical principles for end-of-life decisions,
15. ***perform*** basic clinical skills, practiced on phantom models and advanced clinical skills, practiced on simulated/standardized patients (approach to patient with gastrointestinal clinical condition-C4), required at primary health care service.
16. ***to convey*** knowledge on use of phytotherapy in an evidence based manner and drug interactions in phytotherapy.

COMMITTEE IV - GASTROINTESTINAL SYSTEM
COMMITTEE ASSESSMENT MATRIX

LEARNING OBJECTIVES	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of MCQs			
			CE	FE	IE	Total
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.	GE	O. Tarçın	20	6	6	**32**
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.		A. Yeşil				
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.		M. Ergün				
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.	PEDS	S. Sözübir	2	0	0	**2**
1.0.,2.0.,3.0.,4.0.,6.0.,6.0.,7.1.	IM	Y. Küçükardalı	3	1	1	**5**
2.0.,6.0.	PP	M. Kaçar	4	1	1	**6**
2.0.,6.0.	PT	I. D. Ekici	21	7	7	**35**
2.0.,6.0.,7.4.		F. Özkan				
2.0.,3.0.,4.0.,6.0.,7.3.	EM	S. Sarıkaya	1	0	0	**1**
2.0.,3.0.,4.0.,6.0.,7.0.	IDCM	M. Sönmezoglu	7	2	2	**11**
2.0.,3.0.,4.0.,6.0.,7.4.		Y. Gürol				
2.0.,3.0.,4.0.,6.0.,7.4.		G. Çelik				
3.0.,4.0.,5.0.	PH	R.E. Sezer	5	2	2	**9**
3.0.,4.0.,5.0.		H.A.Taşyıkan				
5.0.	PED	M. Ugras	3	1	1	**5**
7.3.	FM	H. Akan	2	0	0	**2**
7.3.		Ö. Tanrıöver				
7.5.	RAD	E. Kocakoç	2	0	0	**2**
9.0.	GS	Ö. Gökçe	2	0	0	**2**
10.0.	PC	E. Genç	6	2	2	**10**
10.0.		F. Kaleağasıoğlu				
11.0.	MG	A.Ç. Kuskucu	1	0	0	**1**
13.0.	BS	Ç. Kaspar	5	1	1	**7**
14.0.	BED	E. Vatanoglu	3	1	1	**5**
	PHR (PHY)	E. Yesilada	3	0	0	**3**
		TOTAL	**90**	**24/200****	**24/200****	**138**

LEARNING OBJECTIVES	DISCIPLINE	LECTURER/INSTRUCTOR	NUMBER of EMQs			TOTAL
1.0.,2.0.,3.0.,4.0.,6.0.,7.0.	GE	O. Tarçın	3	-	-	3
2.0.,6.0.,7.4.	PT	F. Özkan	2	-	-	2
		TOTAL	**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 points**

*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

MCQ: Multiple Choice Question

EMQ: Extending Matching Question

CE: Committee Exam

CS: Committee Score

FE: Final Exam

ICE: Incomplete Exam

pts: Points

****24** out of 200 FE and ICE MCQs will be from Committee IV (Each question is of worth **0.5** pts).

COMMITTEE IV - GASTROINTESTINAL SYSTEM
WEEK I / 14-18 Dec 2015

	Monday 14-Dec-2015	Tuesday 15-Dec-2015	Wednesday 16-Dec-2015	Thursday 17-Dec-2015	Friday 18-Dec-2015
09.00- 09.50	**Introductory Session** Introduction to Committee IV *Head of Commitee*	**Lecture** Oral Pathology F. Özkan	**Lecture** Pathology of Stomach I F. Özkan	**Independent Learning**	**Lecture** Malabsorbtion A. Yeşil
10.00- 10.50	**Lecture** Semiology I Y. Küçükardalı	**Lecture** Pathology of Esophagus I F. Özkan	**Lecture** Pathology of Stomach II F. Özkan		**Lecture** Inflammatory Bowel Disease A. Yeşil
11.00- 11.50	**Lecture** Semiology II Y. Küçükardalı	**Lecture** Pathology of Esophagus II F. Özkan	**Lecture** Acute Gastroenteritis M. Sönmezoğlu		**Lecture** Functional GI Disorders & Irritable Bowel Disease A. Yeşil
12.00- 12.50	**Lecture** Relation Between Two Variables I Ç. Kaspar	**Lecture** Food Poisoning Y. Gürol	**Lecture** Digestive & Antidiarrheal Drugs F. Kaleağasıoğlu		**Lecture** Laxatives F. Kaleağasıoğlu
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Relation Between Two Variables II Ç. Kaspar	**Lecture** Epidemiology, Prevention and Control of Obesity I H.A.Taşyıkan	**Lecture** Emetic & Antiemetic Agents F. Kaleağasıoğlu	**Lecture** Approach to the Patient with Abdominal Pain Regarding to Primary Care Ö. Tanrıöver	**Pathology Laboratory** (Gastrointestinal System) F. Özkan/ I.D. Ekici **Group A IL** / **Group B**
15.00- 15.50	**Lecture** Pathophysiology of Gastro–intestinal Disorders I M. Kaçar	**Lecture** Epidemiology, Prevention and Control of Obesity II H.A.Taşyıkan	**Lecture** Relation Between Several Variables I Ç. Kaspar	**Lecture** Clinical Approach to the Patient with Acute Abdominal Pain S. Sarıkaya	**Group A** / **Group B IL**
16.00- 16.50	**Lecture** Pathophysiology of Gastro–intestinal Disorders II M. Kaçar	**Lecture** Public Health and Nutrition I R.E. Sezer	**Lecture** Relation Between Several Variables II Ç. Kaspar	**Lecture** Approach to the Patient with Diarrhea Regarding to Primary Care H. Akan	
17.00-17.50	**Independent Learning**	**Lecture** Public Health and Nutrition II R.E. Sezer	**Lecture** The Ethics of Testing and Screening I E. Vatanoğlu	**Lecture** Gastrointestinal Bleedings in Children S. Sözübir	**Lecture** The Ethics of Testing and Screening II E. Vatanoğlu

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE IV - GASTROINTESTINAL SYSTEM WEEK II / 21-25 Dec 2015

	Monday 21-Dec-2015	Tuesday 22-Dec-2015	Wednesday 23-Dec-2015	Thursday 24-Dec-2015	Friday 25-Dec-2015
09.00- 09.50	**Lecture** Gastritis and Helicobacter Pylori M. Ergün	**Lecture** Peptic Ulcer Disease O. Tarçın	**Lecture** Premalignant Lesion of the Colon O. Tarçın	**Independent Learning**	**Lecture** Autoimmune Hepatitis A. Yeşil
10.00- 10.50	**Lecture** Gastroeusophegeal Reflux (GE) and Esophageal Motility Disorder M. Ergün	**Lecture** Tumors of Eusophagus, Stomach and Small Intestine A. Yeşil	**Lecture** Malignant Lesions of the Colon O. Tarçın		**Lecture** Wilson Disease and Hemochromatisis A. Yeşil
11.00- 11.50	**Lecture** Agents used in the Treatment of Peptic Ulcer I E. Genç	**Lecture** Pathology of Intestinal Diseases I F. Özkan	**Lecture** Hepatitis I G. Çelik		**Lecture** Pathology of Liver I F. Özkan
12.00- 12.50	**Lecture** Agents used in the Treatment of Peptic Ulcer II E. Genç	**Lecture** Pathology of Intestinal Diseases II F. Özkan	**Lecture** Hepatitis II M. Sönmezoğlu		**Lecture** Pathology of Liver II F. Özkan
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**ICP-CSL** (History taking and physical examination of gastrointestinal system) Ö.Sönmez / S. Özdemir	**Pathology Laboratory** (Gastrointestinal System) F. Özkan/ I.D. Ekici **Group A** / **Group B IL**	**ICP-CSL** (History taking and physical examination of gastrointestinal system) O. Ö.Eren / S. Özdemir	**Lecture** Pathology of Appendix & Peritoneum F. Özkan	**ICP-CSL** (History taking and physical examination of gastrointestinal system) Ö.Sönmez / S. Özdemir
15.00- 15.50	**Group A IL** / **Group B** / **Group C IL** / **Group D IL**	**Group A IL** / **Group B**	**Group A** / **Group B IL** / **Group C IL** / **Group D IL**	**Lecture** Jaundice M. Ergün	**Group A IL** / **Group B IL** / **Group C** / **Group D IL**
16.00- 16.50				**Lecture** Chronic Viral Hepatitis M. Ergün	
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Lecture** Cirrhosis and Complications M. Ergün	**Independent Learning**

COMMITTEE IV - GASTROINTESTINAL SYSTEM
WEEK III / 28 Dec 2015-1-Jan 2016

	Monday 28-Dec-2015	Tuesday 29-Dec-2015	Wednesday 30-Dec-2015	Thursday 31-Dec-2015	Friday 1-Jan-2015
09.00- 09.50	**Lecture** Acute Liver Failure A. Yeşil	**Lecture** Acute and Chronic Pancreatitis A. Yeşil	**Lecture** Drug Induced Liver Disease M. Ergün	**Multidisciplinary Case Discussion Panel**	**NEW YEAR HOLIDAY**
10.00- 10.50	**Lecture** Disease of the Bile Duct and Gall Bladder A. Yeşil	**Lecture** Tumors of the Bile Ducts and Pancreas O. Tarçın	**Lecture** Mass Lesions of the Liver M. Ergün	**Multidisciplinary Case Discussion Panel**	
11.00- 11.50	**Lecture** Pathology of Liver & Biliary System I I. D. Ekici	**Lecture** Pathology of Liver & Biliary System III I. D. Ekici	**Lecture** Alcoholic and Nonalcoholic Liver Disease Y. Küçükardalı	**Independent learning**	
12.00- 12.50	**Lecture** Pathology of Liver & Biliary System II I. D. Ekici	**Lecture** Pathology of Liver & Biliary System IV I. D. Ekici	**Lecture** Complex diseases-Inherited Gastrointestinal System Disorders A.Ç. Kuşkucu		
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**ICP-CSL** (History taking and physical examination of gastrointestinal system) O. Ö.Eren / S. Özdemir	**Lecture** Organ Transplantation and Ethics I E. Vatanoğlu	**Lecture** Phytotherapy-IV E. Yeşilada	**Independent learning**	**NEW YEAR HOLIDAY**
15.00- 15.50	**Group A IL** / **Group B IL** / **Group C IL** / **Group D**	**Lecture** Organ Transplantation and Ethics II E. Vatanoğlu	**Lecture** Phytotherapy-V E. Yeşilada		
16.00- 16.50		**Lecture** Transplantation of Liver Ö. Gökçe	**Lecture** Phytotherapy-VI E. Yeşilada		
17.00-17.50	**Independent Learning**	**Lecture** Radiology of Gastrointestinal System E. Kocakoç	**Lecture** Clinical Nutrition M. Uğraş		

COMMITTEE IV - GASTROINTESTINAL SYSTEM
WEEK IV / 4-8 Jan 2016

	Monday 4-Jan-2015	Tuesday 5-Jan- 2015	Wednesday 6-Jan-2015	Thursday 7-Jan-2015	Friday 8-Jan-2015
09.00- 09.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					COMMITTEE EXAM
11.00- 11.50					
12.00- 12.50					
12.50 – 14.00	LUNCH BREAK				
14.00- 14.50	Independent Learning	Independent Learning	Independent Learning	Independent Learning	**Program Evaluation Session** Committee IV Coordination Committee Members
15.00 -15.50					Independent Learning
16.00 - 16.50					
17.00 - 17.50					

COMMITTEE V - ENDOCRINOLOGY and REPRODUCTIVE SYSTEMS

DISTRIBUTION of LECTURE HOURS

January 25, 2016 – February 26, 2016

COMMITTEE DURATION: 5 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	PATHOLOGY	PT	20				**20**
	OBST & GYNEC	OBS-GYN	16				**16**
	ENDOCRINOLOGY	END	13				**13**
	INTERNAL MEDICINE	IM	2				**2**
	PHARMACOLOGY	PC	11				**11**
	MEDICAL GENETICS	MG	6				**6**
	INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	3		1x2=2 (2 Groups)		**5**
	PATHOPHYSIOLOGY	PP	5				**5**
	BIOSTATISTICS	BS	2			1X2=2	**4**
	PUBLIC HEALTH	PH	4				**4**
	FAMILY MEDICINE	FM	4				**4**
	PEDIATRICS	PED	3				**3**
	PHYTOTHERAPY	PHR (PHY)	2				**2**
	RADIOLOGY	RAD	1				**1**
	HISTOLOGY	HST	1				**1**
	SCIENTIFIC PROJECTS- III	SP	1				**1**
	BIOMEDICAL ETHICS&DEONTOLOGY		4				**4**
	INTERDISCIPLINARY	MCDP				2	**2**
MED 303	**INTRODUCTION TO CLINICAL PRACTICE III**	ICP III			1x3=3 (4 Groups)		**3**
TOTAL			**98**		**5**	**4**	**107**

Coordination Committee

HEAD	Ferda Özkan, MD Prof
SECRETARY	Hasan Aydın, MD Assoc Prof
MEMBER	Işın D. Ekici, MD, Prof
MEMBER	Rükset Attar, MD Assoc Prof

COMMITTEE V - ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM

LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
OBSTETRICS and GYNECOLOGY	N. Cem Fıçıcıoğlu, MD Prof. Meral Aban, MD Prof. Selçuk Özden, MD Prof. Oluş Api, MD Assoc. Prof. Rukset Attar, MD Assoc. Prof. Gazi Yıldırım, MD Assoc. Prof.
ENDOCRINOLOGY	Hasan Aydın, MD Assoc. Prof.
INTERNAL MEDICINE	Yaşar Küçükardalı, MD Prof.
PATHOLOGY	Ferda Özkan, MD Prof. Işın Doğan Ekici, MD Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD PhD Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD Prof. Ferda Kaleağasıoğlu, MD Assoc. Prof.
PEDIATRICS	Öznur Küçük, MD Assist. Prof. Mustafa Berber, MD, Assist. Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD Prof. Hale Arık Taşyıkan, MD Assist. Prof.
PHYTOTHERAPY	Erdem Yeşilada, MD PhD Prof.
FAMILY MEDICINE	Özlem Tanrıöver, MD Assoc. Prof. Ayşe Arzu Akalın, MD Assist. Prof.
RADIOLOGY	Neslihan Taşdelen, MD, Assoc. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD PhD Assist. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Gülden Çelik, MD Prof. Meral Sönmezoğlu, MD Prof. Yeşim Gürol , MD Assoc. Prof.
HISTOLOGY & EMBRYOLOGY	Oya Alagöz, MD, Assist. Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD Assist. Prof.
BIOMEDICAL ETHICS&DEONTOLOGY	Elif Vatanoğlu, MD PhD Assoc. Prof.
SCIENTIFIC PROJECTS- III	Gülderen Yanıkkaya Demirel, MD Assoc. Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Rukset Attar, MD Assoc. Prof. Gazi Yıldırım, MD Assoc. Prof. Oluş Api, MD Assoc. Prof.

COMMITTEE V - ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM
AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, embryology, histology and physiology of endocrine and reproductive systems,
2. ***to convey*** knowledge on health care service practices related to reproductive care,
3. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
4. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
5. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to endocrine and reproductive systems,
6. ***to convey*** knowledge on mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
7. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to endocrine and reproductive systems, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
8. ***to convey*** knowledge on pharmacology of drugs that are effective on endocrine and reproductive systems or on clinical conditions involving endocrine and reproductive systems,
9. ***to convey*** knowledge on genetics of endocrine and reproductive systems,
10. ***to convey*** knowledge on phytotherapeutic agents that are effective on endocrine system or on clinical conditions involving endocrine system,
11. ***to convey*** knowledge on design and biostatistical analysis of survival research,
12. ***to convey*** knowledge on legal regulations and ethical principles related to reproductive care,
13. ***to equip with*** basic and advanced clinical skills (*normal spontaneous vaginal delivery on phantom model-C5*) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0. ***recall*** anatomy, embryology, histology and physiology of endocrine and reproductive systems,
2.0. ***explain*** physiology of normal spontaneous vaginal delivery,
3.0. ***define*** practice of reproductive care,
4.0. ***explain*** etiopathogenesis of clinical conditions (menstrual cycle/developmental conditions/congenital and sexually transmitted infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
5.0. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,
6.0. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to endocrine and reproductive systems,

7.0. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to endocrine and reproductive systems,

8.0. at multi-system level and/or related to endocrine and reproductive systems,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

8.1. practice of history taking and physical examination (gynecological-C5, breast-C5)

8.2. evaluation of emergency case

8.3. approach to healthy individual or patient (pregnancy-C5)

8.4. laboratory tests/examinations (venous blood collection-C5, throat swab specimen-C5, sputum sample collection-C5, thyroid function tests-C5, diabetes tests-C5, rapid screening [antigen/antibody] tests-C5, throat culture-C5, sputum culture-C5)

8.5. imaging tests/examinations (radiological examinations in gynecology-C5, breast imaging-C5, radioisotope imaging of thyroid and parathyroid-C5)

8.6. point of care testing (diabetes tests-C5, rapid screening [antigen/antibody] tests-C5)

8.7. making preliminary diagnosis or definitive diagnosis decision

8.8. making non-intervention or intervention decision

8.9. practicing non-intervention or intervention

8.10. referral/transport of healthy individual or patient

9.0. ***explain*** pharmacology of drugs (hypothalamic and pituitary hormones, drugs effecting functions and action of oxytocin and ADH, thyroid and antithyroid drugs, adrenocortical hormones and drugs, insulin and oral antidiabetic drugs, estrogens, progestines and inhibitors) that are effective on endocrine and reproductive systems or on clinical conditions involving endocrine and reproductive systems,

10.0. ***explain*** genetics of endocrine and reproductive systems,

11.0. ***explain*** mechanisms of action for phytotherapeutic agents that are effective on endocrine system or in clinical conditions related to endocrine system,

12.0. ***define*** design and biostatistical analysis of survival research,

13.0. ***explain*** legal regulations and ethical principles related to reproductive care,

14.0. ***perform*** basic clinical skills, practiced on phantom models (normal spontaneous vaginal delivery-C5), and advanced clinical skills, practiced on simulated/standardized patients required at primary health care service.

COMMITTEE V - ENDOCRINE SYSTEM and REPRODUCTIVE SYSTEM
COMMITTEE ASSESSMENT MATRIX

LEARNING OBJECTIVES	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of MCQs			
			CE	FE	IE	Total
1.0	HST	O. Alagöz	1	0	0	**1**
1.0-8.0	OBS-GYN	C. Fıçıcıoglu	17	4	4	**25**
1.0-8.0		M. Aban				
1.0-8.0		S. Özden				
1.0-8.0		O. Api				
1.0-8.0		R. Attar				
1.0-8.0		G.Yıldırım				
1.0, 4.0-8.0	END	H. Aydın	10	3	3	**16**
1.0, 4.0-8.0	IM	Y. Küçükardalı	3	1	1	**5**
1.0, 4.0-8.0	PED	Ö. Küçük	4	1	1	**6**
1.0, 4.0-8.0		M. Berber				
1.0, 4.0, 7.0, 8.4	PT	F. Özkan	15	4	4	**23**
1.0, 4.0, 7.0, 8.4		I.D. Ekici				
4.0, 5.0, 6.0, 7.0, 8.0	IDCM	M. Sönmezoglu	3	1	1	**5**
4.0, 5.0, 6.0, 7.0, 8.4		G. Çelik				
4.0, 7.0	PP	M. Kaçar	4	1	1	**6**
5.0, 6.0	PH	R.E. Sezer	3	1	1	**5**
5.0, 6.0		H.A.Taşyıkan				
6.0, 8.0,8.1, 8.3	FM	A Akalın	4	1	1	**6**
8.3,		Ö. Tanrıöver				
8.5,	RAD	N. Taşdelen	1	0	0	**1**
9.0	PC	E. Genç	10	3	3	**16**
9.0		F.Kaleagasıoglu				
10.0	MG	A. Ç. Kuskucu	6	2	2	**10**
12.0	BS	Ç. Kaspar	3	1	1	**5**
	PHR (PHY)	E. Yesilada	2	0	0	**2**
10.0	BED	E.Vatanoğlu	4	2	2	**8**
		TOTAL	**90**	**25/200****	**25/200****	**140**

LEARNING OBJECTIVES	DISCIPLINE	LECTURER/INSTRUCTOR	NUMBER of EMQs			TOTAL
1.0, 4.0-8.0	END	H. Aydın	2	-	-	**2**
1.0-8.0	OBS-GYN	O.Api	2	-	-	**2**
1.0, 4.0, 7.0, 8.4	PT	F. Özkan	1			**1**
		TOTAL	**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 points**

*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

MCQ: Multiple Choice Question

EMQ: Extending Matching Question

CE: Committee Exam; **CS:** Committee Score; **FE:** Final Exam; **ICE:** Incomplete Exam

pts: Points

****25** out of 200 FE and ICE MCQs will be from Committee V (Each question is of worth **0.5** pts).

COMMITTEE V - ENDOCRINOLOGY and REPRODUCTIVE SYSTEMS
WEEK I / 25-29 Jan 2016

	Monday 25-Jan-2016	Tuesday 26-Jan-2016	Wednesday 27-Jan-2016	Thursday 28-Jan-2016	Friday 29-Jan-2016
09.00- 09.50	**Introductory Session** Introduction to Committee V Head of Committee	**Lecture** Disorders of Posterior Pituitary Gland H. Aydın	**Lecture** Pathology of Thyroid & Parathyroid I F. Özkan	**Independent Learning**	**Lecture** Hypoglycemia H. Aydın
10.00- 10.50	**Lecture** Introduction to Endocrinology H. Aydın	**Lecture** Hypopituatirism H. Aydın	**Lecture** Pathology of Thyroid & Parathyroid II F. Özkan		**Lecture** Adrenal Disorders H. Aydın
11.00- 11.50	**Lecture** Hyperfunctioning Disorders of Anterior Pituitary Gland H. Aydın	**Lecture** Pathology of Pituitary Gland I I. D. Ekici	**Lecture** Thyroid Function Tests H. Aydın		**Lecture** Pathology of Adrenal Gland I F. Özkan
12.00- 12.50	**Lecture** Pathology of Endocrine System: Introduction F. Özkan	**Lecture** Pathology of Pituitary Gland II I. D. Ekici	**Lecture** Thyroid Disorders H. Aydın		**Lecture** Pathology of Adrenal Gland II F. Özkan
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Introduction to Endocrine Pharmacology E. Genç	**Lecture** Pathophysiology of Endocrine System Diseases I M. Kaçar	**Lecture** Thyroid and Antithyroid Drugs I E. Genç	**Lecture** Calcium Metabolism H. Aydın	**Lecture** Congenital Adrenal Hyperplasia M. Berber
15.00- 15.50	**Lecture** Hypothalamic and Pituitary Hormones I F. Kaleağasıoğlu	**Lecture** Pathophysiology of Endocrine System Diseases II M. Kaçar	**Lecture** Thyroid and Antithyroid Drugs II E. Genç	**Lecture** Hypercalcemic Diseases H. Aydın	**Lecture** Inborn Errors of Metabolism I A.Ç. Kuşkucu
16.00- 16.50	**Lecture** Hypothalamic and Pituitary Hormones II F. Kaleağasıoğlu	**Lecture** Pathophysiology of Endocrine System Diseases III M. Kaçar	**Lecture** Design of Survival Studies I Ç. Kaspar	**Lecture** Hypocalcemic Diseases H. Aydın	**Lecture** Inborn Errors of Metabolism II A.Ç. Kuşkucu
17.00-17.50	**Program Improvements Session** Phase Coordinator	**Independent Learning**	**Lecture** Design of Survival Studies II Ç. Kaspar	**Lecture** Imaging of Thyroid Glands N. Taşdelen	**Independent learning**

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE V - ENDOCRINOLOGY and REPRODUCTIVE SYSTEMS

WEEK II / 1-5 Feb 2016

	Monday **1-Feb-2016**	**Tuesday** **2-Feb-2016**	**Wednesday** **3-Feb-2016**	**Thursday** **4-Feb-2016**	**Friday** **5-Feb-2016**
09.00- 09.50	**Lecture** Obesity H. Aydın	**Lecture** Introduction to Diabetes Mellitus Y. Küçükardalı	**Lecture** Chromosomal Disorders I A. Ç. Kuşkucu	**Independent Learning**	**Lecture** Puerperal Infections Oluş Api
10.00- 10.50	**Lecture** Diffuse Hormonal Systems and Endocrine Tumor Syndromes H. Aydın	**Lecture** Clinical and Laboratory Findings of Diabetes Mellitus Y. Küçükardalı	**Lecture** Chromosomal Disorders II (Sex chromosomes and their abnormalities) A. Ç. Kuşkucu		**Lecture** Normal and Abnormal Labor Oluş Api
11.00- 11.50	**Lecture** Pathology of Pancreas I I. D. Ekici	**Lecture** Insulin and Oral Antidiabetic Drugs I E. Genç	**Lecture** Pathophysiology of Reproductive System Diseases I M. Kaçar		**Lecture** Pathology of Cervix Uteri I F. Özkan
12.00- 12.50	**Lecture** Pathology of Pancreas II I. D. Ekici	**Lecture** Insulin and Oral Antidiabetic Drugs II E. Genç	**Lecture** Pathophysiology of Reproductive System Diseases II M. Kaçar		**Lecture** Pathology of Cervix Uteri II F. Özkan
12.50-14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Adrenocortical Hormones and Drugs I E. Genç	**Lecture** Epidemiology, Prevention and Control of Type II Diabetes Mellitus R. E. Sezer	**Lecture** Pathology of Breast I F. Özkan	**Lecture** Conditions affecting Vulva & Vagina M. Aban	**ICP-CSL** (Follow-up of pregnancy & stages of normal labour) R. Attar /G. Yıldırım/ Oluş Api
15.00- 15.50	**Lecture** Adrenocortical Hormones and Drugs II E. Genç	**Lecture** Delivery of Family Planning Services I A. Akalın	**Lecture** Pathology of Breast II F. Özkan	**Lecture** The Gynecological History and Examination G. Yıldırım	**Group A IL** / **Group B IL** / **Group C IL** / **Group D**
16.00- 16.50	**Lecture** Analysis of Survival Studies I Ç. Kaspar	**Lecture** Delivery of Family Planning Services II A. Akalın	**Lecture** Medical History for Breast Diseases in Primary Care & Clinical Breast Examination A. Akalın	**Lecture** Endometriosis & Adenomyosis G. Yıldırım	
17.00-17.50	**Lecture** Analysis of Survival Studies II Ç. Kaspar	**Independent Learning**	**Independent Learning**	**Lecture** Pathology of Vulva & Vagina F. Özkan	**Independent Learning**

COMMITTEE V - ENDOCRINOLOGY and REPRODUCTIVE SYSTEMS
WEEK III / 8-12 Feb 2016

	Monday 8-Feb-2016	Tuesday 9-Feb-2016	Wednesday 10-Feb-2016	Thursday 11-Feb-2016	Friday 12-Feb-2016
09.00-09.50	**Lecture** Antenatal Care S. Özden	**Lecture** Normal Pubertal Development Ö. Küçük	**Lecture** Estrogens, Progestines and Inhibitors I F. Kaleağasıoğlu	**Independent Learning**	**Lecture** Embryology O. Alagöz
10.00-10.50	**Lecture** Disorders of Early Pregnancy (Miscarriage; Ectopic; GTD) S. Özden	**Lecture** Pubertal Disorders Ö. Küçük	**Lecture** Estrogens, Progestines and Inhibitors II F. Kaleağasıoğlu		**ICP-CSL** (Follow-up of pregnancy & stages of normal labour) R. Attar/ G. Yıldırım/Oluş Api
11.00-11.50	**Lecture** Pathology of Pregnancy & Placenta F. Özkan	**Lecture** Genetic disorders of gonadal development A. Ç. Kuşkucu	**Lecture** The Menstrual Cycle and Disorders of the Menstrual Cycle R. Attar		**Group A** IL **Group B** **Group C & D** IL
12.00-12.50	**Lecture** General Approach to the Pregnant Woman Ö. Tanrıöver	**Lecture** Prenatal genetic diagnosis and genetic counseling A. Ç. Kuşkucu	**Lecture** Normal and Abnormal Sexual Development & Puberty R. Attar		
12.50-14.00	**LUNCH BREAK**				
14.00-14.50	**Lecture** Scientific Projects- III: Writing Project G. Yanıkkaya Demirel	**Independent Learning**	**ICP-CSL** (Follow-up of pregnancy & stages of normal labour) R. Attar /G. Yıldırım/ Oluş Api	**ICP-CSL** (Follow-up of pregnancy & stages of normal labour) R. Attar /G. Yıldırım/ Oluş Api	**Lecture** Reproductive, Maternal and Child Health I H. A. Taşyıkan
15.00-15.50	**Microbiology Laboratory** (Diagnostic tests of urogenital specimens) İ.C.Acuner/ Y.Gurol/G.Celik **Group A** **Group B** **Group C & D** IL	**Microbiology Laboratory** (Diagnostic tests of urogenital specimens) İ.Ç.Acuner/ Y.Gurol/G.Çelik **Group C** **Group D** **Group A & B** IL	**Group A** IL **Group B** IL **Group C** **Group D** IL	**Group A** **Group B, C & D** IL	**Lecture** Reproductive, Maternal and Child Health II H. A. Taşyıkan
16.00-16.50					**Lecture** Reproductive, Maternal and Child Health III H. A. Taşyıkan
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent learning**	**Independent Learning**	**Independent Learning**

COMMITTEE V - ENDOCRINOLOGY and REPRODUCTIVE SYSTEMS

WEEK IV / 15-19 Feb 2016

	Monday 15-Feb-2016	Tuesday 16-Feb-2016	Wednesday 17-Feb-2016	Thursday 18-Feb-2016	Friday 19-Feb-2016
09.00- 09.50	**Lecture** Menopause C. Fıçıcıoğlu	**Lecture** Malign Diseases of the Uterus and the Cervix M. Aban	**Lecture** Reproductive Ethics I E. Vatanoğlu	**OSCE-I EXAM**	**Independent Learning**
10.00- 10.50	**Lecture** Fertility Control C. Fıçıcıoğlu	**Lecture** Malign Diseases of the Ovary M. Aban	**Lecture** Reproductive Ethics II E. Vatanoğlu		
11.00- 11.50	**Lecture** Infertility C. Fıçıcıoğlu	**Lecture** Pathology of Ovary I F. Özkan	**Lecture** Benign Diseases of the Uterus and the Cervix R. Attar		
12.00- 12.50	**Lecture** Pathology of Uterus I F. Özkan	**Lecture** Pathology of Ovary II F. Özkan	**Lecture** Benign Diseases of the Ovary R. Attar		
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Pathology of Uterus II F. Özkan	**Lecture** Pathology of Treponemal Infections F. Özkan	**Lecture** Reproductive Ethics III E. Vatanoğlu	**OSCE-I EXAM**	**Independent Learning**
15.00- 15.50	**Lecture** Phytotherapy-VII E. Yeşilada	**Lecture** Congenital Infections and Sexually Transmitted Diseases, Genital Infections I G. Çelik	**Lecture** Reproductive Ethics IV E. Vatanoğlu		
16.00- 16.50	**Lecture** Phytotherapy-VIII E. Yeşilada	**Lecture** Congenital Infections and Sexually Transmitted Diseases, Genital Infections II G. Çelik	**Multidisciplinary Case Discussion Panel**		
17.00-17.50	**Independent Learning**	**Lecture** Congenital Infections and Sexually Transmitted Diseases, Genital Infections III M. Sönmezoğlu	**Multidisciplinary Case Discussion Panel**		

COMMITTEE V - ENDOCRINOLOGY and REPRODUCTIVE SYSTEMS

WEEK V / 22-26 Feb 2016

<table>
<tr><th></th><th>Monday
22-Feb-2016</th><th>Tuesday
23-Feb-2016</th><th>Wednesday
24-Feb-2016</th><th>Thursday
25-Feb-2016</th><th>Friday
26-Feb-2016</th></tr>
<tr><td>09.00- 09.50</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td>Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td rowspan="3">COMMITTEE EXAM</td></tr>
<tr><td>11.00- 11.50</td></tr>
<tr><td>12.00- 12.50</td><td rowspan="2">Independent Learning</td><td rowspan="2">Independent Learning</td><td rowspan="2">Independent Learning</td><td rowspan="2">Independent Learning</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="5">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td>Program Evaluation Session
Committee V
Coordination Committee
Members</td></tr>
<tr><td>15.00- 15.50</td><td rowspan="3">Independent Learning</td></tr>
<tr><td>16.00- 16.50</td></tr>
<tr><td>17.00-17.50</td></tr>
</table>

COMMITTEE VI - URINARY SYSTEM

DISTRIBUTION of LECTURE HOURS

February 29, 2016 – March 25, 2016

COMMITTEE DURATION: 4 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	UROLOGY	URO	7				**7**
	NEPHROLOGY	NE	11				**11**
	PATHOLOGY	PT	12		1x2=2 (2 Groups)		**14**
	PATHOPHYSIOLOGY	PP	2				**2**
	PHARMACOLOGY	PC	3				**3**
	PEDIATRICS	PED	1				**1**
	PUBLIC HEALTH	PH	2				**2**
	RADIOLOGY	RAD	1				**1**
	MEDICAL GENETICS	MG	1				**1**
	INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	2		1x2=2 (2 Groups)		**4**
	PEDIATRIC SURGERY	PED-S	1				**1**
	GENERAL SURGERY	GS	1				**1**
	BIOSTATISTICS	BS	2			1x2=2	**4**
	FAMILY MEDICINE	FM	1				**1**
	INTERDISCIPLINARY	MCDP				2	**2**
MED 303	**INTRODUCTION TO CLINICAL PRACTICE III**	ICP III			1x2=2 (4 Groups) 1x3=3 (4 Groups)		**5**
TOTAL			**47**		**9**	**4**	**60**

Coordination Committee

HEAD	Gülçin Kantarcı , MD, Prof
SECRETARY	Zehra Eren, MD, Assoc Prof
MEMBER	Işın D. Ekici, MD, Prof
MEMBER	Ahmet Tunç Özdemir, MD, Assoc Prof

COMMITTEE VI - URINARY SYSTEM
LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
UROLOGY	Faruk Yencilek, MD, Assoc. Prof. Ahmet Tunç Özdemir, MD, Assoc. Prof. Hasbey Hakan Koyuncu, MD, Assist. Prof.
NEPHROLOGY	Gülçin Kantarcı, MD, Prof. Zehra Eren, MD, Assoc. Prof.
PATHOLOGY	Ferda Özkan, MD, Prof. Işın Doğan Ekici, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD PhD Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD Prof.
PEDIATRICS	Ozan Özkaya, MD Prof.
PUBLIC HEALTH	Hale Arık Taşyıkan, MD Assist. Prof.
RADIOLOGY	Ercan Kocakoç, MD Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu,MD PhD Assist. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Gülden Çelik, MD, Prof. Yeşim Gürol, MD, Assoc. Prof Ibrahim Çağatay Acuner, MD, Assoc. Prof Meral Sönmezoğlu, MD, Assoc. Prof.
PEDIATRIC SURGERY	Selami Sözübir, MD, Prof.
GENERAL SURGERY	Özcan Gökçe, MD, Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD, Assist. Prof.
FAMILY MEDICINE	Hülya Akan, MD Assoc. Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Rukset Attar, MD Assoc. Prof. Gazi Yıldırım, MD Assoc. Prof. Oluş Api, MD Assoc. Prof. Güldal İzbırak, MD, Assoc. Prof. Ayşe Arzu Akalın, MD Assist. Prof. Gülay Çiler Erdağ, MD Assist. Prof. Defne Çöl,MD Assist. Prof.

COMMITTEE VI - URINARY SYSTEM
AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of urinary system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to urinary system,
5. ***to convey*** knowledge on mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to urinary system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, **at the** level of primary health care service,
7. ***to convey*** knowledge on pharmacology of drugs that are effective on urinary system or on clinical conditions involving urinary system,
8. ***to convey*** knowledge on genetics of urinary system,
9. ***to convey*** knowledge on phytotherapeutic agenst that are effective on urinary system or on clinical conditions involving urinary system,
10. ***to convey*** knowledge on use of biostatistical software and presentation of results,
11. ***to convey*** knowledge on legal regulations and ethical principles related to reproductive care,
12. ***to equip with*** basic and advanced clinical skills *(gynecological examination-C6, "Pap-smear" collection-C6, intrauterine device placement-C6, breast examination-C6, physical examination in neonate, infant and prepubertal/pubertal child-C6)* required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1. ***recall*** anatomy, histology and physiology of urinary system,
2. ***explain*** etiopathogenesis of clinical conditions (renal hemodynamics, acid-base equilibrium, renal clinical conditions, urinary system stones, urinary system infections) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,
3. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to cardiovascular and respiratory systems,
4. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to urinary system,
5. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to urinary system,

6. at multi-system level and/or related to urinary system,
   - for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
   - in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
   - for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

6.1. practice of history taking and physical examination (neonatal, prepubertal/pubertal-C6)
6.2. evaluation of emergency case (urological emergencies-C6)
6.3. approach to healthy individual or patient (urethral-vaginal-cervical discharge/swab specimen-C6, fecal specimen collection-C6)
6.4. laboratory tests/examinations (urethral-vaginal-cervical discharge culture-C6, fecal culture-C6)
6.5. imaging tests/examinations (uroradiology-C6, renal scintigraphy (GFR, ERPF, Renogram)-C6)
6.6. point of care testing
6.7. making preliminary diagnosis or definitive diagnosis decision
6.8. making non-intervention or intervention decision
6.9. practicing non-intervention or intervention
6.10. referral/transport of healthy individual or patient

7. ***explain*** pharmacology of drugs that are effective on urinary system or on clinical conditions involving urinary system,
8. ***explain*** pharmacology of androgens and anabolic steroids, and drugs that affect bone mineral homeostasis,
9. ***explain*** genetics of urinary system,
10. ***explain*** mechanisms of action for action for phytotherapeutic agents that are effective on urinary system or in clinical conditions related to urinary system,
11. ***define*** use of biostatistical software and presentation of results,
12. ***perform*** basic clinical skills, practiced on phantom models, and advanced clinical skills, practiced on simulated/standardized patients (gynecological examination-C6, “Pap-smear” collection-C6, intrauterine device placement-C6, breast examination-C6, physical examination in neonate, infant and prepubertal/pubertal child-C6), required at primary health care service.

COMMITTEE VI - URINARY SYSTEM
COMMITTEE ASSESSMENT MATRIX

LEARNING OBJECTIVES	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of MCQs			
			CE	FE	IE	Total
1.0.-6.0.	GS	Ö. Gökçe	2	0	0	**2**
1.0.-6.0.	NE	G. Kantarcı	20	6	6	**32**
1.0.-6.0.		Z. Eren				
1.0.-6.0.	PED	O. Özkaya	4	2	2	**8**
1.0.-6.0.	PED-S	S. Sözübir	2	0	0	**2**
1.0.-6.0.	URO	F. Yencilek	12	3	3	**18**
1.0.-6.0.		H . Koyuncu				
1.0.-6.0.		A.T.Özdemir				
1.0., 2.0., 5.0., 6.4.	PT	I D. Ekici	20	6	6	**32**
2.0., 5.0.	PP	M. Kaçar	4	1	1	**6**
2.0.-6.0.	IDCM	M. Sönmezoglu	6	2	2	**10**
2.0.-5.0., 6.4.		G. Çelik				
3.0., 4.0.	PH	H. A. Taşyıkan	3	1	1	**5**
6.3.	FM	H. Akan	2	1	1	**4**
6.5.	RAD	E. Kocakoç	2	0	0	**2**
7.0., 8.0.	PC	E. Genç	6	1	1	**8**
9.0.	MG	A.Ç. Kuskucu	1	0	0	**1**
11.0.	BS	Ç. Kaspar	6	2	2	**10**
		TOTAL	**90**	**25/200****	**25/200****	**140**

LEARNING OBJECTIVES	DISCIPLINE	LECTURER/INSTRUCTOR	NUMBER of EMQs			TOTAL
1.0.-6.0.	URO	A.T.Özdemir	2	-	-	**2**
1.0.-6.0.	NE	G. Kantarci	2	-	-	**2**
1.0., 2.0., 5.0., 6.4.	PT	I D. Ekici	1			**1**
		TOTAL	**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 points**

*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

MCQ: Multiple Choice Question

EMQ: Extending Matching Question

CE: Committee Exam

CS: Committee Score

FE: Final Exam

ICE: Incomplete Exam

pts: Points

****25** out of 200 FE and ICE MCQs will be from Committee VI (Each question is of worth **0.5** pts).

COMMITTEE VI - URINARY SYSTEM

WEEK I / 29 Feb-4 Mar 2016

	Monday 29-Feb-2016	Tuesday 01-Mar-2016	Wednesday 02-Mar-2016	Thursday 03-Mar-2016	Friday 04-Mar-2016
09.00- 09.50	**Introductory Session** Introduction to Commitee VI Head of Committee	**Lecture** Urolithiasis-I Faruk Yencilek	**Lecture** Pathology of Tubulointerstitial Disease I I. D. Ekici	**Independent Learning**	**Independent Learning**
10.00- 10.50	**Lecture** Pathophysiology of Urinary System Diseases I M. Kaçar	**Lecture** Urolithiasis-II Faruk Yencilek	**Lecture** Pathology of Tubulointerstitial Disease II I. D. Ekici		**Lecture** Upper and Lower Urinary Tract Infections II M. Sönmezoğlu
11.00- 11.50	**Lecture** Pathophysiology of Urinary System Diseases II M. Kaçar	**Lecture** Pathology of Male Genital System I I. D. Ekici	**Lecture** Tubulointerstitial Diseases Z. Eren		**Lecture** Nephritic and Nephrotic Syndrome O. Özkaya
12.00- 12.50	**Lecture** Renovascular Pathology I. D. Ekici	**Lecture** Pathology of Male Genital System II I. D. Ekici	**Independent Learning**		**Lecture** Approach to the Urinary Tract Infections H. Akan
12.50-14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Renal Cystic Disease I. D. Ekici	**Lecture** Clinical study of renal functions and urinary findings Z. Eren	**ICP-CSL** (Gynecological examination, PAP smear obtaining & Clinical breast examination) R.Attar/G.Yıldırım/ O. Api/ A.Akalın/G.İzbırak	**Lecture** Pathology of Glomerular Diseases I I. D. Ekici	**Lecture** Nephritic Syndrome Z. Eren
15.00- 15.50	**Independent Learning**	**Lecture** Acute Kidney Injury G.Kantarcı	**Group A** **Group B IL** **ICP-CSL** (Physical examination of the newborn and child patient) F. Bakar/S. Biçer / D.Çöl/M.Berber/ Ö.Küçük **Group C1 YH** **Group C2 & D IL**	**Lecture** Pathology of Glomerular Diseases II I. D. Ekici	**Lecture** Nephrotic Syndrome Z.Eren
16.00- 16.50		**Lecture** Physical examination of newborn patient M. Berber	**Group C1 IL**	**Lecture** Pathology of Glomerular Diseases III I. D. Ekici	**Independent Learning**
17.00-17.50		**Lecture** Physical examination of child patient D. Çöl	**Independent Learning**	**Lecture** Upper and Lower Urinary Tract Infections I G. Çelik	

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE VI - URINARY SYSTEM WEEK II / 7-11 Mar 2016

	Monday 07-Mar-2016	Tuesday 08-Mar-2016	Wednesday 09-Mar-2016	Thursday 10-Mar-2016	Friday 11-Mar-2016
09.00- 09.50	**Lecture** Fluid, Electrolyte & Acid/Base Balance I G.Kantarcı	**Lecture** Fluid, Electrolyte & Acid/Base Balance III Z. Eren	**Lecture** Benign Prostatic Hyperplasia-I H. Koyuncu	**Independent Learning**	**Microbiology Laboratory** (Diagnostic tests for urinary specimens) İ.Ç.Acuner/ Y.Gurol/G.Çelik — Group A; Group B IL; Group C & D IL
10.00- 10.50	**Lecture** Fluid, Electrolyte & Acid/Base Balance II G.Kantarcı	**Lecture** Fluid, Electrolyte & Acid/Base Balance IV Z. Eren	**Lecture** Benign Prostatic Hyperplasia-II H. Koyuncu	**ICP-CSL** (Gynecological examination, PAP smear obtaining / Clinical breast examination) R. Attar/G.Yıldırım/O.Api/ A.Akalın/G.İzbırak	Group A IL; Group B
11.00- 11.50	**Lecture** Urologic Oncology I A. T. Özdemir	**Lecture** Congenital Anomalies of Urinary System I. D. Ekici	**Lecture** Pathology of Urinary System Tumors I. D. Ekici	Group A IL; Group B; Group C & D IL	**Microbiology Laboratory** (Diagnostic tests for urinary specimens) İ.Ç.Acuner/ — Group A & B IL; Group C; Group D
12.00- 12.50	**Lecture** Urologic Oncology II A. T. Özdemir	**Lecture** Congenital Anomalies of The Urinary System S. Sözübir	**Lecture** Transplantation of Kidney Ö. Gökçe		Group C IL; Group D
12.50-14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Pathology of Bladder I. D. Ekici	**ICP-CSL** (Physical examination of the newborn and child patient) F. Bakar/S. Biçer / D.Çöl/M.Berber/ Ö.Küçük; **ICP-CSL** (Gynecological examination, PAP smear obtaining /Clinical breast examination) R.Attar/G.Yıldırım/O. Api/A.Akalın/ G.İzbırak	**ICP-CSL** (Physical examination of the newborn and child patient) F. Bakar/S. Biçer /D.Çöl/M.Berber/ Ö.Küçük; **ICP-CSL** (Gynecological examination, PAP smear obtaining/Clinical breast examination) R.Attar/ G.Yıldırım/ O. Api/A.Akalın/ G.İzbırak	**ICP-CSL** (Physical examination of the newborn and child patient) F. Bakar/S. Biçer /D.Çöl/ M.Berber/Ö.Küçük	**Lecture** Agents Effecting Bone Mineral Homeostasis I E. Genç
15.00- 15.50	**Lecture** The Presentation of the Results I Ç. Kaspar	Group A1 YH; Group A2 & B IL; Group C; Group D IL	Group A, B2 IL; Group B1 YH; Group C IL; Group D	Group A, B, C & D2 IL; Group D1 YH	**Lecture** Agents Effecting Bone Mineral Homeostasis II E. Genç
16.00- 16.50	**Lecture** The Presentation of the Results II Ç. Kaspar	Group A1 IL; Group A2 & B IL; Group C; Group D IL	Group A, B2 IL; Group B1 IL; Group C IL; Group D	Group A, B, C & D2 IL; Group 1 IL	**Lecture** Androgens & Anabolic Steroids E. Genç
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Lecture** Imaging of Urinary System E. Kocakoç

COMMITTEE VI - URINARY SYSTEM WEEK III / 14-18 Mar 2016

	Monday 14-Mar-2016	Tuesday 15-Mar-2016	Wednesday 16-Mar-2016	Thursday 17-Mar-2016	Friday 18-Mar-2016
09.00- 09.50	PHYSICIANS' DAY	Pathology Laboratory (Urinary System) I. D. Ekici/F. Özkan — Group A IL / Group B	**Lecture** Urologic Emergencies F. Yençilek	Independent Learning	**Independent Learning**
10.00- 10.50		Pathology Laboratory (Urinary System) I. D. Ekici/F. Özkan — Group A / Group B IL	**Lecture** Polygenic Disorders A. Ç. Kuşkucu		
11.00- 11.50			**Lecture** Chronic Kidney Disease G. Kantarcı		**Lecture** Using Statistical Programs I Ç. Kaspar
12.00- 12.50		**Independent Learning**	**Lecture** The Kidney Systemic Disease and Inherited Disorders G. Kantarcı		**Lecture** Using Statistical Programs II Ç. Kaspar
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	PHYSICIANS' DAY	Pathology Laboratory (Urinary System) I. D. Ekici/F. Özkan — Group A / Group B IL	**ICP-CSL** (Physical examination of the newborn and child patient) F. Bakar/S. Biçer/D.Çöl/M.Berber/Ö.Küçük	Independent Learning	**ICP-CSL** (Physical examination of the newborn and child patient) F. Bakar/S. Biçer / D.Çöl/M.Berber/Ö.Küçük
15.00- 15.50		Pathology Laboratory (Urinary System) I. D. Ekici/F. Özkan — Group A IL / Group B	Group A IL / Group B IL / Group C IL / Group D2 YH		Group A IL / Group B2 YH / Group C IL / Group D IL
16.00- 16.50		Pathology Laboratory (Urinary System) I. D. Ekici/F. Özkan — Group A IL / Group B	**ICP-CSL** (Physical examination of the newborn and child patient) F. Bakar/S.Biçer/D.Çöl/M.Berber/Ö.Küçük		**ICP-CSL** (Physical examination of the newborn and child patient) F. Bakar/S. Biçer/D.Çöl/M.Berber/Ö.Küçük
17.00-17.50		**Independent Learning**	Group A IL / Group B IL / Group C2 YH / Group D IL		Group A2 YH / Group B IL / Group C IL / Group D IL

COMMITTEE VI - URINARY SYSTEM WEEK IV / 21-25 Mar 2016

<table>
<tr><th></th><th>Monday
21-Mar-2016</th><th>Tuesday
22-Mar-2016</th><th>Wednesday
23-Mar-2016</th><th>Thursday
24-Mar-2016</th><th>Friday
25-Mar-2016</th></tr>
<tr><td>09.00- 09.50</td><td>Lecture
Epidemiology, Prevention and Control of Sexually Transmitted Diseases I
H.A. Taşyıkan</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td>Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td>Lecture
Epidemiology, Prevention and Control of Sexually Transmitted Diseases II
H.A. Taşyıkan</td><td rowspan="3">COMMITTEE EXAM</td></tr>
<tr><td>11.00- 11.50</td><td>Multidisciplinary Case Discussion Panel
(Urology/Pathology/Nephrology)</td></tr>
<tr><td>12.00- 12.50</td><td>Multidisciplinary Case Discussion Panel
(Urology/Pathology/Nephrology)</td><td rowspan="2">Independent Learning</td><td rowspan="2">Independent Learning</td><td rowspan="2">Independent Learning</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="4">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td rowspan="3">Independent Learning</td><td>Program Evaluation Session
Committee VI
Coordination Committee Members</td></tr>
<tr><td>15.00- 15.50</td><td rowspan="3">Independent Learning</td></tr>
<tr><td>16.00- 16.50</td></tr>
<tr><td>17.00-17.50</td><td></td><td></td><td></td><td></td></tr>
</table>

COMMITTEE VII - NERVOUS SYSTEM AND PYSCHIATRY

DISTRIBUTION of LECTURE HOURS

March 28, 2016 – May 6, 2016

COMMITTEE DURATION: 6 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	NEUROLOGY	NR	13	1x4=4 (2 Groups)			**17**
	PSYCHIATRY	PCH	12				**12**
	CHILD PSYCHIATRY	C-PCH	3				**3**
	NEUROSURGERY	NRS	16	1x2=2 (2 Groups)			**18**
	PATHOLOGY	PT	11		1x2=2 (2 Groups)		**13**
	PATHOPHYSIOLOGY	PP	2				**2**
	PHARMACOLOGY	PC	14				**14**
	PEDIATRICS	PED	4				**4**
	PUBLIC HEALTH	PH	5				**5**
	FAMILY MEDICINE	FM	4				**4**
	RADIOLOGY	RAD	1				**1**
	MEDICAL GENETICS	MG	3				**3**
	INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	IDCM	2				**2**
	OPHTALMOLOGY	OPT	3				**3**
	ANESTHESIOLOGY & REANIMATION	ANS	2				**2**
	BIOISTATISTICS	BS	2			1x2=2	**4**
	SCIENTIFIC PROJECTS- III	SP	1				**1**
	INTERDISCIPLINARY	MCDP				2	**2**
MED 303	**INTRODUCTION TO CLINICAL PRACTICE III**	ICP III			2x3=6 (4 Groups)		**6**
TOTAL			**98**	**6**	**8**	**4**	**116**

Coordination Committee

HEAD	Başar Atalay, MD, Prof
SECRETARY	Burcu Örmeci, MD, Assoc. Prof
MEMBER	Işın D. Ekici, MD, Prof.
MEMBER	Oğuzhan Zahmacıoğlu, MD, Assist. Prof

COMMITTEE VII - NERVOUS SYSTEM and PSYCHIATRY
LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	**LECTURERS**
NEUROLOGY	Berrin Aktekin, MD, Prof. Burcu Örmeci, MD, Assoc. Prof.
PSYCHIATRY	Hakan Atalay, MD, Assoc. Prof. N. Berfu Akbaş, MD, Assist. Prof.
CHILD PSYCHIATRY	Oğuzhan Zahmacıoğlu, MD, Assist. Prof
NEUROSURGERY	M.Gazi Yaşargil, MD, Prof. Uğur Türe, MD, Prof. Başar Atalay, MD, Prof.
PATHOLOGY	Ferda Özkan, MD, Prof Işın Doğan Ekici, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD, PhD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Ferda Kaleağasıoğlu, MD Assoc. Prof.
PEDIATRICS	Mustafa Berber, MD, Assist. Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof
FAMILY MEDICINE	Güldal İzbırak, MD, Assoc. Prof. Hülya Akan, MD, Assoc. Prof. Ayşe Arzu Akalın, MD, Assist. Prof
RADIOLOGY	Ayşegül Sarsılmaz, MD, Assist.Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, PhD, Assist. Prof.
INFECTIOUS DISEASES & CLINICAL MICROBIOLOGY	Gülden Çelik, MD, Prof Meral Sönmezoğlu, MD, Prof.
OPHTALMOLOGY	Şule Ziylan, MD, Prof. Vildan Öztürk, MD, Assist. Prof.
ANESTHESIOLOGY & REANIMATION	Özge Köner, MD, Prof.
BIOSTATISTICS	Çiğdem Kaspar, PhD, Assist. Prof.
SCIENTIFIC PROJECTS- III	Gülderen Yanıkkaya Demirel, MD Assoc. Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Uğur Anıl Bingöl, MD Assist. Prof Turhan Özler MD, Assoc. Prof Hakan Koyuncu, MD Assist. Prof N. Berfu Akbaş, MD Assist. Prof Oğuzhan Zahmacıoğlu, MD Assist. Prof Burcu Örmeci, MD Assoc. Prof. Müzeyyen Doğan, MD Assoc. Prof. Şule Ziylan, MD, Prof.

COMMITTEE VII - NERVOUS SYSTEM and PSYCHIATRY
AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of nervous system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to nervous system and psychiatry,
5. ***to convey*** knowledge on mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to nervous system and psychiatry, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** necessary knowledge on drugs that are effective on nervous system or on clinical conditions related to nervous system and psychiatry ,
8. ***to convey*** necessary knowledge on professional standards, organizational ethics, and ethics of psychiatry***,***
9. ***to convey*** necessary knowledge on common problems in medical research,
10. ***to convey*** knowledge on phytotherapeutic agents,
11. ***to equip with*** basic and advanced clinical skills *(suturing and tying-C7, neuropsychiatric evaluation-C7)* required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0. ***recall*** anatomy, histology and physiology of nervous system,
2.0. ***define*** biochemical and psychodynamical basis of behavior,
3.0. ***grade*** physical, psychosocial and cognitive development of child,
4.0. ***explain*** etiopathogenesis of clinical conditions (central and peripheral nervous system disorders, epilepsy, organic brain syndromes, CNS tumors, psychiatric disorders/diseases) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,
5.0. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to to nervous system and psychiatry,
6.0. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to nervous system and psychiatry,

7.0. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to nervous system and psychiatry,

8.0. at multi-system level and/or related to cardiovascular and respiratory systems system,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

8.1. practice of history taking and physical examination (neurological/neuropsychiatric-C7)

8.2. evaluation of emergency case (neurological emergencies-C7)

8.3. approach to healthy individual or patient (neurological symptoms-C7, headache-C7, depression-C7, dementia-C7)

8.4. laboratory tests/examinations

8.5. imaging tests/examinations (conventional neuroradiological examinations-C7, spinal neuroradiology-C7, cranial CT-C7, cranial MRI-C7, brain perfusion scintigraphy-C7, brain PET-C7)

8.6. point of care testing

8.7. making preliminary diagnosis or definitive diagnosis decision

8.8. making non-intervention or intervention decision

8.9. practicing non-intervention or intervention

8.10. referral/transport of healthy individual or patient

9.0. ***explain*** pharmacology of drugs (parkinsonism and other movement disorders, antiepileptics, CNS stimulants and hallusinogenic drugs, sedative/hypnotic drugs, opioid analgesics and antagonists, general/local anesthetics, antipsychotic drugs, bipolar disease and lithium, antidepressant drugs, alcohols, drug dependence and abuse) that are effective on nervous system or on clinical conditions related to nervous system and psychiatry,

10.0.***describe*** professional standards, organizational ethics, and ethics in psychiatry,

11.0.***describe*** phytotherapeutic agents (“HMPs, Nutraceutics”),

12.0. ***list*** common problems in medical research,

13.0. ***perform*** basic clinical skills, practiced on phantom models (suturing and tying-C7), and advanced clinical skills, practiced on simulated/standardized patients (neuropsychiatric evaluation-C7), required at primary health care service.

COMMITTEE VII - NERVOUS SYSTEM and PSYCHIATRY
COMMITTEE ASSESSMENT MATRIX

LEARNING OBJECTIVES	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of MCQs			
			CE	FE	IE	Total
1.0., 2.0., 4.0.-8.0., 10.0.	PCH	H. Atalay	8	2	2	**12**
1.0., 2.0., 4.0.-8.0., 10.0.		B.Akbas				
1.0., 3.0.-8.0.	PED	M. Berber	4	2	2	**8**
1.0., 3.0.-8.0.						
1.0., 4.0., 7.0.	PT	F. Özkan	10	2	2	**14**
1.0., 4.0., 7.0.		I.D. Ekici				
1.0., 4.0.-8.0.	ANS	Ö. Köner	2	0	0	**2**
1.0., 4.0.-8.0.	NR	B. Aktekin	13	4	4	**21**
1.0., 4.0.-8.0.		B. Örmeci				
1.0., 4.0.-8.0.	NRS	M.G.Yaşargil	13	3	3	**19**
1.0., 4.0.-8.0.		B. Atalay				
1.0., 4.0.-8.0.		U. Türe				
1.0., 4.0.-8.0.	OPT	Ş. Ziylan	3	0	0	**3**
1.0., 4.0.-8.0.	OPT	V. Öztürk				
2.0.	MG	A.Ç. Kuskucu	4	2	2	**8**
2.0.-8.0., 10.0.	C-PCH	O. Zahmacıoglu	5	1	1	**7**
4.0., 7.0.	PP	M. Kaçar	2	1	1	**4**
4.0.-7.0, 8.4.	IDCM	G. Çelik	2	2	2	**6**
4.0.-8.0.		M. Sönmezoglu				
5.0., 6.0.	PH	R.E. Sezer	2	0	0	**2**
8.3.	FM	H. Akan	4	2	2	**8**
8.3.		G. Izbırak				
8.3.		A. Akalın				
8.5.	RAD	A. Sarsılmaz	2	0	0	**2**
9.0.	PC	E. Genç	13	3	3	**19**
9.0.		F. Kaleağasıoğlu				
12.0.	BS	Ç. Kaspar	3	1	1	**5**
		TOTAL	**90**	**25/200****	**25/200****	**140**
LEARNING OBJECTIVES	**DISCIPLINE**	**LECTURER/INSTRUCTOR**	**NUMBER of EMQs**			**TOTAL**
1.0., 4.0.-8.0.	NR	B. Ormeci	2	-	-	**2**
1.0., 2.0., 4.0.-8.0., 10.0.	PCH	H. Atalay	1	-	-	**1**
1.0., 4.0.-8.0.	NRS	B. Atalay	2			**2**
		TOTAL	**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 points**

*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

MCQ: Multiple Choice Question

EMQ: Extending Matching Question

CE: Committee Exam

CS: Committee Score

FE: Final Exam

ICE: Incomplete Exam

pts: Points

****25** out of 200 FE and ICE MCQs will be from Committee VII (Each question is of worth **0.5** pts).

COMMITTEE VII - NERVOUS SYSTEM AND PYSCHIATRY
WEEK I / 28 Mar-1 Apr 2016

	Monday 28-Mar-2016	Tuesday 29-Mar-2016	Wednesday 30-Mar-2016	Thursday 31-Mar-2016	Friday 01-Apr-2016
09.00- 09.50	Introduction to Commitee VII Head of Committee	**Lecture** Cerebral Lobes and their Disorders B. Örmeci	**Lecture** Clinical Presentation, Anatomic Concepts and Diagnosis in a Neurosurgical Patient B. Atalay	**Independent Learning**	**Lecture** Cerebrovascular Disease B. Örmeci
10.00- 10.50	**Lecture** Signs and Symptoms in Neurology B. Aktekin	**Lecture** Demyelinating Disorders B. Örmeci	**Lecture** Pediatric Neurosurgery B. Atalay		**Lecture** Dementia B. Örmeci
11.00- 11.50	**Lecture** Cranial Nerves I B. Aktekin	**Lecture** Demyelinating Disorders B. Örmeci	**Lecture** Hydrocephalus B. Atalay		**Lecture** Extrapyramidal System Disorders B. Örmeci
12.00- 12.50	**Lecture** Cranial Nerves II B. Aktekin	**Lecture** Introduction to Central Nervous System Pharmacology E. Genç	**Lecture** Conventional Neuroradiological Examinations A. Sarsılmaz		**Lecture** Pharmacological Approach to Parkinsonism & Other Movement Disorders E. Genç
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Pathophysiology of Nervous System Diseases I M. Kaçar	**Lecture** Pathology of Myelin & Neuronal Storage Diseases I I. D. Ekici	**Independent Learning**	**Independent Learning**	**Lecture** Neurodegenerative Disorders I F. Özkan
15.00- 15.50	**Lecture** Pathophysiology of Nervous System Diseases I M. Kaçar	**Lecture** Pathology of Myelin & Neuronal Storage Diseases II I. D. Ekici			**Lecture** Neurodegenerative Disorders II F. Özkan
16.00- 16.50	**Independent Learning**	**Lecture** Developmental Disorders of CNS I. D. Ekici			**Lecture** Neurodegenerative Disorders M. Berber
17.00-17.50		**Independent Learning**			**Independent Learning**

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE VII - NERVOUS SYSTEM AND PYSCHIATRY
WEEK II / 4-8 Apr 2016

	Monday 04-Apr-2016	Tuesday 05-Apr -2016	Wednesday 06-Apr -2016	Thursday 07-Apr -2016	Friday 08-Apr-2016
09.00- 09.50	**Lecture** Peripheral Nerve Disorders B. Aktekin	**Lecture** Headache in Neurologic Patient B. Örmeci	**Neurology Clinical Training** B. Aktekin	**Independent Learning Group A**	**Pathology Laboratory** (Urinary System) I. D. Ekici/F. Özkan; **Group A IL**; **Group B**
10.00- 10.50	**Lecture** Epilepsy B. Aktekin	**Lecture** Neurological Emergencies B. Örmeci	**Group A**; **Group B**; **Group C IL**; **Group D IL**		**Group A**; **Group B IL**
11.00- 11.50	**Lecture** Antiepileptics E. Genç	**Lecture** Cranial Trauma & İntracranial Hemorrhage I F. Özkan			
12.00- 12.50	**Independent Learning**	**Lecture** Cranial Trauma & İntracranial Hemorrhage II F. Özkan			**Independent Learning**
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Neurosurgical Infections B. Atalay	**Lecture** Surgical Neuroanatomy U. Türe	**Lecture** Infectious Diseases of CNS I F. Özkan	**Neurology Clinical Training** B. Örmeci	**Independent Learning**
15.00- 15.50	**Lecture** Spinal Cord Compression and Spinal Tumors B. Atalay	**Lecture** Cerebrovascular Diseases in Neurosurgery I U. Türe	**Lecture** Infectious Diseases of CNS II F. Özkan	**Group A IL**; **Group B IL**; **Group C**; **Group D**	**Lecture** Acute and Chronic Meningitis, Encephalitis II M. Sönmezoğlu
16.00- 16.50	**Lecture** Peripheral Nerve Compression Sydromes B. Atalay	**Lecture** Cerebrovascular Diseases in Neurosurgery II U. Türe	**Lecture** Infectious Disease of the Nervous System M. Berber		**Lecture** Headache in Primary Care A. Akalın
17.00-17.50	**Independent Learning**	**Independent Learning**	**Lecture** Acute and Chronic Meningitis, Encephalitis I G. Çelik		**Independent Learning**

COMMITTEE VII - NERVOUS SYSTEM AND PYSCHIATRY
WEEK III / 11-15 Apr 2016

	Monday 11-Apr-2016	Tuesday 12-Apr -2016	Wednesday 13-Apr -2016	Thursday 14-Apr -2016	Friday 15-Apr-2016
09.00- 09.50	**Lecture** Intracranial tumors I M. Gazi Yaşargil	**Lecture** Functional Neurosurgery B. Atalay	**Neurosurgery Clinical Trainig** B. Atalay	**Independent Learning**	**Neurosurgery Clinical Trainig** B. Atalay
10.00- 10.50	**Lecture** Intracranial tumors II M. Gazi Yaşargil	**Lecture** Spinal Trauma in Neurosurgery B. Atalay	**Group A** / **Group B** / **Group C IL** / **Group D IL**		**Group A IL** / **Group B IL** / **Group C** / **Group D**
11.00- 11.50	**Lecture** Degenerative Diseases of the Spine and the Spinal Cord I B. Atalay	**Lecture** Cranial Trauma in Neurosurgery B. Atalay	**Lecture** Public Health and Aging I R. E. Sezer		**Lecture** Opioid Analgesics & Antagonists I E. Genç
12.00- 12.50	**Lecture** Degenerative Diseases of the Spine and the Spinal Cord II B. Atalay	**Independent Learning**	**Lecture** Public Health and Aging II R. E. Sezer		**Lecture** Opioid Analgesics & Antagonists II E. Genç
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Tumors of CNS I **I. D. Ekici**	**Lecture** Cerebral Malformations M. Berber	**Lecture** Diseases of Optic Nerves and Visual Fields V. Öztürk	**Lecture** Paralytic Strabismus and Nistagmus S. Ziylan	**Lecture** Introduction to Psychiatry H. Atalay
15.00- 15.50	**Lecture** Tumors of CNS II **I. D. Ekici**	**Lecture** Mental and Motor Development M. Berber	**Lecture** Pupilla V. Öztürk	**Lecture** Scientific Projects- III: Writing Project G. Yanıkkaya Demirel	**Lecture** Signs and Symptoms in Psychiatry H. Atalay
16.00- 16.50	**Independent Learning**	**Independent Learning**	**Independent Learning**	**Lecture** Some Common Problems in Medical Research I Ç. Kaspar	**Lecture** Power analysis and sample size calculation I Ç. Kaspar
17.00-17.50				**Lecture** Some Common Problems in Medical Research II Ç. Kaspar	**Lecture** Power analysis and sample size calculation II Ç. Kaspar

COMMITTEE VII - NERVOUS SYSTEM AND PYSCHIATRY
WEEK IV / 18-22 Apr 2016

	Monday 18-Apr-2016	Tuesday 19-Apr -2016	Wednesday 20-Apr -2016	Thursday 21-Apr -2016	Friday 22-Apr-2016
09.00- 09.50	**Lecture** Developmental Psychopathology: Risk and Protective Factors in Mental Development H. Atalay	**Lecture** Schizophrenia and Psychosis I H. Atalay	**Lecture** Introduction to Child and Adolescent Psychiatry Oğuzhan Zahmacıoğlu	**Independent Learning**	**Lecture** Organic Brain Syndromes B. Akbaş
10.00- 10.50	**Lecture** Psychopharmacology H. Atalay	**Lecture** Schizophrenia and Psychosis II H. Atalay	**Lecture** Common Childhood Psychiatric Problems Oğuzhan Zahmacıoğlu		**Lecture** Drug Addiction & Alcoholism B. Akbaş
11.00- 11.50	**Lecture** Psychotherapies B. Akbaş	**Lecture** Antipsychotic Drugs F. Kaleagasioglu	**Lecture** Mental Development in Childhood and Adolescence Oğuzhan Zahmacıoğlu		**Lecture** Mood Disorders B. Akbaş
12.00- 12.50	**Lecture** Genetic Aspects of Psychiatric Disorders A. Ç. Kuşkucu	**Lecture** Bipolar Disease & Lithium F. Kaleağasıoğlu	**Lecture** Depression in Primary Care G. İzbırak		**Lecture** Antidepressant Drugs E. Genç
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Pathology Laboratory** (Nervous System) I. D. Ekici/F. Özkan **Group A IL** / **Group B**	**Lecture** CNS stimulants and Hallusinogenic Drugs E. Genç	**ICP-CSL** (Neurological examination & psychiatric examination) N.B.Akbaş/O.Zahmacıoğlu/B.Örmeci **Group A**	**ICP-CSL** (Suturing technique) M. Doğan **Group A IL** / **Group B IL** / **Group C IL** / **Group D**	**Lecture** Genetic Etiology of Mental Retardation I A. Ç. Kuşkucu
15.00- 15.50	**Group A** / **Group B IL**	**Lecture** Culture, Health and Illness R. E Sezer	**Group B IL** / **Group C IL** / **Group D IL**		**Lecture** Genetic Etiology of Mental Retardation II A. Ç. Kuşkucu
16.00- 16.50		**Lecture** Behavioral Determinants of Health and Disease R. E. Sezer			**Independent Learning**
17.00-17.50	**Independent Learning**	**Lecture** Epidemiology of Mental Disorders R. E. Sezer	**Independent Learning**	**Independent Learning**	

COMMITTEE VII - NERVOUS SYSTEM AND PYSCHIATRY
WEEK V / 25-29 Apr 2016

	Monday 25-Apr-2016	Tuesday 26-Apr -2016	Wednesday 27-Apr -2016	Thursday 28-Apr -2016	Friday 29-Apr-2016
09.00- 09.50	**ICP-CSL** (Neurological examination & psychiatric examination) N.B.Akbaş/O.Zahmacıoğlu/ B.Örmeci	**ICP-CSL** (Neurological examination & psychiatric examination) N.B.Akbaş/O.Zahmacıoğlu/ B.Örmeci	**ICP-CSL** (Neurological examination & psychiatric examination) N.B.Akbaş/O.Zahmacıoğlu/B.Örmeci	**Independent Learning**	**Lecture** Anxiety Disorders I B. Akbaş
10.00- 10.50					**Lecture** Anxiety Disorders II B. Akbaş
11.00- 11.50	**Group A IL** **Group B IL** **Group C** **Group D IL**	**Group A IL** **Group B IL** **Group C IL** **Group D**	**Group A IL** **Group B** **Group C IL** **Group D IL**		**Lecture** Sedative / Hypnotic Drugs I E. Genç
12.00- 12.50					**Lecture** Sedative / Hypnotic Drugs II E. Genç
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**ICP-CSL** (Suturing technique) T. Özler	**ICP-CSL** (Suturing technique) M. F. Çelikmen	**ICP-CSL** (Suturing technique) Ş. Ziylan	**Independent Learning**	**Lecture** Drug Dependence & Abuse E. Genç
15.00- 15.50	**Group A IL** **Group B** **Group C IL** **Group D IL**	**Group A IL** **Group B IL** **Group C** **Group D IL**	**Group A** **Group B IL** **Group C IL** **Group D IL**		**Lecture** The Alcohols E. Genç
16.00- 16.50					**Lecture** Approach to Smoking Patient in Primary Care H. Akan
17.00-17.50	**Independent Learning**	**Independent Learning**	**Independent Learning**		Approach to the Patient with Dementia in Primary Care H. Akan

COMMITTEE VII - NERVOUS SYSTEM AND PYSCHIATRY
WEEK VI / 2-6 May 2016

<table>
<tr><th></th><th>Monday
02-May-2016</th><th>Tuesday
03-May-2016</th><th>Wednesday
04-May-2016</th><th>Thursday
05-May-2016</th><th>Friday
06-May-2016</th></tr>
<tr><td>09.00- 09.50</td><td>Lecture
Introduction to General Anesthesia
Ö. Köner</td><td rowspan="4">Independent Learning
SPRING FEST</td><td rowspan="4">Independent Learning
SPRING FEST</td><td rowspan="4">Independent Learning
SPRING FEST</td><td>Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td>Lecture
Anesthetic Agents
Ö. Köner</td><td rowspan="3">COMMITTEE EXAM</td></tr>
<tr><td>11.00- 11.50</td><td>Lecture
Local Anesthetics
E. Genç</td></tr>
<tr><td>12.00- 12.50</td><td>Lecture
General Anesthetics
E. Genç</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="5">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td>Multidisciplinary Case Discussion Panel
(Neurology)</td><td rowspan="5">Independent Learning
SPRING FEST</td><td rowspan="5">Independent Learning
SPRING FEST</td><td rowspan="5">Independent Learning
SPRING FEST</td><td>Program Evaluation Session
Committee VII
Coordination Committee
Members</td></tr>
<tr><td>15.00- 15.50</td><td>Multidisciplinary Case Discussion Panel
(Neurology)</td><td rowspan="4">Independent Learning</td></tr>
<tr><td>16.00- 16.50</td><td rowspan="2">Independent Learning
SPRING FEST</td></tr>
<tr><td>17.00-17.50</td></tr>
</table>

COMMITTEE VIII - MUSCULOSKELETAL SYSTEM

DISTRIBUTION of LECTURE HOURS

May 9, 2016 – June 6, 2016

COMMITTEE DURATION: 4 WEEKS

MED 302	INTRODUCTION TO CLINICAL SCIENCES	ABBR.	THEO.	PRAC.	LAB/CSL	DISCUSSION	TOTAL
DISCIPLINE	ORTHOPAEDICS & TRAUMATOLOGY	ORT	20				**20**
	PHYSICAL THERAPY & REHABILITATION	PTR	4				**4**
	RHEUMATOLOGY	RHE	8				**8**
	PATHOLOGY	PT	11		1x2=2 (4 Groups)		**13**
	PATHOPHYSIOLOGY	PP	2				**2**
	PHARMACOLOGY	PC	7				**7**
	PUBLIC HEALTH	PH	5				**5**
	FAMILY MEDICINE	FM	2				**2**
	MEDICAL GENETICS	MG	2				**2**
	RADIOLOGY	RAD	1				**1**
	BIOMEDICAL ETHICS & DEONTOLOGY	BED	2				**2**
	EMERGENCY MEDICINE	EM	1				**1**
	BIOSTATISTICS	BS	2			1x2	**4**
	INTERDISCIPLINARY	MCDP				2	**2**
MED 303	**INTRODUCTION TO CLINICAL PRACTICE III**	ICP III			1x3=3 (4 Groups)		**3**
TOTAL			**67**	**0**	**5**	**4**	**76**

Coordination Committee

HEAD	Melih Güven, MD, Assoc. Prof
SECRETARY	Turhan Özler, MD, Assoc. Prof
MEMBER	Işın D. Ekici, MD, Prof.
MEMBER	Müge Bıçakçıgil, MD, Assoc. Prof

COMMITTEE VIII - MUSCULOSKELETAL SYSTEM
LECTURERS

MED 302 INTRODUCTION TO CLINICAL SCIENCES	
DISCIPLINE	**FACULTY**
ORTHOPAEDICS & TRAUMATOLOGY	Faik Altıntaş, MD, Prof. Uğur Şaylı, MD, Prof. Turhan Özler, MD, Assoc Prof. Melih Güven, MD, Assoc.Prof. Çağatay Uluçay, MD, Assoc. Prof. Budak Akman, MD
PHYSICAL THERAPY & REHABILITATION	Ece Aydoğ, MD, Prof.
RHEUMATOLOGY	Müge Bıçakçıgil, MD, Assoc. Prof
PATHOLOGY	Ferda Özkan, MD, Prof Işın Doğan Ekici, MD, Prof.
PATHOPHYSIOLOGY	Mehtap Kaçar, MD PhD, Assoc. Prof.
PHARMACOLOGY	Ece Genç, PhD, Prof. Ferda Kaleağasıoğlu, MD, Assoc. Prof.
PUBLIC HEALTH	Recep Erol Sezer, MD, Prof Hale Arık Taşyıkan, MD, Assist. Prof
FAMILY MEDICINE	Özlem Tanrıöver, MD, Assoc. Prof Hülya Akan, MD, Assoc. Prof.
MEDICAL GENETICS	Ayşegül Çınar Kuşkucu, MD, PhD Assist. Prof.
RADIOLOGY	Neslihan Taşdelen, MD, Assoc. Prof.
BIOMEDICAL ETHICS & DEONTOLOGY	Elif Vatanoğlu, MD, PhD, Assoc. Prof.
EMERGENCY MEDICINE	Sezgin Sarıkaya, MD, Assoc.Prof
BIOSTATISTICS	Çiğdem Kaspar, PhD, Assist. Prof.

MED 303 INTRODUCTION TO CLINICAL PRACTICE III	
DISCIPLINE	**LECTURERS**
CLINICAL SKILLS LAB	Turhan Özler, MD, Assoc. Prof. Budak Akman, MD Serdar Özdemir, MD, Assist. Prof

COMMITTEE VIII - MUSCULOSKELETAL SYSTEM
AIMS and LEARNING OBJECTIVES

AIMS

In evidence based manner,

1. ***to remind*** knowledge on anatomy, histology and physiology of musculoskeletal system,
2. ***to convey*** knowledge on etiopathogenesis of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
3. ***to convey*** knowledge on epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
4. ***to convey*** necessary knowledge on prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to musculoskeletal system,
5. ***to convey*** knowledge on mechanims of occurence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,
6. ***to convey*** necessary knowledge together with performance measures on health care processes, clinical decision making process, clinical decisions and clinical practices required for managing clinical conditions related to musculoskeletal system, which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency, at the level of primary health care service,
7. ***to convey*** necessary knowledge on pharmacology of drugs that are effective on musculoskeletal system or on clinical conditions related to musculoskeletal system,
8. ***to convey*** necessary knowledge on ethics in biomedical research,
9. ***to convey*** necessary knowledge on clinical research methods and searching medical literature,
10. ***to convey*** necessary knowledge on phytotherapeutic agents,
11. ***to equip with*** basic and advanced clinical skills (peripheral venous catheter insertion-C8, physical examination of musculoskeletal system-C8) required at primary health care service level.

LEARNING OBJECTIVES

At the end of this committee, student should be able to:

1.0. ***recall*** anatomy, histology and physiology of musculoskeletal system,

2.0. ***explain*** etiopathogenesis of clinical conditions (congenital, traumatic, metabolic, degenerative, onocological conditions of bone, rheumotological disorders, disaeses/disorders of connective tissue, vascular diseases, pathological posture, pain) which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,

3.0. ***explain*** epidemiology of clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,

4.0. ***explain*** prevention of clinical conditions, and protection or improvement of health against those clinical conditions related to musculoskeletal system,

5.0. ***describe*** mechanisms of occurrence for frequently encountered clinical complaints, symptoms, signs and findings in clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency related to musculoskeletal system,

6.0. at multi-system level and/or related to cardiovascular and respiratory systems system,

- for healthy conditions in an individual or community with a request against clinical conditions that pose risks,
- in an individual with clinical complaint, symptom, sign or laboratory/imaging finding or in a community,
- for clinical conditions which are frequent in community and/or pose high risk for individual or community health, and/or life-threatening or constitute an emergency,

explain in an evidence-based manner and together with performance measures from the aspects of reliability, practicality and outcomes,

- health care processes, clinical decision making process, clinical decisions and clinical practices

which are required for management at primary health care service level:

6.1. practice of history taking and physical examination (musculoskeletal-C8)
6.2. evaluation of emergency case (trauma-C8)
6.3. approach to healthy individual or patient (musculoskeletal dysfunction-C8)
6.4. laboratory tests/examinations (monitarization of drug therapy-C8)
6.5. imaging tests/examinations (radiological imaging of musculoskeletal system-C8, radiological examinations in benign ve malign tumors of bones-C8, bone scintigraphy-C8)
6.6. point of care testing
6.7. making preliminary diagnosis or definitive diagnosis decision
6.8. making non-intervention or intervention decision
6.9. practicing non-intervention or intervention
6.10. referral/transport of healthy individual or patient
7.0. ***explain*** pharmacology of drugs (non-opioid analgesics, skeletal muscle relaxants, disease modifying antirheumatic drugs) that are effective on musculoskeletal system or on clinical conditions related to musculoskeletal system,
8.0. ***explain*** effects of phytotherapeutic agents on musculoskeletal system or on clinical conditions related to musculoskeletal system,
9.0. ***list*** ethical principles in biomedical research,
10.0.***explain*** use of biostatistics in clinical research and for evidence search in medical literature,
11.0. ***perform*** basic clinical skills, practiced on phantom models (peripheral venous catheter insertion-C8), and advanced clinical skills, practiced on simulated/standardized patients (physical examination of musculoskeletal system-C8), required at primary health care service.

COMMITTEE VIII - MUSCULOSKELETAL SYSTEM
COMMITTEE ASSESSMENT MATRIX

LEARNING OBJECTIVES	DISCIPLINE	LECTURER/ INSTRUCTOR	NUMBER of MCQs			
			CE	FE	IE	Total
1.0.-6.0.	ORT	F. Altıntas	20	5	5	**30**
1.0.-6.0.		U. Şaylı				
1.0.-6.0.		T. Özler				
1.0.-6.0.		M. Güven				
1.0.-6.0.		Ç. Uluçay				
1.0.-6.0.		B.Akman				
1.0.-6.0.	PTR	E. Aydog	6	2	2	**10**
1.0.-6.0.	RHE	M. Bıçakçıgil	10	3	3	**16**
1.0., 2.0., 5.0.	PP	M. Kaçar	3	1	1	**5**
1.0., 2.0., 5.0.	PT	F. Özkan	16	3	3	**22**
1.0., 2.0., 5.0.		I.D.Ekici				
2.0.	MG	A.Ç.Kuskucu	2	1	1	**4**
3.0., 4.0.	PH	R.E. Sezer	7	2	2	**11**
3.0., 4.0.		H.A.Taşyıkan				
6.2.	EM	S.Sarıkaya	1	0	0	**1**
6.3.	FM	H. Akan	2	2	2	**6**
6.3.		Ö. Tanrıöver				
6.5.	RAD	N.Taşdelen	2	0	0	**2**
7.0.	PC	F.Kaleağasıoğlu	12	4	4	**20**
7.0.		E. Genç				
9.0.	BED	E. Vatanoglu	3	1	1	**5**
10.0.	BS	Ç. Kaspar	6	1	1	**8**
		TOTAL	**90**	**25/200****	**25/200****	**140**

LEARNING OBJECTIVES	DISCIPLINE	LECTURER/INSTRUCTOR	NUMBER of EMQs			TOTAL
1.0.-6.0.	RHE	M. Bıçakçıgil	2	-	-	2
1.0.-6.0.	ORT	M.Güven	2	-	-	2
1.0.-6.0.	PTR	E. Aydog	1			1
		TOTAL	**5**	**-**	**-**	**5**

CS*= 90 pts (MCQ) **+ 10 pts** (EMQ) **= 100 points**

*Each MCQ has a value of **1** points; each EMQ question has a value of **2** points.

MCQ: Multiple Choice Question

EMQ: Extending Matching Question

CE: Committee Exam

CS: Committee Score

FE: Final Exam

ICE: Incomplete Exam

pts: Points

****25** out of 200 FE and ICE MCQs will be from Committee VIII (Each question is of worth **0.5** pts).

COMMITTEE VIII - MUSCULOSKELETAL SYSTEM
WEEK I / 9-13 May 2016

	Monday 09-May-2016	Tuesday 10-May-2016	Wednesday 11-May-2016	Thursday 12-May-2016	Friday 13-May-2016
09.00- 09.50	**Independent Learning**	**Lecture** Public Health and Physical Activity I R. E. Sezer	**Lecture** Trauma T. Özler	**Independent Learning**	**Lecture** Degenerative Joint Disease F. Özkan
10.00- 10.50		**Lecture** Public Health and Physical Activity II R. E. Sezer	**Lecture** Upper Extremity Trauma T. Özler		**Lecture** Degenerative Osteoarthrosis F. Altıntaş
11.00- 11.50	Introduction to Commitee VIII Head of Committee	**Lecture** Congenital & Metabolic Diseases of Bone I F. Özkan	**Lecture** Lower Extremity Trauma U. Şaylı		**Lecture** Osteoporosis and Osteoarthritis Treatment, Rehabilitation E. Aydoğ
12.00- 12.50	**Lecture** Introduction to Musculoskeletal System F. Altıntaş	**Lecture** Congenital & Metabolic Diseases of Bone II F. Özkan	**Lecture** Principles of Fracture Healing U. Şaylı		**Lecture** Soft Tissue Pain E. Aydoğ
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Pathophysiology of Musculoskeletal System Disorders M. Kaçar	**Lecture** Introduction to Occupational Health R. E. Sezer	**Lecture** Bone and Joint İnfections **I. D. Ekici**	**Lecture** Sport Injuries I T. Özler	**Lecture** Spondylarthropaties M. Bıçakçıgil
15.00- 15.50	**Lecture** Pathophysiology of Musculoskeletal System Disorders M. Kaçar	**Lecture** Epidemiology, Prevention and Control of Occupational Diseases and Injuries I H.A. Taşyıkan	**Lecture** Osteomyelitis and Septic Artritis B. Akman	**Lecture** Sport Injuries II T. Özler	**Lecture** Inflammatory Polyarthritis & Rheumatoid Arthritis M. Bıçakçıgil
16.00- 16.50	**Independent Learning**	**Lecture** Epidemiology, Prevention and Control of Occupational Diseases and Injuries II H.A. Taşyıkan	**Lecture** Neuromuscular Disease B.Akman	**Lecture** Imaging of Musculoskeletal System N. Tasdelen	**Independent Learning**
17.00-17.50		**Independent Learning**	**Independent Learning**	**Independent Learning**	

IL: Independent Learning, CSL: Clinical Skills Learning, YH: Yeditepe University Hospital. Student groups for laboratory/practice sessions will be announced by coordinators.

COMMITTEE VIII - MUSCULOSKELETAL SYSTEM
WEEK II / 16-20 May 2016

	Monday 16-May-2016	Tuesday 17-May-2016	Wednesday 18-May-2016	Thursday 19-May-2016	Friday 20-May-2016
09.00- 09.50	**Lecture** Neck, Shoulder and Wrist Pain E. Aydoğ	**Lecture** Connective Tissue Disorders I M. Bıçakçıgil	**Lecture** Vasculitis I F. Özkan	**NATIONAL HOLIDAY**	**Independent Learning**
10.00- 10.50	**Lecture** Low Back, Hip and Ankle Pain E. Aydoğ	**Lecture** Connective Tissue Disorders II M. Bıçakçıgil	**Lecture** Vasculitis II F. Özkan		
11.00- 11.50	**Lecture** Approach to the Patient with Backpain in Primary Care Ö. Tanrıöver	**Lecture** Nonsteroidal Antiinflammatory Drugs I E. Genç	**Lecture** Vasculitis I M. Bıçakçıgil		
12.00- 12.50	**Lecture** Skeletal Muscle Relaxants E. Genç	**Lecture** Nonsteroidal Antiinflammatory Drugs II E. Genç	**Lecture** Vasculitis II M. Bıçakçıgil		
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Miscellanous Rheumatological Disorders I M. Bıçakçıgil	**Lecture** Disease Modifying Antirheumatic Drugs F. Kaleağasıoğlu	**Lecture** Myopathies I. D. Ekici	**NATIONAL HOLIDAY**	**Independent Learning**
15.00- 15.50	**Lecture** Miscellanous Rheumatological Disorders II M. Bıçakçıgil	**Lecture** Pharmacology Case Studies F. Kaleağasıoğlu	**Lecture** Fibromyalgia in Primary Care H. Akan		
16.00- 16.50	**Independent Learning**	**Lecture** Medical Literature I Ç. Kaspar	**Independent Learning**		
17.00-17.50		**Lecture** Medical Literature II Ç. Kaspar			

COMMITTEE VIII - MUSCULOSKELETAL SYSTEM
WEEK III / 23-27 May 2016

	Monday 23-May-2016	Tuesday 24-May-2016	Wednesday 25-May-2016	Thursday 26-May-2016	Friday 27-May-2016
09.00- 09.50	**Lecture** Traumatic Dislocations Ç. Uluçay	**Lecture** Fractures of Children M. Güven	**Pathology Laboratory** (Musculoskeletal System) I. D. Ekici/F. Özkan **Group A** / **Group B IL**	**Independent Learning**	**Lecture** Bone tumors I I. D. Ekici
10.00- 10.50	**Lecture** Spinal Deformities Ç. Uluçay	**Lecture** Developmental Disorders of the Skeleton M. Güven	**Group A IL** / **Group B**		**Lecture** Bone tumors II I. D. Ekici
11.00- 11.50	**Lecture** Upper Extremity Disorders Ç. Uluçay	**Lecture** Congenital Dislocation of the Hip M. Güven			**Lecture** Benign Tumors of Bone M. Güven
12.00- 12.50	**Lecture** Lower Extremity Disorders Ç. Uluçay	**Lecture** Foot Deformities Ç. Uluçay	**Independent Learning**		**Lecture** Malignant Tumors of Bone M. Güven
12.50 – 14.00	**LUNCH BREAK**				
14.00- 14.50	**Lecture** Osteoporosis B.Akman	**Lecture** Initial Approach to Trauma Patient S. Sarıkaya	**ICP-CSL** (Physical examination of the musculoskeletal system) T. Özler/ S.Özdemir	**Lecture** Microsurgery and Replantation B.Akman	**ICP-CSL** (Physical examination of the musculoskeletal system) Ç. Uluçay/ S.Özdemir
15.00- 15.50	**ICP-CSL** (Physical examination of the musculoskeletal system) T. Özler/ S.Özdemir	**Lecture** Skeletal Dysplasias A. Ç. Kuşkucu	**Group A IL** / **Group B** / **Group C IL** / **Group D IL**	**ICP-CSL** (Physical examination of the musculoskeletal system) Ç. Uluçay/ S.Özdemir	**Group A** / **Group B IL** / **Group C IL** / **Group D IL**
16.00- 16.50	**Group A IL** / **Group B IL** / **Group C** / **Group D IL**	**Lecture** Muscular Dystrophies A. Ç.Kuşkucu		**Group A IL** / **Group B IL** / **Group C IL** / **Group D**	
17.00-17.50		**Independent Learning**	**Independent Learning**		**Independent Learning**

COMMITTEE VIII - MUSCULOSKELETAL SYSTEM
WEEK IV / 30 May -3 June 2016

<table>
<tr><th></th><th>Monday
30-May-2016</th><th>Tuesday
31-May-2016</th><th>Wednesday
01-Jun-2016</th><th>Thursday
02-Jun -2016</th><th>Friday
03-Jun -2016</th></tr>
<tr><td>09.00- 09.50</td><td>Lecture
Tumors of Soft Tissues I
F. Özkan</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td rowspan="4">Independent Learning</td><td>Independent Learning</td></tr>
<tr><td>10.00- 10.50</td><td>Lecture
Tumors of Soft Tissues II
F. Özkan</td><td rowspan="3">COMMITTEE EXAM</td></tr>
<tr><td>11.00- 11.50</td><td>Lecture
Clinical Trials I
Ç. Kaspar</td></tr>
<tr><td>12.00- 12.50</td><td>Lecture
Clinical Trials II
Ç. Kaspar</td></tr>
<tr><td>12.50 – 14.00</td><td colspan="5">LUNCH BREAK</td></tr>
<tr><td>14.00- 14.50</td><td>Multidisciplinary Case Discussion Panel</td><td rowspan="5">Independent Learning</td><td rowspan="5">Independent Learning</td><td rowspan="5">Independent Learning</td><td>Program Evaluation Session
Committee VIII
Coordination Committee Members</td></tr>
<tr><td>15.00- 15.50</td><td>Multidisciplinary Case Discussion Panel</td><td rowspan="4">Independent Learning</td></tr>
<tr><td>16.00- 16.50</td><td rowspan="3">Independent Learning</td></tr>
<tr><td>17.00-17.50</td></tr>
</table>

COMMITTEE VIII - MUSCULOSKELETAL SYSTEM
WEEK IV / 6 -10 June 2016

	Monday 06-Jun-2016	Tuesday 07-Jun-2016	Wednesday 08-Jun-2016	Thursday 09-Jun -2016	Friday 10-Jun -2016
09.00- 09.50	OSCE-II EXAM	Independent Learning	Independent Learning	Independent Learning	Independent Learning
10.00- 10.50					
11.00- 11.50					
12.00- 12.50					
12.50 – 14.00	LUNCH BREAK				
14.00- 14.50	OSCE-II EXAM	Independent Learning	Independent Learning	Independent Learning	Independent Learning
15.00- 15.50					
16.00- 16.50					
17.00-17.50					

STUDENT COUNSELING

Student counseling is a structured development process established between the student and the consultant that aims to maximize student success by focusing the student to her/his target. Although the major component of this relationship is the student, the faculties also take part by bringing the requirements of this interaction to their systems. The targeted outcomes of the consultant-student interaction are success in the exams, success in the program, and preparation for the professional life.
The aim of counseling is to help students to solve their problems, to give professional guidance, to provide coaching, to contribute to adopting the habit of lifelong learning, to provide information about the University and Faculty, to follow their success and failure and to help them select courses.
The consultants selected among Basic Medical Sciences instructors for the first three years transfer the students to Clinical Sciences instructors for the following three years.

The topics that will be addressed by the consultants are as follows:

a. Inform students about the university, faculty and surrounding facilities
b. Inform students about the courses and help them select courses
c. Inform students about the education and assessment regulations
d. Follow students attendance to lectures and success
e. In case of failure, investigate the causes and cooperate with the students to overcome them
f. Help students in career planning
g. Contribute to students adapting the habit of lifelong learning
h. Guide students to counseling services of the university
i. Set a role model as long as the professional susceptibility, professional guidance, intellectual responsibility, interaction with peers, ethics, professional values are concerned
j. Contribute to cultivation of professional and intellectual development in a rapidly changing world
k. Inform the coordinator when there are unsolved problems of the students

Consultant-student relationship is a dynamic and mutual process carried out within the campus and the hospital. It is recommended that the consultant and the student meet at least twice during a semester.

The expectations from the student are as follows:

a) Contribute to improvement of satisfaction level in the problem areas
b) Report the social and economic conditions that require consultant's help
c) Specify expectations from the education and the department from which this training is taken
d) Give feedback on the counseling services regarding their satisfaction level

Student counsellors will be appointed after finalization of the class list and will be announced to the students.
After the announcement of the counsellors on the information board, each student is expected to contact his/her counsellor until the end of the current committee.

LIST OF STUDENT COUNSELING - PHASE III

	STUDENT NUMBER	NAME	SURNAME	COUNSELOR
1	20130800096	MUSTAPHA	ABU RACHED	ASSOC. PROF. ÜNAL USLU
2	20130800093	YASHAR	ADİBNİA	ASSOC. PROF. ÜNAL USLU
3	20120800065	ALİ ERDİ	AFACAN	ASSOC. PROF. ÜNAL USLU
4	20130800026	SEDA	AKKIZ	ASSIST. PROF. DENİZ KIRAÇ
5	20120800032	YİĞİT	AKSOY	ASSIST. PROF. DENİZ KIRAÇ
6	20130800053	SENA	AKYILDIZ	ASSIST. PROF. DENİZ KIRAÇ
7	20120800044	DAMLA	ALTUNOK	ASSIST. PROF. ÇİĞDEM KASPAR
8	20130800095	CEMRE	ARDIÇ	ASSIST. PROF. ÇİĞDEM KASPAR
9	20130800077	DOĞUKAN	ARSLAN	PROF. BAYRAM YILMAZ
10	20120800012	ALARA	ATAACAR	PROF. BAYRAM YILMAZ
11	20120800026	GALİP EKİN	BENLİ	PROF GÜLDEN ÇELİK
12	20130800053	BEYZA	BÜYÜKÖREN	ASSIST. PROF. AKİF MAHARRAMOV
13	20130800057	CANER	ÇECE	ASSIST. PROF. AKİF MAHARRAMOV
14	20130800036	BEHİÇ	ÇELİK	PROF DR GÜLDEN ÇELİK
15	20140800101	ECE	DEMİRKIRKAN	PROF. ECE GENÇ
16	20130800023	ÖZGÜL GİZEM	DİKENCİK	PROF. TURGAY İSBİR
17	20130800016	MELİS	ERDAL	ASSOC. PROF. ELİF VATANOĞLU
18	20120800003	MERVE	ERİŞ	ASSOC. PROF. ELİF VATANOĞLU
19	2012080010	İZGİ AYÇIL	GENCAN	ASSOC. PROF. YEŞİM GÜROL
20	20120800072	NAZ	GÜÇLÜ	ASSOC. PROF. YEŞİM GÜROL
21	2012080004	DİLARA	GÜLŞAN	ASSOC. PROF. YEŞİM GÜROL
22	20130800024	GİZEM	GÜNGÖR	ASSOC. PROF. YEŞİM GÜROL
23	20120800066	METEHAN	HERGÜNER	ASSOC. PROF. ÇAĞATAY ACUNER
24	20130800052	MÜNİRE NAZLI	HÖBEK	ASSOC. PROF. ÇAĞATAY ACUNER
25	20120800043	ELİF RABİA	İÇÖZ	ASSOC. PROF. ÇAĞATAY ACUNER
26	20120800050	ECE	İLTÜMÜR	PROF. ECE GENÇ
27	20130800037	AYDIN	İŞLETME	PROF. ECE GENÇ
28	20120800057	ECEM	KAHRAMAN	ASSIST. PROF. ALEV CUMBUL
29	20120800051	GİZEM NAZ	KAHRAMAN	ASSIST. PROF. ALEV CUMBUL
30	20130800063	MÜGE	KALAYCIOĞLU	ASSIST. PROF. ALEV CUMBUL
31	20130800082	NESİBE GÖKÇE	KALYONCU	ASSIST. PROF. ALEV CUMBUL

32	20120800064	FATMA CANAN	KARABAŞ	ASSOC. PROF. ÖZLEM TANRIÖVER
33	20130800019	DEFNE CANSU	KARAMANLI	ASSOC. PROF. ÖZLEM TANRIÖVER
34	20120800053	SALİHA NAZLI	KARDAŞ	ASSOC. PROF. ÖZLEM TANRIÖVER
35	2014080090	BUSE	KAYMAKÇI	ASSIST. PROF. BİLGE GÜVENÇ TUNA
36	20120800054	ÇAĞDAŞ ROBİN	KIRAN	ASSOC. PROF. HÜLYA AKAN
37	20130800038	İREM NUR	KİRAZ	ASSOC. PROF. HÜLYA AKAN
38	20130800011	UMUT	KOÇ	ASSOC. PROF. HÜLYA AKAN
39	20130800060	BİLGE	KÖYLÜ	PROF. İNCİ ÖZDEN
40	20130800039	DOĞA	KURUOĞLU	PROF. İNCİ ÖZDEN
41	20120800060	ETKİN BENGİSU	KUTSAL	PROF. İNCİ ÖZDEN
42	20120800067	DİLARA	MEDET	PROF. JALE ÇOBAN
43	20130800081	FATMA SARAAD	MOHAMUD	ASSIST. PROF. ARZU AKALIN
44	20120800041	MUSTAFA FATİH	ÖĞÜNÇLÜ	PROF. JALE ÇOBAN
45	20130800027	TANSU ŞUA	ÖKTEM	ASSIST. PROF. ARZU AKALIN
46	20140800095	CEMELMAS	ÖZAKINSEL	ASSOC. PROF. KAAN YÜCEL
47	20130800073	MELİS	ÖZGER	ASSIST. PROF. ARZU AKALIN
48	20130800025	HELİN DİCLE	ÖZBEK	ASSIST. PROF. ARZU AKALIN
49	20130800002	BURHAN OSMAN	ÖZTÜRK	PROF. ECE GENÇ
50	20130800041	HAZAL	SAĞKOL	PROF. ECE GENÇ
51	20140800087	ÖZÜM CANSU	SAHİN	ASSIST. PROF. BİLGE GÜVENÇ TUNA
52	20120800006	MUSTAFA	SELİMOĞLU	ASSIST. PROF. HALE ARIK
53	20120800007	MEHMET İLHAN	SESİGÜZEL	ASSIST. PROF. AYŞEGÜL KUŞKUCU
54	20130800030	IRMAK	SINAL	ASSIST. PROF. AYŞEGÜL KUŞKUCU
55	20130800013	LEVENT AKMAN	SOLİM	ASSIST. PROF. AYŞEGÜL KUŞKUCU
56	20130800034	UFUK	ŞANKO	PROF. FERDA ÖZKAN
57	20130800058	MÜMİN BERKAY	ŞEN	PROF. FERDA ÖZKAN
58	20120800084	BURÇİN	TAK	PROF. FERDA ÖZKAN
59	20120800024	EGEMEN	TAVRAK	PROF. FERDA ÖZKAN
60	20130800049	ZEYNEP BİRKE	TOKSÖZ	PROF. IŞIN DOĞAN EKİCİ
61	20130800022	MİRAÇ BERFU	TOKUÇ	PROF. IŞIN DOĞAN EKİCİ
62	20130800061	ECE	TOPRAKÇI	PROF. IŞIN DOĞAN EKİCİ
63	20130800040	ASUDE	TURA	ASSOC. PROF. GÜLDEREN YANIKKAYA DEMİREL
64	20130800014	TALAT TAYGUN	TURAN	ASSOC. PROF. GÜLDEREN YANIKKAYA DEMİREL

65	20120800008	AYKUT	UÇAR	ASSOC. PROF. GÜLDEREN YANIKKAYA DEMİREL
66	20130800017	EZGİ	URTEKİN	ASSOC. PROF. SONER DOĞAN
67	20130800067	GÖKALP ARİF	UTKUGÜN	ASSOC. PROF. SONER DOĞAN
68	20130800044	SEZİN	ÜNVER	ASSOC. PROF. SONER DOĞAN
69	20120800062	YELİZ	YANIKOĞLU	ASSOC. PROF. SONER DOĞAN
70	20120800011	İREM	YAPAR	ASSIST. PROF. DENİZ KIRAÇ
71	20120800063	YAĞMUR	YAVUZ	ASSIST. PROF. ÇİĞDEM KASPAR
72	20120800016	MEHMET YAĞIZ	YENİGÜN	ASSIST. PROF. ÇİĞDEM KASPAR
73	20140800092	MERVE SEZER	YILDIRIM	ASSIST. PROF. ÇİĞDEM KASPAR
74	20130800062	EZGİ	YILDIZ	ASSOC. PROF. KAAN YÜCEL
75	20120800071	BÜŞRA	YILDIZ	ASSIST. PROF. BİLGE GÜVENÇ TUNA
76	20120800061	İLKİM ECE	YILDIZ	ASSOC. PROF. ÜNAL USLU
77	20130800018	ŞERİFE DİLARA	YOZGATLI	PROF. JALE ÇOBAN
78	20120800081	MUSTAFA FADIL	YUNIS	ASSOC. PROF. SONER DOĞAN
79	20120800013	BÜŞRA	ZENGİN	PROF. İNCİ ÖZDEN

CONTACT

Faculty Secretary :
Tel: +90 216 578 05 93

Dean Secretary:
Tel: +90 216 578 05 05 – 06
Fax: +90 216 578 05 75

Student Affairs :
Tel: 0216 578 06 86

Documents Affairs:
Tel: 0216 578 05 23

Coordinator/ Co-coordinator:

Ferda Kaleağasıoğlu, MD, Assoc. Prof. (Coordinator), 216 578 00 (1551) / ferda.kaleagasioglu@yeditepe.edu.tr

Yeşim Gürol, MD, Assoc. Prof (Co-coordinator), 216 578 00 00 (3793) /yesimg@yeditepe.edu.tr

Ayşegül Ç. Kuşkucu, MD, Assist. Prof. (Co-coordinator), 216 578 00 00 (5777) / aysegul.kuskucu@yeditepe.edu.tr

Hale Arık Taşyıkan, MD, MPH, Assist. Prof. (Co-coordinator), 216 578 00 00 (6300) / hale.arik@yeditepe.edu.tr

Işın Doğan Ekici MD, Prof. (Co-coordinator), 216 578 00 00 (3774) / idogan@yeditepe.edu.tr

Özlem Tanrıöver MD, Assoc. Prof. (ICP Coordinator), 216 578 00 00 (3742) / otanriover@yeditepe.edu.tr

A. Arzu Akalın MD, Assist. Prof. (ICP Co-coordinator), 216 578 00 00 (1525) /arzu.akalin@yeditepe.edu.tr

Address:

Yeditepe University Faculty of Medicine
İnönü Mah. Kayışdağı Caddesi,
26 Ağustos Yerleşimi,
34755 Ataşehir, İstanbul

Web : www.yeditepe.edu.tr
http://www.med.yeditepe.edu.tr
e-mail: tipfakdek@yeditepe.edu.tr

YEDİTEPE UNIVERSITY
FACULTY OF MEDICINE

İnönü Mah. Kayışdağı Caddesi,
26 Ağustos Yerleşimi,
34755 Ataşehir, İstanbul

+ 90 216 578 00 00

www.yeditepe.edu.tr
http://www.yeditepe.edu.tr/fakulteler/tip-fakultesi
tipfakdek@yeditepe.edu.tr